[
      {
          "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf": [
              {
                  "question": "What is the recommended ivacaftor dose for a patient with the CFTR G551D mutation?",
                  "answer": {
                      "Drug Name": "ivacaftor",
                      "Gene Name": "CFTR",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf",
                      "Content to Search": "Recommended ivacaftor dosage for patients with the CFTR G551D genotype."
                  }
              },
              {
                  "question": "What is the risk of elevated transaminases for patients with a responsive CFTR genotype taking ivacaftor?",
                  "answer": {
                      "Drug Name": "ivacaftor",
                      "Gene Name": "CFTR",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf",
                      "Content to Search": "Incidence rates or quantified risk of elevated transaminases in patients on ivacaftor therapy."
                  }
              },
              {
                  "question": "What is the target for sweat chloride concentration reduction with ivacaftor therapy in responsive CFTR genotypes?",
                  "answer": {
                      "Drug Name": "ivacaftor",
                      "Gene Name": "CFTR",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf",
                      "Content to Search": "Pharmacodynamic data on expected sweat chloride reduction following ivacaftor treatment."
                  }
              },
              {
                  "question": "Which CFTR genotypes are considered responsive to ivacaftor therapy according to the CPIC guideline?",
                  "answer": {
                      "Drug Name": "ivacaftor",
                      "Gene Name": "CFTR",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf",
                      "Content to Search": "List of CFTR genotypes for which ivacaftor therapy is recommended."
                  }
              },
              {
                  "question": "What is the mechanism of action of ivacaftor on the CFTR protein channel?",
                  "answer": {
                      "Drug Name": "ivacaftor",
                      "Gene Name": "CFTR",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf",
                      "Content to Search": "Description of ivacaftor's function as a CFTR potentiator."
                  }
              },
              {
                  "question": "What is the recommended ivacaftor dose for a pediatric patient aged 6-11 with a responsive CFTR genotype?",
                  "answer": {
                      "Drug Name": "ivacaftor",
                      "Gene Name": "CFTR",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf",
                      "Content to Search": "Pediatric dosing protocol for ivacaftor in children aged 6 to 11 years."
                  }
              }
          ]
      },
      {
          "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf": [
              {
                  "question": "What is the recommended efavirenz dose for a CYP2B6 poor metabolizer?",
                  "answer": {
                      "Drug Name": "efavirenz",
                      "Gene Name": "CYP2B6",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf",
                      "Content to Search": "Dose adjustment protocol for efavirenz in CYP2B6 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of CNS adverse effects for a CYP2B6 poor metabolizer taking efavirenz?",
                  "answer": {
                      "Drug Name": "efavirenz",
                      "Gene Name": "CYP2B6",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf",
                      "Content to Search": "Quantified risk data for CNS adverse effects in CYP2B6 poor metabolizers using efavirenz."
                  }
              },
              {
                  "question": "What is the suggested therapeutic range for plasma efavirenz concentrations to minimize toxicity?",
                  "answer": {
                      "Drug Name": "efavirenz",
                      "Gene Name": "CYP2B6",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf",
                      "Content to Search": "Therapeutic window or plasma concentration range for efavirenz."
                  }
              },
              {
                  "question": "What diplotypes define a CYP2B6 intermediate metabolizer?",
                  "answer": {
                      "Drug Name": "efavirenz",
                      "Gene Name": "CYP2B6",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf",
                      "Content to Search": "Diplotype definitions corresponding to the CYP2B6 intermediate metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the function of the CYP2B6*6 allele in efavirenz metabolism?",
                  "answer": {
                      "Drug Name": "efavirenz",
                      "Gene Name": "CYP2B6",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf",
                      "Content to Search": "Description of the CYP2B6*6 allele's impact on enzyme function and efavirenz metabolism."
                  }
              },
              {
                  "question": "What is the dosing recommendation for efavirenz in children weighing <40kg with a CYP2B6 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "efavirenz",
                      "Gene Name": "CYP2B6",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf",
                      "Content to Search": "Pediatric dosing guidance for efavirenz in children under 40kg who are CYP2B6 poor metabolizers."
                  }
              }
          ]
      },
      {
          "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf": [
              {
                  "question": "How should the starting dose of methadone be adjusted for a CYP2B6 ultrarapid metabolizer?",
                  "answer": {
                      "Drug Name": "methadone",
                      "Gene Name": "CYP2B6",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf",
                      "Content to Search": "Dose adjustment protocol for methadone initiation in CYP2B6 ultrarapid metabolizers."
                  }
              },
              {
                  "question": "What is the risk of opioid overdose for a CYP2B6 poor metabolizer on a standard methadone dose?",
                  "answer": {
                      "Drug Name": "methadone",
                      "Gene Name": "CYP2B6",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf",
                      "Content to Search": "Quantified risk data for toxicity or overdose in CYP2B6 poor metabolizers using methadone."
                  }
              },
              {
                  "question": "What is the expected impact of the CYP2B6 ultrarapid metabolizer phenotype on (R)-methadone plasma concentrations?",
                  "answer": {
                      "Drug Name": "methadone",
                      "Gene Name": "CYP2B6",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf",
                      "Content to Search": "Pharmacokinetic data on (R)-methadone plasma levels in CYP2B6 ultrarapid metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes correspond to the CYP2B6 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "methadone",
                      "Gene Name": "CYP2B6",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2B6 poor metabolizer category."
                  }
              },
              {
                  "question": "How does the CYP2B6 enzyme contribute to the metabolism of methadone?",
                  "answer": {
                      "Drug Name": "methadone",
                      "Gene Name": "CYP2B6",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf",
                      "Content to Search": "Description of CYP2B6's role in methadone's metabolic pathway."
                  }
              },
              {
                  "question": "Are there specific methadone dosing recommendations for pregnant patients who are CYP2B6 poor metabolizers?",
                  "answer": {
                      "Drug Name": "methadone",
                      "Gene Name": "CYP2B6",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf",
                      "Content to Search": "Dosing adjustments for methadone in pregnant patients with CYP2B6 poor metabolizer status."
                  }
              }
          ]
      },
      {
          "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf": [
              {
                  "question": "What is the recommended therapeutic alternative to clopidogrel for a CYP2C19 poor metabolizer undergoing percutaneous coronary intervention (PCI)?",
                  "answer": {
                      "Drug Name": "clopidogrel",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf",
                      "Content to Search": "Alternative antiplatelet therapy recommendations for CYP2C19 poor metabolizers post-PCI."
                  }
              },
              {
                  "question": "What is the increased risk of major adverse cardiovascular events (MACE) for a CYP2C19 poor metabolizer taking clopidogrel?",
                  "answer": {
                      "Drug Name": "clopidogrel",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf",
                      "Content to Search": "Risk multipliers or incidence rates for MACE in CYP2C19 poor metabolizers on clopidogrel."
                  }
              },
              {
                  "question": "What is the expected plasma concentration of the active metabolite of clopidogrel in a CYP2C19 ultrarapid metabolizer compared to a normal metabolizer?",
                  "answer": {
                      "Drug Name": "clopidogrel",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf",
                      "Content to Search": "Pharmacokinetic data comparing active metabolite concentrations of clopidogrel across CYP2C19 phenotypes."
                  }
              },
              {
                  "question": "What diplotypes define a CYP2C19 poor metabolizer?",
                  "answer": {
                      "Drug Name": "clopidogrel",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C19 poor metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C19 enzyme in the bioactivation of clopidogrel?",
                  "answer": {
                      "Drug Name": "clopidogrel",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf",
                      "Content to Search": "Explanation of CYP2C19's function in converting clopidogrel to its active metabolite."
                  }
              },
              {
                  "question": "Are there specific clopidogrel dosing recommendations for pediatric patients with a CYP2C19 loss-of-function allele?",
                  "answer": {
                      "Drug Name": "clopidogrel",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf",
                      "Content to Search": "Pediatric dosing guidance for clopidogrel based on CYP2C19 genotype."
                  }
              }
          ]
      },
      {
          "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf": [
              {
                  "question": "What is the recommended dexlansoprazole dose for a CYP2C19 poor metabolizer?",
                  "answer": {
                      "Drug Name": "dexlansoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for dexlansoprazole in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "What is the risk of treatment failure with standard dexlansoprazole dosing for a CYP2C19 ultrarapid metabolizer?",
                  "answer": {
                      "Drug Name": "dexlansoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using dexlansoprazole."
                  }
              },
              {
                  "question": "What is the expected area under the curve (AUC) for dexlansoprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
                  "answer": {
                      "Drug Name": "dexlansoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on dexlansoprazole exposure in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C19 rapid metabolizer?",
                  "answer": {
                      "Drug Name": "dexlansoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Diplotype definitions corresponding to the CYP2C19 rapid metabolizer phenotype."
                  }
              },
              {
                  "question": "How does CYP2C19 polymorphism affect the first-pass metabolism of dexlansoprazole?",
                  "answer": {
                      "Drug Name": "dexlansoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Description of CYP2C19's role in dexlansoprazole's mechanism and metabolism."
                  }
              },
              {
                  "question": "Is dose adjustment for dexlansoprazole needed for pediatric patients who are CYP2C19 poor metabolizers?",
                  "answer": {
                      "Drug Name": "dexlansoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Pediatric dosing guidance for dexlansoprazole in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "What is the recommended esomeprazole dose for a CYP2C19 poor metabolizer?",
                  "answer": {
                      "Drug Name": "esomeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for esomeprazole in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "What is the risk of treatment failure with standard esomeprazole dosing for a CYP2C19 ultrarapid metabolizer?",
                  "answer": {
                      "Drug Name": "esomeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using esomeprazole."
                  }
              },
              {
                  "question": "What is the expected area under the curve (AUC) for esomeprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
                  "answer": {
                      "Drug Name": "esomeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on esomeprazole exposure in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C19 ultrarapid metabolizer?",
                  "answer": {
                      "Drug Name": "esomeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Diplotype definitions corresponding to the CYP2C19 ultrarapid metabolizer phenotype."
                  }
              },
              {
                  "question": "How does CYP2C19 polymorphism affect the first-pass metabolism of esomeprazole?",
                  "answer": {
                      "Drug Name": "esomeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Description of CYP2C19's role in esomeprazole's mechanism and metabolism."
                  }
              },
              {
                  "question": "Is dose adjustment for esomeprazole needed for pediatric patients who are CYP2C19 poor metabolizers?",
                  "answer": {
                      "Drug Name": "esomeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Pediatric dosing guidance for esomeprazole in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "What is the recommended lansoprazole dose for a CYP2C19 poor metabolizer?",
                  "answer": {
                      "Drug Name": "lansoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for lansoprazole in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "What is the risk of treatment failure with standard lansoprazole dosing for a CYP2C19 ultrarapid metabolizer?",
                  "answer": {
                      "Drug Name": "lansoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using lansoprazole."
                  }
              },
              {
                  "question": "What is the expected area under the curve (AUC) for lansoprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
                  "answer": {
                      "Drug Name": "lansoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on lansoprazole exposure in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C19 intermediate metabolizer?",
                  "answer": {
                      "Drug Name": "lansoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Diplotype definitions corresponding to the CYP2C19 intermediate metabolizer phenotype."
                  }
              },
              {
                  "question": "How does CYP2C19 polymorphism affect the first-pass metabolism of lansoprazole?",
                  "answer": {
                      "Drug Name": "lansoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Description of CYP2C19's role in lansoprazole's mechanism and metabolism."
                  }
              },
              {
                  "question": "Is dose adjustment for lansoprazole needed for pediatric patients who are CYP2C19 poor metabolizers?",
                  "answer": {
                      "Drug Name": "lansoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Pediatric dosing guidance for lansoprazole in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "What is the recommended omeprazole dose for a CYP2C19 poor metabolizer?",
                  "answer": {
                      "Drug Name": "omeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for omeprazole in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "What is the risk of treatment failure with standard omeprazole dosing for a CYP2C19 ultrarapid metabolizer?",
                  "answer": {
                      "Drug Name": "omeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using omeprazole."
                  }
              },
              {
                  "question": "What is the expected area under the curve (AUC) for omeprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
                  "answer": {
                      "Drug Name": "omeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on omeprazole exposure in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C19 poor metabolizer?",
                  "answer": {
                      "Drug Name": "omeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Diplotype definitions corresponding to the CYP2C19 poor metabolizer phenotype."
                  }
              },
              {
                  "question": "How does CYP2C19 polymorphism affect the first-pass metabolism of omeprazole?",
                  "answer": {
                      "Drug Name": "omeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Description of CYP2C19's role in omeprazole's mechanism and metabolism."
                  }
              },
              {
                  "question": "Is dose adjustment for omeprazole needed for pediatric patients who are CYP2C19 poor metabolizers?",
                  "answer": {
                      "Drug Name": "omeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Pediatric dosing guidance for omeprazole in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "What is the recommended pantoprazole dose for a CYP2C19 poor metabolizer?",
                  "answer": {
                      "Drug Name": "pantoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for pantoprazole in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "What is the risk of treatment failure with standard pantoprazole dosing for a CYP2C19 ultrarapid metabolizer?",
                  "answer": {
                      "Drug Name": "pantoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using pantoprazole."
                  }
              },
              {
                  "question": "What is the expected area under the curve (AUC) for pantoprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
                  "answer": {
                      "Drug Name": "pantoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on pantoprazole exposure in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C19 normal metabolizer?",
                  "answer": {
                      "Drug Name": "pantoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Diplotype definitions corresponding to the CYP2C19 normal metabolizer phenotype."
                  }
              },
              {
                  "question": "How does CYP2C19 polymorphism affect the first-pass metabolism of pantoprazole?",
                  "answer": {
                      "Drug Name": "pantoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Description of CYP2C19's role in pantoprazole's mechanism and metabolism."
                  }
              },
              {
                  "question": "Is dose adjustment for pantoprazole needed for pediatric patients who are CYP2C19 poor metabolizers?",
                  "answer": {
                      "Drug Name": "pantoprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Pediatric dosing guidance for pantoprazole in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "What is the recommended rabeprazole dose for a CYP2C19 poor metabolizer?",
                  "answer": {
                      "Drug Name": "rabeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for rabeprazole in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "What is the risk of treatment failure with standard rabeprazole dosing for a CYP2C19 ultrarapid metabolizer?",
                  "answer": {
                      "Drug Name": "rabeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using rabeprazole."
                  }
              },
              {
                  "question": "What is the expected area under the curve (AUC) for rabeprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
                  "answer": {
                      "Drug Name": "rabeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on rabeprazole exposure in CYP2C19 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C19 rapid metabolizer?",
                  "answer": {
                      "Drug Name": "rabeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Diplotype definitions corresponding to the CYP2C19 rapid metabolizer phenotype."
                  }
              },
              {
                  "question": "How does CYP2C19 polymorphism affect the first-pass metabolism of rabeprazole?",
                  "answer": {
                      "Drug Name": "rabeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Description of CYP2C19's role in rabeprazole's mechanism and metabolism."
                  }
              },
              {
                  "question": "Is dose adjustment for rabeprazole needed for pediatric patients who are CYP2C19 poor metabolizers?",
                  "answer": {
                      "Drug Name": "rabeprazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
                      "Content to Search": "Pediatric dosing guidance for rabeprazole in CYP2C19 poor metabolizers."
                  }
              }
          ]
      },
      {
          "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf": [
              {
                  "question": "What is the recommended initial intravenous voriconazole dose for a CYP2C19 ultrarapid metabolizer?",
                  "answer": {
                      "Drug Name": "voriconazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf",
                      "Content to Search": "Dose adjustment protocol for intravenous voriconazole in CYP2C19 ultrarapid metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of hepatotoxicity for a CYP2C19 poor metabolizer taking a standard dose of voriconazole?",
                  "answer": {
                      "Drug Name": "voriconazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf",
                      "Content to Search": "Quantified risk data for hepatotoxicity in CYP2C19 poor metabolizers using voriconazole."
                  }
              },
              {
                  "question": "What is the target trough plasma concentration for voriconazole to ensure efficacy and minimize toxicity?",
                  "answer": {
                      "Drug Name": "voriconazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf",
                      "Content to Search": "Therapeutic drug monitoring values or target trough concentration range for voriconazole."
                  }
              },
              {
                  "question": "What diplotypes are classified as CYP2C19 intermediate metabolizers?",
                  "answer": {
                      "Drug Name": "voriconazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C19 intermediate metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the primary metabolic pathway for voriconazole, and what is the role of CYP2C19?",
                  "answer": {
                      "Drug Name": "voriconazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf",
                      "Content to Search": "Description of voriconazole's metabolism and the specific function of the CYP2C19 enzyme."
                  }
              },
              {
                  "question": "How should voriconazole dosing be adjusted for a pediatric patient who is a CYP2C19 poor metabolizer?",
                  "answer": {
                      "Drug Name": "voriconazole",
                      "Gene Name": "CYP2C19",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf",
                      "Content to Search": "Pediatric dosing adjustments for voriconazole in CYP2C19 poor metabolizers."
                  }
              }
          ]
      },
      {
          "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf": [
              {
                  "question": "What is the recommended initial dose of aceclofenac for a patient with a CYP2C9 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "aceclofenac",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for aceclofenac in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking aceclofenac?",
                  "answer": {
                      "Drug Name": "aceclofenac",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using aceclofenac."
                  }
              },
              {
                  "question": "What is the expected increase in aceclofenac exposure (AUC) in a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "aceclofenac",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on aceclofenac exposure in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
                  "answer": {
                      "Drug Name": "aceclofenac",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C9 enzyme in the metabolism of aceclofenac?",
                  "answer": {
                      "Drug Name": "aceclofenac",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's function in aceclofenac's metabolic pathway."
                  }
              },
              {
                  "question": "Are there specific recommendations for aceclofenac use in elderly patients who are also CYP2C9 poor metabolizers?",
                  "answer": {
                      "Drug Name": "aceclofenac",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing guidance for aceclofenac in elderly CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Is a dose adjustment for aceclofenac recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "aceclofenac",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for aceclofenac based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with aceclofenac in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "aceclofenac",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using aceclofenac."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of aceclofenac?",
                  "answer": {
                      "Drug Name": "aceclofenac",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on aceclofenac exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "aceclofenac",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of aceclofenac?",
                  "answer": {
                      "Drug Name": "aceclofenac",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in aceclofenac's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for aceclofenac dosing?",
                  "answer": {
                      "Drug Name": "aceclofenac",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for aceclofenac therapy."
                  }
              },
              {
                  "question": "Is a dose adjustment for low-dose aspirin recommended based on CYP2C9 genotype for cardioprotection?",
                  "answer": {
                      "Drug Name": "aspirin",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing recommendations for low-dose aspirin based on CYP2C9 status."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with high-dose aspirin in patients with reduced-function CYP2C9 alleles?",
                  "answer": {
                      "Drug Name": "aspirin",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Risk data for adverse effects with high-dose aspirin in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "How does the CYP2C9*3 allele affect the pharmacokinetics of aspirin?",
                  "answer": {
                      "Drug Name": "aspirin",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on aspirin related to the CYP2C9*3 allele."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "aspirin",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C9 to the overall clearance of aspirin?",
                  "answer": {
                      "Drug Name": "aspirin",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's role in aspirin metabolism."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for aspirin dosing in any special population?",
                  "answer": {
                      "Drug Name": "aspirin",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for aspirin therapy in special populations."
                  }
              },
              {
                  "question": "Is a dose adjustment for aspirin recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "aspirin",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for aspirin based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with aspirin in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "aspirin",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using aspirin."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of aspirin?",
                  "answer": {
                      "Drug Name": "aspirin",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on aspirin exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "aspirin",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of aspirin?",
                  "answer": {
                      "Drug Name": "aspirin",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in aspirin's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for aspirin dosing?",
                  "answer": {
                      "Drug Name": "aspirin",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for aspirin therapy."
                  }
              },
              {
                  "question": "What is the recommended initial dose of celecoxib for a patient with a CYP2C9 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "celecoxib",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for celecoxib in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of cardiovascular events for a CYP2C9 poor metabolizer taking celecoxib?",
                  "answer": {
                      "Drug Name": "celecoxib",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for cardiovascular events in CYP2C9 poor metabolizers using celecoxib."
                  }
              },
              {
                  "question": "What is the expected increase in celecoxib exposure (AUC) in a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "celecoxib",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on celecoxib exposure in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
                  "answer": {
                      "Drug Name": "celecoxib",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C9 enzyme in the metabolism of celecoxib?",
                  "answer": {
                      "Drug Name": "celecoxib",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's function in celecoxib's metabolic pathway."
                  }
              },
              {
                  "question": "Are there specific recommendations for celecoxib use in pediatric patients who are also CYP2C9 poor metabolizers?",
                  "answer": {
                      "Drug Name": "celecoxib",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing guidance for celecoxib in pediatric CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Is a dose adjustment for celecoxib recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "celecoxib",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for celecoxib based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with celecoxib in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "celecoxib",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using celecoxib."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of celecoxib?",
                  "answer": {
                      "Drug Name": "celecoxib",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on celecoxib exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "celecoxib",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of celecoxib?",
                  "answer": {
                      "Drug Name": "celecoxib",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in celecoxib's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for celecoxib dosing?",
                  "answer": {
                      "Drug Name": "celecoxib",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for celecoxib therapy."
                  }
              },
              {
                  "question": "What is the recommended initial dose of diclofenac for a patient with a CYP2C9 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "diclofenac",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for diclofenac in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of hepatotoxicity for a CYP2C9 poor metabolizer taking diclofenac?",
                  "answer": {
                      "Drug Name": "diclofenac",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for hepatotoxicity in CYP2C9 poor metabolizers using diclofenac."
                  }
              },
              {
                  "question": "What is the expected increase in diclofenac exposure (AUC) in a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "diclofenac",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on diclofenac exposure in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "diclofenac",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C9 enzyme in the metabolism of diclofenac?",
                  "answer": {
                      "Drug Name": "diclofenac",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's function in diclofenac's metabolic pathway."
                  }
              },
              {
                  "question": "Are there specific recommendations for diclofenac use in elderly patients who are also CYP2C9 poor metabolizers?",
                  "answer": {
                      "Drug Name": "diclofenac",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing guidance for diclofenac in elderly CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Is a dose adjustment for diclofenac recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "diclofenac",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for diclofenac based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with diclofenac in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "diclofenac",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using diclofenac."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of diclofenac?",
                  "answer": {
                      "Drug Name": "diclofenac",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on diclofenac exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "diclofenac",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of diclofenac?",
                  "answer": {
                      "Drug Name": "diclofenac",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in diclofenac's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for diclofenac dosing?",
                  "answer": {
                      "Drug Name": "diclofenac",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for diclofenac therapy."
                  }
              },
              {
                  "question": "What is the recommended initial dose of flurbiprofen for a patient with a CYP2C9 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "flurbiprofen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for flurbiprofen in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking flurbiprofen?",
                  "answer": {
                      "Drug Name": "flurbiprofen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using flurbiprofen."
                  }
              },
              {
                  "question": "What is the expected increase in flurbiprofen exposure (AUC) in a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "flurbiprofen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on flurbiprofen exposure in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
                  "answer": {
                      "Drug Name": "flurbiprofen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C9 enzyme in the metabolism of flurbiprofen?",
                  "answer": {
                      "Drug Name": "flurbiprofen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's function in flurbiprofen's metabolic pathway."
                  }
              },
              {
                  "question": "Are there specific recommendations for flurbiprofen use in elderly patients who are also CYP2C9 poor metabolizers?",
                  "answer": {
                      "Drug Name": "flurbiprofen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing guidance for flurbiprofen in elderly CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Is a dose adjustment for flurbiprofen recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "flurbiprofen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for flurbiprofen based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with flurbiprofen in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "flurbiprofen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using flurbiprofen."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of flurbiprofen?",
                  "answer": {
                      "Drug Name": "flurbiprofen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on flurbiprofen exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "flurbiprofen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of flurbiprofen?",
                  "answer": {
                      "Drug Name": "flurbiprofen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in flurbiprofen's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for flurbiprofen dosing?",
                  "answer": {
                      "Drug Name": "flurbiprofen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for flurbiprofen therapy."
                  }
              },
              {
                  "question": "What is the recommended initial dose of ibuprofen for a patient with a CYP2C9 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "ibuprofen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for ibuprofen in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking ibuprofen?",
                  "answer": {
                      "Drug Name": "ibuprofen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using ibuprofen."
                  }
              },
              {
                  "question": "What is the expected increase in ibuprofen exposure (AUC) in a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "ibuprofen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on ibuprofen exposure in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "ibuprofen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C9 enzyme in the metabolism of ibuprofen?",
                  "answer": {
                      "Drug Name": "ibuprofen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's function in ibuprofen's metabolic pathway."
                  }
              },
              {
                  "question": "Are there specific recommendations for ibuprofen use in pediatric patients who are also CYP2C9 poor metabolizers?",
                  "answer": {
                      "Drug Name": "ibuprofen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing guidance for ibuprofen in pediatric CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Is a dose adjustment for ibuprofen recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "ibuprofen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for ibuprofen based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with ibuprofen in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "ibuprofen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using ibuprofen."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of ibuprofen?",
                  "answer": {
                      "Drug Name": "ibuprofen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on ibuprofen exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "ibuprofen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of ibuprofen?",
                  "answer": {
                      "Drug Name": "ibuprofen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in ibuprofen's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for ibuprofen dosing in pediatric patients?",
                  "answer": {
                      "Drug Name": "ibuprofen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for ibuprofen therapy in pediatric populations."
                  }
              },
              {
                  "question": "What is the recommended initial dose of indomethacin for a patient with a CYP2C9 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "indomethacin",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for indomethacin in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking indomethacin?",
                  "answer": {
                      "Drug Name": "indomethacin",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using indomethacin."
                  }
              },
              {
                  "question": "What is the expected increase in indomethacin exposure (AUC) in a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "indomethacin",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on indomethacin exposure in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
                  "answer": {
                      "Drug Name": "indomethacin",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C9 enzyme in the metabolism of indomethacin?",
                  "answer": {
                      "Drug Name": "indomethacin",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's function in indomethacin's metabolic pathway."
                  }
              },
              {
                  "question": "Are there specific recommendations for indomethacin use in elderly patients who are also CYP2C9 poor metabolizers?",
                  "answer": {
                      "Drug Name": "indomethacin",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing guidance for indomethacin in elderly CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Is a dose adjustment for indomethacin recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "indomethacin",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for indomethacin based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with indomethacin in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "indomethacin",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using indomethacin."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of indomethacin?",
                  "answer": {
                      "Drug Name": "indomethacin",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on indomethacin exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "indomethacin",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of indomethacin?",
                  "answer": {
                      "Drug Name": "indomethacin",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in indomethacin's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for indomethacin dosing?",
                  "answer": {
                      "Drug Name": "indomethacin",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for indomethacin therapy."
                  }
              },
              {
                  "question": "What is the recommended initial dose of lornoxicam for a patient with a CYP2C9 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "lornoxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for lornoxicam in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking lornoxicam?",
                  "answer": {
                      "Drug Name": "lornoxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using lornoxicam."
                  }
              },
              {
                  "question": "What is the expected increase in lornoxicam exposure (AUC) in a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "lornoxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on lornoxicam exposure in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "lornoxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C9 enzyme in the metabolism of lornoxicam?",
                  "answer": {
                      "Drug Name": "lornoxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's function in lornoxicam's metabolic pathway."
                  }
              },
              {
                  "question": "Are there specific recommendations for lornoxicam use in elderly patients who are also CYP2C9 poor metabolizers?",
                  "answer": {
                      "Drug Name": "lornoxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing guidance for lornoxicam in elderly CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Is a dose adjustment for lornoxicam recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "lornoxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for lornoxicam based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with lornoxicam in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "lornoxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using lornoxicam."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of lornoxicam?",
                  "answer": {
                      "Drug Name": "lornoxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on lornoxicam exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "lornoxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of lornoxicam?",
                  "answer": {
                      "Drug Name": "lornoxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in lornoxicam's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for lornoxicam dosing?",
                  "answer": {
                      "Drug Name": "lornoxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for lornoxicam therapy."
                  }
              },
              {
                  "question": "What is the recommended initial dose of lumiracoxib for a patient with a CYP2C9 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "lumiracoxib",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for lumiracoxib in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of hepatotoxicity for a CYP2C9 poor metabolizer taking lumiracoxib?",
                  "answer": {
                      "Drug Name": "lumiracoxib",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for hepatotoxicity in CYP2C9 poor metabolizers using lumiracoxib."
                  }
              },
              {
                  "question": "What is the expected increase in lumiracoxib exposure (AUC) in a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "lumiracoxib",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on lumiracoxib exposure in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
                  "answer": {
                      "Drug Name": "lumiracoxib",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C9 enzyme in the metabolism of lumiracoxib?",
                  "answer": {
                      "Drug Name": "lumiracoxib",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's function in lumiracoxib's metabolic pathway."
                  }
              },
              {
                  "question": "Are there specific recommendations for lumiracoxib use in elderly patients who are also CYP2C9 poor metabolizers?",
                  "answer": {
                      "Drug Name": "lumiracoxib",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing guidance for lumiracoxib in elderly CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Is a dose adjustment for lumiracoxib recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "lumiracoxib",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for lumiracoxib based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with lumiracoxib in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "lumiracoxib",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using lumiracoxib."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of lumiracoxib?",
                  "answer": {
                      "Drug Name": "lumiracoxib",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on lumiracoxib exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "lumiracoxib",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of lumiracoxib?",
                  "answer": {
                      "Drug Name": "lumiracoxib",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in lumiracoxib's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for lumiracoxib dosing?",
                  "answer": {
                      "Drug Name": "lumiracoxib",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for lumiracoxib therapy."
                  }
              },
              {
                  "question": "What is the recommended initial dose of meloxicam for a patient with a CYP2C9 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "meloxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for meloxicam in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking meloxicam?",
                  "answer": {
                      "Drug Name": "meloxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using meloxicam."
                  }
              },
              {
                  "question": "What is the expected increase in meloxicam exposure (AUC) in a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "meloxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on meloxicam exposure in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "meloxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C9 enzyme in the metabolism of meloxicam?",
                  "answer": {
                      "Drug Name": "meloxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's function in meloxicam's metabolic pathway."
                  }
              },
              {
                  "question": "Are there specific recommendations for meloxicam use in elderly patients who are also CYP2C9 poor metabolizers?",
                  "answer": {
                      "Drug Name": "meloxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing guidance for meloxicam in elderly CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Is a dose adjustment for meloxicam recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "meloxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for meloxicam based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with meloxicam in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "meloxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using meloxicam."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of meloxicam?",
                  "answer": {
                      "Drug Name": "meloxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on meloxicam exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "meloxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of meloxicam?",
                  "answer": {
                      "Drug Name": "meloxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in meloxicam's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for meloxicam dosing?",
                  "answer": {
                      "Drug Name": "meloxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for meloxicam therapy."
                  }
              },
              {
                  "question": "What is the recommended initial dose of nabumetone for a patient with a CYP2C9 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "nabumetone",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for nabumetone in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking nabumetone?",
                  "answer": {
                      "Drug Name": "nabumetone",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using nabumetone."
                  }
              },
              {
                  "question": "What is the expected increase in exposure to nabumetone's active metabolite in a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "nabumetone",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on nabumetone's active metabolite exposure in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
                  "answer": {
                      "Drug Name": "nabumetone",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C9 enzyme in the metabolism of nabumetone's active metabolite?",
                  "answer": {
                      "Drug Name": "nabumetone",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's function in the metabolic pathway of nabumetone's active metabolite."
                  }
              },
              {
                  "question": "Are there specific recommendations for nabumetone use in elderly patients who are also CYP2C9 poor metabolizers?",
                  "answer": {
                      "Drug Name": "nabumetone",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing guidance for nabumetone in elderly CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Is a dose adjustment for nabumetone recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "nabumetone",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for nabumetone based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with nabumetone in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "nabumetone",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using nabumetone."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of nabumetone?",
                  "answer": {
                      "Drug Name": "nabumetone",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on nabumetone exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "nabumetone",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of nabumetone?",
                  "answer": {
                      "Drug Name": "nabumetone",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in nabumetone's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for nabumetone dosing?",
                  "answer": {
                      "Drug Name": "nabumetone",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for nabumetone therapy."
                  }
              },
              {
                  "question": "What is the recommended initial dose of naproxen for a patient with a CYP2C9 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "naproxen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for naproxen in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking naproxen?",
                  "answer": {
                      "Drug Name": "naproxen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using naproxen."
                  }
              },
              {
                  "question": "What is the expected increase in naproxen exposure (AUC) in a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "naproxen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on naproxen exposure in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "naproxen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C9 enzyme in the metabolism of naproxen?",
                  "answer": {
                      "Drug Name": "naproxen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's function in naproxen's metabolic pathway."
                  }
              },
              {
                  "question": "Are there specific recommendations for naproxen use in elderly patients who are also CYP2C9 poor metabolizers?",
                  "answer": {
                      "Drug Name": "naproxen",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing guidance for naproxen in elderly CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Is a dose adjustment for naproxen recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "naproxen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for naproxen based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with naproxen in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "naproxen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using naproxen."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of naproxen?",
                  "answer": {
                      "Drug Name": "naproxen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on naproxen exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "naproxen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of naproxen?",
                  "answer": {
                      "Drug Name": "naproxen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in naproxen's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for naproxen dosing?",
                  "answer": {
                      "Drug Name": "naproxen",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for naproxen therapy."
                  }
              },
              {
                  "question": "What is the recommended initial dose of piroxicam for a patient with a CYP2C9 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "piroxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for piroxicam in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking piroxicam?",
                  "answer": {
                      "Drug Name": "piroxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using piroxicam."
                  }
              },
              {
                  "question": "What is the expected increase in piroxicam exposure (AUC) in a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "piroxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on piroxicam exposure in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
                  "answer": {
                      "Drug Name": "piroxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C9 enzyme in the metabolism of piroxicam?",
                  "answer": {
                      "Drug Name": "piroxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's function in piroxicam's metabolic pathway."
                  }
              },
              {
                  "question": "Are there specific recommendations for piroxicam use in elderly patients who are also CYP2C9 poor metabolizers?",
                  "answer": {
                      "Drug Name": "piroxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing guidance for piroxicam in elderly CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Is a dose adjustment for piroxicam recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "piroxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for piroxicam based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with piroxicam in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "piroxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using piroxicam."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of piroxicam?",
                  "answer": {
                      "Drug Name": "piroxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on piroxicam exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "piroxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of piroxicam?",
                  "answer": {
                      "Drug Name": "piroxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in piroxicam's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for piroxicam dosing?",
                  "answer": {
                      "Drug Name": "piroxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for piroxicam therapy."
                  }
              },
              {
                  "question": "What is the recommended initial dose of tenoxicam for a patient with a CYP2C9 poor metabolizer phenotype?",
                  "answer": {
                      "Drug Name": "tenoxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for tenoxicam in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking tenoxicam?",
                  "answer": {
                      "Drug Name": "tenoxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using tenoxicam."
                  }
              },
              {
                  "question": "What is the expected increase in tenoxicam exposure (AUC) in a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "tenoxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on tenoxicam exposure in CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
                  "answer": {
                      "Drug Name": "tenoxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
                  }
              },
              {
                  "question": "What is the role of the CYP2C9 enzyme in the metabolism of tenoxicam?",
                  "answer": {
                      "Drug Name": "tenoxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C9's function in tenoxicam's metabolic pathway."
                  }
              },
              {
                  "question": "Are there specific recommendations for tenoxicam use in elderly patients who are also CYP2C9 poor metabolizers?",
                  "answer": {
                      "Drug Name": "tenoxicam",
                      "Gene Name": "CYP2C9",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dosing guidance for tenoxicam in elderly CYP2C9 poor metabolizers."
                  }
              },
              {
                  "question": "Is a dose adjustment for tenoxicam recommended based on CYP2C8 genotype?",
                  "answer": {
                      "Drug Name": "tenoxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Dose adjustment protocol for tenoxicam based on CYP2C8 genotype."
                  }
              },
              {
                  "question": "Is there an increased risk of adverse events with tenoxicam in patients with reduced-function CYP2C8 alleles?",
                  "answer": {
                      "Drug Name": "tenoxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using tenoxicam."
                  }
              },
              {
                  "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of tenoxicam?",
                  "answer": {
                      "Drug Name": "tenoxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Pharmacokinetic data on tenoxicam exposure related to the CYP2C8*3 allele."
                  }
              },
              {
                  "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
                  "answer": {
                      "Drug Name": "tenoxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Allele function table or definitions for CYP2C8."
                  }
              },
              {
                  "question": "What is the contribution of CYP2C8 to the overall clearance of tenoxicam?",
                  "answer": {
                      "Drug Name": "tenoxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Description of CYP2C8's role in tenoxicam's metabolic pathway."
                  }
              },
              {
                  "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for tenoxicam dosing?",
                  "answer": {
                      "Drug Name": "tenoxicam",
                      "Gene Name": "CYP2C8",
                      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
                      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for tenoxicam therapy."
                  }
              }
          ]
      },
      {
      "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf": [
        {
          "question": "What is the recommended initial fosphenytoin dose for an adult who is a CYP2C9 intermediate metabolizer?",
          "answer": {
            "Drug Name": "fosphenytoin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Dose adjustment protocol for fosphenytoin in CYP2C9 intermediate metabolizers"
          }
        },
        {
          "question": "What is the increased risk of neurotoxicity from fosphenytoin in a CYP2C9 poor metabolizer?",
          "answer": {
            "Drug Name": "fosphenytoin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Quantified risk data for neurotoxicity in CYP2C9 poor metabolizers using fosphenytoin"
          }
        },
        {
          "question": "How does the CYP2C9 poor metabolizer phenotype affect the plasma concentration of phenytoin after fosphenytoin administration?",
          "answer": {
            "Drug Name": "fosphenytoin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Plasma concentration data for phenytoin in CYP2C9 poor metabolizers after fosphenytoin administration"
          }
        },
        {
          "question": "What diplotypes define a CYP2C9 intermediate metabolizer?",
          "answer": {
            "Drug Name": "fosphenytoin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype"
          }
        },
        {
          "question": "How is fosphenytoin converted to phenytoin, and what is the role of CYP2C9 in the subsequent metabolism?",
          "answer": {
            "Drug Name": "fosphenytoin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Mechanism of fosphenytoin conversion and the role of CYP2C9 in phenytoin metabolism"
          }
        },
        {
          "question": "What is the fosphenytoin dosing recommendation for a neonate with a CYP2C9 poor metabolizer phenotype?",
          "answer": {
            "Drug Name": "fosphenytoin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for fosphenytoin in neonates with CYP2C9 poor metabolizer status"
          }
        },
        {
          "question": "What is the dosing recommendation for fosphenytoin in a patient who is positive for the HLA-B*15:02 allele?",
          "answer": {
            "Drug Name": "fosphenytoin",
            "Gene Name": "HLA-B",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Dosing recommendation or alternative therapy for fosphenytoin in HLA-B*15:02 positive individuals"
          }
        },
        {
          "question": "What is the quantified risk of fosphenytoin-induced toxic epidermal necrolysis (TEN) in an HLA-B*15:02 carrier?",
          "answer": {
            "Drug Name": "fosphenytoin",
            "Gene Name": "HLA-B",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Incidence rates or risk multipliers for TEN in HLA-B*15:02 carriers taking fosphenytoin"
          }
        },
        {
          "question": "Does the presence of the HLA-B*15:02 allele alter the pharmacokinetic profile of phenytoin derived from fosphenytoin?",
          "answer": {
            "Drug Name": "fosphenytoin",
            "Gene Name": "HLA-B",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Pharmacokinetic data (e.g., plasma concentration) of phenytoin based on HLA-B*15:02 status after fosphenytoin administration"
          }
        },
        {
          "question": "What is the correspondence between the HLA-B*15:02 genotype and the phenotype of high risk for fosphenytoin-induced SJS/TEN?",
          "answer": {
            "Drug Name": "fosphenytoin",
            "Gene Name": "HLA-B",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Definition of the high-risk phenotype associated with the HLA-B*15:02 allele for fosphenytoin use"
          }
        },
        {
          "question": "What is the mechanism by which the HLA-B*15:02 allele is thought to trigger an adverse immune response to fosphenytoin?",
          "answer": {
            "Drug Name": "fosphenytoin",
            "Gene Name": "HLA-B",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Immunological mechanism of HLA-B*15:02-mediated adverse reaction to fosphenytoin"
          }
        },
        {
          "question": "In which pediatric populations is HLA-B*15:02 screening recommended before initiating fosphenytoin therapy?",
          "answer": {
            "Drug Name": "fosphenytoin",
            "Gene Name": "HLA-B",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Recommendations for HLA-B*15:02 screening in specific pediatric or ethnic populations before fosphenytoin use"
          }
        },
        {
          "question": "What is the recommended initial phenytoin dose for a CYP2C9 poor metabolizer?",
          "answer": {
            "Drug Name": "phenytoin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Initial dose and adjustment protocol for phenytoin in CYP2C9 poor metabolizers"
          }
        },
        {
          "question": "What is the increased risk of phenytoin toxicity for a CYP2C9 intermediate metabolizer?",
          "answer": {
            "Drug Name": "phenytoin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Quantified risk data for phenytoin toxicity in CYP2C9 intermediate metabolizers"
          }
        },
        {
          "question": "What is the target therapeutic range for plasma phenytoin concentrations?",
          "answer": {
            "Drug Name": "phenytoin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Therapeutic window or plasma concentration range for phenytoin"
          }
        },
        {
          "question": "What diplotypes define a CYP2C9 poor metabolizer?",
          "answer": {
            "Drug Name": "phenytoin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype"
          }
        },
        {
          "question": "What is the role of the CYP2C9 enzyme in phenytoin metabolism?",
          "answer": {
            "Drug Name": "phenytoin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Function of CYP2C9 enzyme in the metabolic pathway of phenytoin"
          }
        },
        {
          "question": "What is the recommended phenytoin dosing adjustment for a pediatric patient who is a CYP2C9 poor metabolizer?",
          "answer": {
            "Drug Name": "phenytoin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Pediatric dosing adjustments for phenytoin based on CYP2C9 poor metabolizer status"
          }
        },
        {
          "question": "How should phenytoin dosing be managed for a patient who is a positive carrier of the HLA-B*15:02 allele?",
          "answer": {
            "Drug Name": "phenytoin",
            "Gene Name": "HLA-B",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Clinical recommendation for phenytoin use in HLA-B*15:02 positive patients"
          }
        },
        {
          "question": "What is the risk of developing Stevens-Johnson syndrome (SJS) when taking phenytoin for a patient with the HLA-B*15:02 allele?",
          "answer": {
            "Drug Name": "phenytoin",
            "Gene Name": "HLA-B",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Risk multiplier or incidence rate of SJS in HLA-B*15:02 carriers using phenytoin"
          }
        },
        {
          "question": "Is there an established therapeutic window for phenytoin that differs based on HLA-B genotype?",
          "answer": {
            "Drug Name": "phenytoin",
            "Gene Name": "HLA-B",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Information on whether HLA-B genotype affects the therapeutic range of phenytoin"
          }
        },
        {
          "question": "Which HLA-B allele is most strongly associated with phenytoin-induced severe cutaneous adverse reactions (SCARs)?",
          "answer": {
            "Drug Name": "phenytoin",
            "Gene Name": "HLA-B",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Specific HLA-B allele linked to high risk of SCARs with phenytoin"
          }
        },
        {
          "question": "What is the function of the HLA-B gene in the immune system?",
          "answer": {
            "Drug Name": "phenytoin",
            "Gene Name": "HLA-B",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Basic function and role of the HLA-B gene"
          }
        },
        {
          "question": "Are there specific recommendations regarding phenytoin use and HLA-B*15:02 testing in certain ethnic populations?",
          "answer": {
            "Drug Name": "phenytoin",
            "Gene Name": "HLA-B",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
            "Content to Search": "Recommendations for HLA-B*15:02 screening in specific populations before phenytoin initiation"
          }
        }
      ]
    },
    {
      "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf": [
        {
          "question": "How should the initial warfarin dose be adjusted for a patient with a CYP2C9 *3/*3 genotype (poor metabolizer)?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Dose adjustment protocol or dosing algorithm for warfarin in CYP2C9 poor metabolizers"
          }
        },
        {
          "question": "What is the increased risk of bleeding for a warfarin patient who is a CYP2C9 intermediate metabolizer?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Quantified risk data for bleeding events in CYP2C9 intermediate metabolizers on warfarin"
          }
        },
        {
          "question": "What is the target INR (International Normalized Ratio) range for a patient on warfarin, and how does CYP2C9 genotype affect the time to reach this range?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Data on time to stable INR based on CYP2C9 genotype"
          }
        },
        {
          "question": "What diplotypes define a CYP2C9 intermediate metabolizer in the context of warfarin dosing?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype"
          }
        },
        {
          "question": "What is the function of the CYP2C9 enzyme in the metabolism of warfarin?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Role of CYP2C9 in the metabolic pathway of S-warfarin"
          }
        },
        {
          "question": "What is the recommended warfarin dosing algorithm for a pediatric patient with a CYP2C9 poor metabolizer phenotype?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Pediatric-specific warfarin dosing guidance for CYP2C9 poor metabolizers"
          }
        },
        {
          "question": "How does the presence of the CYP4F2*3 allele influence the stable maintenance dose of warfarin?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "CYP4F2",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Percentage or numerical dose adjustment for warfarin in carriers of the CYP4F2*3 allele"
          }
        },
        {
          "question": "Is there a quantified risk of subtherapeutic INR associated with the CYP4F2*3 variant in patients taking warfarin?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "CYP4F2",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Risk data for achieving subtherapeutic INR in patients with the CYP4F2*3 variant"
          }
        },
        {
          "question": "What is the effect of the CYP4F2*3 variant on vitamin K plasma concentrations during warfarin therapy?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "CYP4F2",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Data on plasma vitamin K levels in relation to CYP4F2 genotype"
          }
        },
        {
          "question": "What CYP4F2 genotype is associated with a need for a higher warfarin dose?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "CYP4F2",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Definition of the CYP4F2 genotype that requires increased warfarin dosage"
          }
        },
        {
          "question": "What is the function of the CYP4F2 enzyme in relation to vitamin K metabolism?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "CYP4F2",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Role of the CYP4F2 enzyme in the vitamin K cycle"
          }
        },
        {
          "question": "Are there specific warfarin dosing considerations for patients with the CYP4F2*3 variant and comorbid liver disease?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "CYP4F2",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Dosing adjustments for warfarin in patients with both CYP4F2*3 variant and liver comorbidities"
          }
        },
        {
          "question": "What is the recommended starting dose of warfarin for a patient with the VKORC1 -1639G>A (AA) genotype, indicating increased sensitivity?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "VKORC1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Specific starting dose or dose reduction percentage for warfarin in patients with VKORC1 -1639G>A (AA) genotype"
          }
        },
        {
          "question": "What is the relative risk of over-anticoagulation for a patient with a sensitive VKORC1 genotype when starting warfarin?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "VKORC1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Quantified risk data for supratherapeutic INR in patients with a sensitive VKORC1 genotype"
          }
        },
        {
          "question": "How does the VKORC1 -1639G>A genotype affect the pharmacodynamics of warfarin, specifically the dose-response relationship?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "VKORC1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Pharmacodynamic data describing the effect of VKORC1 genotype on warfarin dose-response"
          }
        },
        {
          "question": "What VKORC1 genotypes correspond to the 'high sensitivity' phenotype for warfarin?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "VKORC1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Genotype definitions for the high sensitivity warfarin phenotype related to VKORC1"
          }
        },
        {
          "question": "What is the role of the VKORC1 enzyme in the vitamin K cycle, and how does warfarin inhibit it?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "VKORC1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Mechanism of action of warfarin on the VKORC1 enzyme within the vitamin K cycle"
          }
        },
        {
          "question": "How is warfarin dosing adjusted for an elderly patient with a sensitive VKORC1 genotype?",
          "answer": {
            "Drug Name": "warfarin",
            "Gene Name": "VKORC1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
            "Content to Search": "Dosing recommendations for warfarin in elderly patients with a sensitive VKORC1 genotype"
          }
        }
      ]
    },
    {
      "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf": [
        {
          "question": "What is the recommended atomoxetine starting dose for a CYP2D6 poor metabolizer?",
          "answer": {
            "Drug Name": "atomoxetine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf",
            "Content to Search": "Recommended starting dose and titration schedule for atomoxetine in CYP2D6 poor metabolizers"
          }
        },
        {
          "question": "What is the increased risk of cardiovascular adverse effects for a CYP2D6 poor metabolizer taking atomoxetine?",
          "answer": {
            "Drug Name": "atomoxetine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf",
            "Content to Search": "Quantified risk data for adverse effects like increased blood pressure or tachycardia in CYP2D6 poor metabolizers"
          }
        },
        {
          "question": "What is the expected plasma concentration (AUC) of atomoxetine in a CYP2D6 poor metabolizer compared to a normal metabolizer?",
          "answer": {
            "Drug Name": "atomoxetine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf",
            "Content to Search": "Pharmacokinetic data, specifically area under the curve (AUC) values, for atomoxetine in CYP2D6 poor vs. normal metabolizers"
          }
        },
        {
          "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
          "answer": {
            "Drug Name": "atomoxetine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf",
            "Content to Search": "Diplotype definitions and corresponding activity scores for the CYP2D6 ultrarapid metabolizer phenotype"
          }
        },
        {
          "question": "What is the primary metabolic pathway for atomoxetine, and what is the role of the CYP2D6 enzyme?",
          "answer": {
            "Drug Name": "atomoxetine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf",
            "Content to Search": "Description of atomoxetine metabolism and the specific function of the CYP2D6 enzyme in that process"
          }
        },
        {
          "question": "What is the recommended atomoxetine dose for a child weighing over 70kg who is a CYP2D6 poor metabolizer?",
          "answer": {
            "Drug Name": "atomoxetine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf",
            "Content to Search": "Specific dosing guidance for atomoxetine in pediatric patients >70kg with CYP2D6 poor metabolizer status"
          }
        }
      ]
    },
      {
        "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf": [
            {
                "question": "What is the recommended ondansetron dosing adjustment for a CYP2D6 ultrarapid metabolizer?",
                "answer": {
                    "Drug Name": "ondansetron",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
                    "Content to Search": "Dose adjustment protocol or alternative therapy for ondansetron in CYP2D6 ultrarapid metabolizers"
                }
            },
            {
                "question": "What is the increased risk of treatment failure for a CYP2D6 ultrarapid metabolizer taking a standard dose of ondansetron?",
                "answer": {
                    "Drug Name": "ondansetron",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
                    "Content to Search": "Quantified risk data for lack of efficacy in CYP2D6 ultrarapid metabolizers using ondansetron"
                }
            },
            {
                "question": "What are the expected plasma concentrations of ondansetron in a CYP2D6 poor metabolizer compared to a normal metabolizer?",
                "answer": {
                    "Drug Name": "ondansetron",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
                    "Content to Search": "Plasma concentration data or pharmacokinetic parameters for ondansetron in CYP2D6 poor metabolizers"
                }
            },
            {
                "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
                "answer": {
                    "Drug Name": "ondansetron",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2D6 ultrarapid metabolizer phenotype"
                }
            },
            {
                "question": "What is the role of the CYP2D6 enzyme in the metabolism of ondansetron?",
                "answer": {
                    "Drug Name": "ondansetron",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
                    "Content to Search": "Description of CYP2D6's metabolic pathway for ondansetron"
                }
            },
            {
                "question": "Are there specific ondansetron dosing recommendations for pediatric CYP2D6 ultrarapid metabolizers?",
                "answer": {
                    "Drug Name": "ondansetron",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
                    "Content to Search": "Pediatric dosing recommendations for ondansetron based on CYP2D6 ultrarapid metabolizer status"
                }
            },
            {
                "question": "How should tropisetron dosing be modified for a CYP2D6 poor metabolizer?",
                "answer": {
                    "Drug Name": "tropisetron",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
                    "Content to Search": "Dose modification protocol for tropisetron in CYP2D6 poor metabolizers"
                }
            },
            {
                "question": "What is the quantified risk of adverse effects for CYP2D6 poor metabolizers when using tropisetron?",
                "answer": {
                    "Drug Name": "tropisetron",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
                    "Content to Search": "Incidence rates or risk multipliers for adverse effects in CYP2D6 poor metabolizers taking tropisetron"
                }
            },
            {
                "question": "What is the suggested therapeutic range for plasma tropisetron concentrations?",
                "answer": {
                    "Drug Name": "tropisetron",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
                    "Content to Search": "Therapeutic range for plasma tropisetron concentrations"
                }
            },
            {
                "question": "What diplotypes define a CYP2D6 poor metabolizer?",
                "answer": {
                    "Drug Name": "tropisetron",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2D6 poor metabolizer phenotype"
                }
            },
            {
                "question": "What is the function of the CYP2D6*4 allele in relation to drug metabolism?",
                "answer": {
                    "Drug Name": "tropisetron",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
                    "Content to Search": "Functional description of the non-functional CYP2D6*4 allele"
                }
            },
            {
                "question": "What is the recommended tropisetron dose for a pregnant patient who is a CYP2D6 poor metabolizer?",
                "answer": {
                    "Drug Name": "tropisetron",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
                    "Content to Search": "Dosing guidance for tropisetron in pregnant CYP2D6 poor metabolizers"
                }
            }
        ]
    },
    {
        "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf": [
            {
                "question": "What is the recommended alternative therapy to tamoxifen for a CYP2D6 poor metabolizer with breast cancer?",
                "answer": {
                    "Drug Name": "tamoxifen",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf",
                    "Content to Search": "Alternative therapy recommendations for tamoxifen in CYP2D6 poor metabolizers"
                }
            },
            {
                "question": "What is the increased risk of breast cancer recurrence for a CYP2D6 intermediate metabolizer on tamoxifen therapy?",
                "answer": {
                    "Drug Name": "tamoxifen",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf",
                    "Content to Search": "Quantified risk of disease recurrence for CYP2D6 intermediate metabolizers taking tamoxifen"
                }
            },
            {
                "question": "What are the target plasma concentrations for endoxifen, the active metabolite of tamoxifen?",
                "answer": {
                    "Drug Name": "tamoxifen",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf",
                    "Content to Search": "Therapeutic plasma concentration range for endoxifen"
                }
            },
            {
                "question": "Which CYP2D6 diplotypes are classified as intermediate metabolizers?",
                "answer": {
                    "Drug Name": "tamoxifen",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2D6 intermediate metabolizer phenotype"
                }
            },
            {
                "question": "How does the CYP2D6 enzyme contribute to the bioactivation of tamoxifen?",
                "answer": {
                    "Drug Name": "tamoxifen",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf",
                    "Content to Search": "Mechanism of tamoxifen's metabolic activation to endoxifen by CYP2D6"
                }
            },
            {
                "question": "Are there specific tamoxifen dosing considerations for postmenopausal CYP2D6 poor metabolizers?",
                "answer": {
                    "Drug Name": "tamoxifen",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf",
                    "Content to Search": "Dosing or therapy recommendations for postmenopausal CYP2D6 poor metabolizers on tamoxifen"
                }
            }
        ]
    },
    {
    "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf": [
        {
        "question": "What is the recommended dosing adjustment for atazanavir in a patient with a UGT1A1 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "atazanavir",
            "Gene Name": "UGT1A1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf",
            "Content to Search": "Dosing adjustment protocol or alternative therapy recommendation for atazanavir in UGT1A1 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of hyperbilirubinemia for a UGT1A1 poor metabolizer taking atazanavir?",
        "answer": {
            "Drug Name": "atazanavir",
            "Gene Name": "UGT1A1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf",
            "Content to Search": "Quantified risk data (e.g., odds ratio, incidence rate) of hyperbilirubinemia in UGT1A1 poor metabolizers taking atazanavir."
        }
        },
        {
        "question": "What is the expected impact on bilirubin concentrations in a UGT1A1 poor metabolizer treated with atazanavir?",
        "answer": {
            "Drug Name": "atazanavir",
            "Gene Name": "UGT1A1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf",
            "Content to Search": "Expected bilirubin concentration levels or changes in UGT1A1 poor metabolizers on atazanavir therapy."
        }
        },
        {
        "question": "Which UGT1A1 diplotypes correspond to the intermediate metabolizer phenotype?",
        "answer": {
            "Drug Name": "atazanavir",
            "Gene Name": "UGT1A1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf",
            "Content to Search": "List of UGT1A1 diplotypes that define the intermediate metabolizer phenotype."
        }
        },
        {
        "question": "What is the role of the UGT1A1 enzyme in the metabolism of atazanavir?",
        "answer": {
            "Drug Name": "atazanavir",
            "Gene Name": "UGT1A1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf",
            "Content to Search": "Mechanism of UGT1A1-mediated atazanavir metabolism and its role in bilirubin conjugation."
        }
        },
        {
        "question": "Are there specific atazanavir dosing recommendations for pediatric patients with a UGT1A1 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "atazanavir",
            "Gene Name": "UGT1A1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf",
            "Content to Search": "Atazanavir dosing guidelines for pediatric patients with the UGT1A1 poor metabolizer phenotype."
        }
        }
    ]
    },
        {
        "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf": [
            {
                "question": "What is the recommended starting dose of tacrolimus for a CYP3A5 expresser (intermediate metabolizer)?",
                "answer": {
                    "Drug Name": "tacrolimus",
                    "Gene Name": "CYP3A5",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf",
                    "Content to Search": "Recommended tacrolimus starting dose for CYP3A5 intermediate metabolizers"
                }
            },
            {
                "question": "What is the risk of supratherapeutic tacrolimus concentrations for a CYP3A5 non-expresser (poor metabolizer)?",
                "answer": {
                    "Drug Name": "tacrolimus",
                    "Gene Name": "CYP3A5",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf",
                    "Content to Search": "Quantified risk of toxicity or supratherapeutic concentrations in CYP3A5 poor metabolizers taking tacrolimus"
                }
            },
            {
                "question": "What is the target therapeutic trough concentration range for tacrolimus?",
                "answer": {
                    "Drug Name": "tacrolimus",
                    "Gene Name": "CYP3A5",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf",
                    "Content to Search": "Therapeutic trough concentration range for tacrolimus"
                }
            },
            {
                "question": "Which diplotypes correspond to a CYP3A5 non-expresser (poor metabolizer) phenotype?",
                "answer": {
                    "Drug Name": "tacrolimus",
                    "Gene Name": "CYP3A5",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf",
                    "Content to Search": "Diplotype definitions for the CYP3A5 poor metabolizer phenotype"
                }
            },
            {
                "question": "What is the role of the CYP3A5 enzyme in tacrolimus metabolism?",
                "answer": {
                    "Drug Name": "tacrolimus",
                    "Gene Name": "CYP3A5",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf",
                    "Content to Search": "Function of CYP3A5 enzyme in the metabolic pathway of tacrolimus"
                }
            },
            {
                "question": "What is the recommended tacrolimus dosing for a pediatric kidney transplant recipient who is a CYP3A5 expresser?",
                "answer": {
                    "Drug Name": "tacrolimus",
                    "Gene Name": "CYP3A5",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf",
                    "Content to Search": "Pediatric dosing recommendations for tacrolimus in CYP3A5 expressers"
                }
            }
        ]
    },
    {
        "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf": [
            {
                "question": "How should capecitabine dosing be adjusted for a DPYD intermediate metabolizer?",
                "answer": {
                    "Drug Name": "capecitabine",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Dose adjustment protocol for capecitabine in DPYD intermediate metabolizers"
                }
            },
            {
                "question": "What is the increased risk of severe toxicity for a DPYD poor metabolizer taking capecitabine?",
                "answer": {
                    "Drug Name": "capecitabine",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Quantified risk data for severe toxicity in DPYD poor metabolizers using capecitabine"
                }
            },
            {
                "question": "What is the effect of DPYD poor metabolizer status on fluorouracil (the active metabolite of capecitabine) clearance?",
                "answer": {
                    "Drug Name": "capecitabine",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Pharmacokinetic data on fluorouracil clearance in DPYD poor metabolizers after capecitabine administration"
                }
            },
            {
                "question": "What diplotypes define a DPYD poor metabolizer?",
                "answer": {
                    "Drug Name": "capecitabine",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Diplotype definitions for the DPYD poor metabolizer phenotype"
                }
            },
            {
                "question": "What is the function of the DPYD gene in fluoropyrimidine metabolism?",
                "answer": {
                    "Drug Name": "capecitabine",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Role of the DPYD enzyme in the catabolism of fluoropyrimidines"
                }
            },
            {
                "question": "Are there specific capecitabine dosing recommendations for pediatric patients with DPYD deficiency?",
                "answer": {
                    "Drug Name": "capecitabine",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Pediatric dosing guidance for capecitabine in patients with DPYD deficiency"
                }
            },
            {
                "question": "What is the recommended dose reduction for fluorouracil in a DPYD intermediate metabolizer?",
                "answer": {
                    "Drug Name": "fluorouracil",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Specific dose reduction percentage or value for fluorouracil in DPYD intermediate metabolizers"
                }
            },
            {
                "question": "What is the incidence of grade 3 or higher toxicity in DPYD poor metabolizers treated with standard-dose fluorouracil?",
                "answer": {
                    "Drug Name": "fluorouracil",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Incidence rates of severe toxicity for DPYD poor metabolizers on fluorouracil"
                }
            },
            {
                "question": "What is the expected plasma concentration of fluorouracil in a DPYD poor metabolizer compared to a normal metabolizer?",
                "answer": {
                    "Drug Name": "fluorouracil",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Pharmacokinetic data comparing fluorouracil plasma concentrations between DPYD poor and normal metabolizers"
                }
            },
            {
                "question": "Which genotypes are associated with the DPYD intermediate metabolizer phenotype?",
                "answer": {
                    "Drug Name": "fluorouracil",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Genotype or diplotype definitions for the DPYD intermediate metabolizer phenotype"
                }
            },
            {
                "question": "How does the DPYD enzyme inactivate fluorouracil?",
                "answer": {
                    "Drug Name": "fluorouracil",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Mechanism of action for DPYD enzyme in the inactivation of fluorouracil"
                }
            },
            {
                "question": "Are there specific fluorouracil dosing guidelines for patients with renal impairment and DPYD deficiency?",
                "answer": {
                    "Drug Name": "fluorouracil",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Dosing adjustments for fluorouracil in patients with both renal impairment and DPYD deficiency"
                }
            },
            {
                "question": "What is the recommended dosing adjustment for tegafur in patients with a DPYD poor metabolizer phenotype?",
                "answer": {
                    "Drug Name": "tegafur",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Dose adjustment protocol for tegafur in DPYD poor metabolizers"
                }
            },
            {
                "question": "What is the quantified risk of life-threatening toxicity when administering tegafur to a DPYD poor metabolizer?",
                "answer": {
                    "Drug Name": "tegafur",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Quantified risk data or incidence rates of severe toxicity in DPYD poor metabolizers using tegafur"
                }
            },
            {
                "question": "How does DPYD deficiency affect the pharmacokinetics of tegafur's active metabolite, 5-fluorouracil?",
                "answer": {
                    "Drug Name": "tegafur",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Pharmacokinetic parameters of 5-fluorouracil in DPYD deficient individuals after tegafur administration"
                }
            },
            {
                "question": "What DPYD activity score corresponds to an intermediate metabolizer phenotype?",
                "answer": {
                    "Drug Name": "tegafur",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "DPYD activity score definitions for the intermediate metabolizer phenotype"
                }
            },
            {
                "question": "What is the mechanism by which tegafur is converted to fluorouracil and subsequently metabolized by DPYD?",
                "answer": {
                    "Drug Name": "tegafur",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Metabolic pathway of tegafur to 5-fluorouracil and its subsequent catabolism by DPYD"
                }
            },
            {
                "question": "Are there specific dosing recommendations for tegafur in elderly patients with reduced DPYD activity?",
                "answer": {
                    "Drug Name": "tegafur",
                    "Gene Name": "DPYD",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
                    "Content to Search": "Dosing guidance for tegafur in elderly patients with DPYD intermediate or poor metabolizer status"
                }
            }
        ]
    },
    {
        "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf": [
            {
                "question": "What is the dosing recommendation for carbamazepine in a patient positive for the HLA-A*31:01 allele?",
                "answer": {
                    "Drug Name": "carbamazepine",
                    "Gene Name": "HLA-A",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Clinical dosing recommendation for carbamazepine in HLA-A*31:01 positive individuals"
                }
            },
            {
                "question": "What is the increased risk of maculopapular exanthema (MPE) for an HLA-A*31:01 carrier taking carbamazepine?",
                "answer": {
                    "Drug Name": "carbamazepine",
                    "Gene Name": "HLA-A",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Quantified risk or odds ratio for MPE in HLA-A*31:01 carriers using carbamazepine"
                }
            },
            {
                "question": "Is there a known pharmacokinetic mechanism linking HLA-A*31:01 to carbamazepine-induced adverse reactions?",
                "answer": {
                    "Drug Name": "carbamazepine",
                    "Gene Name": "HLA-A",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Pharmacokinetic data or mechanism linking HLA-A*31:01 and carbamazepine adverse events"
                }
            },
            {
                "question": "What is the clinical implication of testing positive for the HLA-A*31:01 allele before starting carbamazepine?",
                "answer": {
                    "Drug Name": "carbamazepine",
                    "Gene Name": "HLA-A",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Definition of the clinical phenotype or implication for a patient with the HLA-A*31:01 allele regarding carbamazepine use"
                }
            },
            {
                "question": "What is the function of the HLA-A gene in the immune response related to drug hypersensitivity?",
                "answer": {
                    "Drug Name": "carbamazepine",
                    "Gene Name": "HLA-A",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Basic function of the HLA-A gene and its role in antigen presentation leading to drug hypersensitivity"
                }
            },
            {
                "question": "Are there different carbamazepine recommendations for pediatric patients with the HLA-A*31:01 allele?",
                "answer": {
                    "Drug Name": "carbamazepine",
                    "Gene Name": "HLA-A",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Specific dosing or clinical recommendations for carbamazepine in pediatric HLA-A*31:01 carriers"
                }
            },
            {
                "question": "What is the clinical recommendation for carbamazepine use in a patient who tests positive for the HLA-B*15:02 allele?",
                "answer": {
                    "Drug Name": "carbamazepine",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Dosing recommendation or contraindication for carbamazepine in HLA-B*15:02 positive individuals"
                }
            },
            {
                "question": "What is the quantified risk of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in an HLA-B*15:02 positive individual taking carbamazepine?",
                "answer": {
                    "Drug Name": "carbamazepine",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Risk multiplier or incidence rate of SJS/TEN in HLA-B*15:02 carriers taking carbamazepine"
                }
            },
            {
                "question": "Is there a defined therapeutic window for carbamazepine that changes based on HLA-B*15:02 status?",
                "answer": {
                    "Drug Name": "carbamazepine",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Therapeutic drug monitoring values or plasma concentration ranges for carbamazepine in relation to HLA-B*15:02 status"
                }
            },
            {
                "question": "Which populations have a higher prevalence of the HLA-B*15:02 allele, impacting carbamazepine prescribing?",
                "answer": {
                    "Drug Name": "carbamazepine",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Definition of populations with high HLA-B*15:02 allele frequency"
                }
            },
            {
                "question": "What is the proposed immunological mechanism for HLA-B*15:02-mediated carbamazepine hypersensitivity?",
                "answer": {
                    "Drug Name": "carbamazepine",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Mechanism of HLA-B*15:02 involvement in the immune response to carbamazepine"
                }
            },
            {
                "question": "What is the carbamazepine dosing recommendation for a child of Southeast Asian ancestry who is positive for HLA-B*15:02?",
                "answer": {
                    "Drug Name": "carbamazepine",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Pediatric dosing recommendations for carbamazepine in HLA-B*15:02 positive children, particularly of specific ancestries"
                }
            },
            {
                "question": "What is the dosing recommendation for oxcarbazepine in a patient who is a carrier of the HLA-A*31:01 allele?",
                "answer": {
                    "Drug Name": "oxcarbazepine",
                    "Gene Name": "HLA-A",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Clinical dosing recommendation for oxcarbazepine in HLA-A*31:01 positive individuals"
                }
            },
            {
                "question": "What is the risk of oxcarbazepine-induced cutaneous adverse reactions in individuals with the HLA-A*31:01 allele?",
                "answer": {
                    "Drug Name": "oxcarbazepine",
                    "Gene Name": "HLA-A",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Quantified risk data for cutaneous adverse reactions with oxcarbazepine in HLA-A*31:01 carriers"
                }
            },
            {
                "question": "Does the HLA-A*31:01 allele affect the pharmacokinetics of oxcarbazepine or its active metabolite?",
                "answer": {
                    "Drug Name": "oxcarbazepine",
                    "Gene Name": "HLA-A",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Pharmacokinetic data for oxcarbazepine in relation to HLA-A*31:01 status"
                }
            },
            {
                "question": "What is the clinical significance of the HLA-A*31:01 allele for oxcarbazepine therapy?",
                "answer": {
                    "Drug Name": "oxcarbazepine",
                    "Gene Name": "HLA-A",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Definition of clinical phenotype or implication of HLA-A*31:01 positivity for oxcarbazepine use"
                }
            },
            {
                "question": "How does the HLA-A gene's role in antigen presentation relate to potential oxcarbazepine hypersensitivity?",
                "answer": {
                    "Drug Name": "oxcarbazepine",
                    "Gene Name": "HLA-A",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Basic mechanism of HLA-A in immune-mediated reactions to oxcarbazepine"
                }
            },
            {
                "question": "Are there specific guidelines for using oxcarbazepine in pediatric patients with the HLA-A*31:01 allele?",
                "answer": {
                    "Drug Name": "oxcarbazepine",
                    "Gene Name": "HLA-A",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Pediatric dosing or clinical guidance for oxcarbazepine in HLA-A*31:01 positive children"
                }
            },
            {
                "question": "How should oxcarbazepine be prescribed for a patient who is positive for the HLA-B*15:02 allele?",
                "answer": {
                    "Drug Name": "oxcarbazepine",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Dosing recommendation or contraindication for oxcarbazepine in HLA-B*15:02 positive individuals"
                }
            },
            {
                "question": "What is the risk of SJS/TEN when using oxcarbazepine in an HLA-B*15:02 positive patient?",
                "answer": {
                    "Drug Name": "oxcarbazepine",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Quantified risk of SJS/TEN for oxcarbazepine use in HLA-B*15:02 carriers"
                }
            },
            {
                "question": "Are there any therapeutic drug monitoring recommendations for oxcarbazepine based on HLA-B*15:02 status?",
                "answer": {
                    "Drug Name": "oxcarbazepine",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Therapeutic drug monitoring guidance for oxcarbazepine in relation to HLA-B*15:02 status"
                }
            },
            {
                "question": "Does the presence of the HLA-B*15:02 allele have the same predictive value for oxcarbazepine as it does for carbamazepine?",
                "answer": {
                    "Drug Name": "oxcarbazepine",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Comparison of predictive value of HLA-B*15:02 for hypersensitivity between oxcarbazepine and carbamazepine"
                }
            },
            {
                "question": "What is the mechanism of cross-reactivity between carbamazepine and oxcarbazepine in HLA-B*15:02 positive individuals?",
                "answer": {
                    "Drug Name": "oxcarbazepine",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Mechanism of immunological cross-reactivity for carbamazepine and oxcarbazepine in HLA-B*15:02 carriers"
                }
            },
            {
                "question": "What is the recommendation for initiating oxcarbazepine in a pregnant patient who is an HLA-B*15:02 carrier?",
                "answer": {
                    "Drug Name": "oxcarbazepine",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
                    "Content to Search": "Guidance for oxcarbazepine use during pregnancy in HLA-B*15:02 positive individuals"
                }
            }
        ]
    },
    {
        "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf": [
            {
                "question": "What is the dosing recommendation for abacavir in a patient who is positive for the HLA-B*57:01 allele?",
                "answer": {
                    "Drug Name": "abacavir",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf",
                    "Content to Search": "Clinical recommendation and dosing guidance for abacavir in HLA-B*57:01 positive individuals"
                }
            },
            {
                "question": "What is the quantified risk of abacavir hypersensitivity syndrome (AHS) in an individual carrying the HLA-B*57:01 allele?",
                "answer": {
                    "Drug Name": "abacavir",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf",
                    "Content to Search": "Quantified risk, odds ratio, or incidence rate of AHS in HLA-B*57:01 carriers"
                }
            },
            {
                "question": "Is there a known pharmacokinetic interaction between abacavir and the HLA-B*57:01 allele, or is the mechanism purely immunological?",
                "answer": {
                    "Drug Name": "abacavir",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf",
                    "Content to Search": "Pharmacokinetic data or description of the immunological mechanism for abacavir hypersensitivity related to HLA-B*57:01"
                }
            },
            {
                "question": "What is the clinical phenotype associated with being an HLA-B*57:01 carrier in the context of abacavir therapy?",
                "answer": {
                    "Drug Name": "abacavir",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf",
                    "Content to Search": "Definition of the clinical implication or phenotype for an HLA-B*57:01 carrier regarding abacavir use"
                }
            },
            {
                "question": "What is the immunological mechanism by which the HLA-B*57:01 allele leads to abacavir hypersensitivity?",
                "answer": {
                    "Drug Name": "abacavir",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf",
                    "Content to Search": "Description of the immunological mechanism involving HLA-B*57:01 and abacavir"
                }
            },
            {
                "question": "Are there specific guidelines for abacavir use in pediatric patients who are HLA-B*57:01 positive?",
                "answer": {
                    "Drug Name": "abacavir",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf",
                    "Content to Search": "Clinical recommendations for abacavir use in pediatric HLA-B*57:01 carriers"
                }
            }
        ]
    },
    {
        "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf": [
            {
                "question": "What is the dosing recommendation for allopurinol in a patient who tests positive for the HLA-B*58:01 allele?",
                "answer": {
                    "Drug Name": "allopurinol",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf",
                    "Content to Search": "Clinical recommendation and dosing guidance for allopurinol in HLA-B*58:01 positive individuals"
                }
            },
            {
                "question": "What is the increased risk of severe cutaneous adverse reactions (SCARs) for an HLA-B*58:01 carrier taking allopurinol?",
                "answer": {
                    "Drug Name": "allopurinol",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf",
                    "Content to Search": "Quantified risk or odds ratio for SCARs in HLA-B*58:01 carriers taking allopurinol"
                }
            },
            {
                "question": "Does the HLA-B*58:01 allele affect the pharmacokinetics of allopurinol or its active metabolite, oxypurinol?",
                "answer": {
                    "Drug Name": "allopurinol",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf",
                    "Content to Search": "Pharmacokinetic data for allopurinol or oxypurinol in relation to HLA-B*58:01 status"
                }
            },
            {
                "question": "In which ethnic populations is the HLA-B*58:01 allele most prevalent, necessitating pre-screening for allopurinol therapy?",
                "answer": {
                    "Drug Name": "allopurinol",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf",
                    "Content to Search": "Information on ethnic populations with high prevalence of the HLA-B*58:01 allele"
                }
            },
            {
                "question": "What is the proposed mechanism for HLA-B*58:01-mediated allopurinol-induced SCARs?",
                "answer": {
                    "Drug Name": "allopurinol",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf",
                    "Content to Search": "Description of the immunological mechanism involving HLA-B*58:01 and allopurinol"
                }
            },
            {
                "question": "What is the allopurinol dosing recommendation for a patient with chronic kidney disease who is also an HLA-B*58:01 carrier?",
                "answer": {
                    "Drug Name": "allopurinol",
                    "Gene Name": "HLA-B",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf",
                    "Content to Search": "Dosing recommendations for allopurinol in patients with both chronic kidney disease and HLA-B*58:01 positive status"
                }
            }
        ]
    },
        {
        "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf": [
            {
                "question": "What is the recommended dosing for amikacin in an individual with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "amikacin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Dosing recommendations or alternative therapies for amikacin in patients with pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the quantified risk of ototoxicity when administering amikacin to a patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "amikacin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Incidence rates or risk multipliers for amikacin-induced ototoxicity in MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What are the target therapeutic plasma concentrations for amikacin, and how are they affected by MT-RNR1 status?",
                "answer": {
                    "Drug Name": "amikacin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Therapeutic drug monitoring ranges for amikacin and any specific considerations for MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
                "answer": {
                    "Drug Name": "amikacin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
                }
            },
            {
                "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to amikacin-induced ototoxicity?",
                "answer": {
                    "Drug Name": "amikacin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Functional explanation of how MT-RNR1 variants interact with amikacin to cause cellular damage."
                }
            },
            {
                "question": "What is the dosing recommendation for amikacin in a pediatric patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "amikacin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Specific dosing guidance for amikacin in pediatric populations carrying pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the recommended dosing for dibekacin in an individual with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "dibekacin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Dosing recommendations or alternative therapies for dibekacin in patients with pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the quantified risk of ototoxicity when administering dibekacin to a patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "dibekacin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Incidence rates or risk multipliers for dibekacin-induced ototoxicity in MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What are the target therapeutic plasma concentrations for dibekacin, and how are they affected by MT-RNR1 status?",
                "answer": {
                    "Drug Name": "dibekacin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Therapeutic drug monitoring ranges for dibekacin and any specific considerations for MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
                "answer": {
                    "Drug Name": "dibekacin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
                }
            },
            {
                "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to dibekacin-induced ototoxicity?",
                "answer": {
                    "Drug Name": "dibekacin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Functional explanation of how MT-RNR1 variants interact with dibekacin to cause cellular damage."
                }
            },
            {
                "question": "What is the dosing recommendation for dibekacin in a pediatric patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "dibekacin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Specific dosing guidance for dibekacin in pediatric populations carrying pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the recommended dosing for gentamicin in an individual with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "gentamicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Dosing recommendations or alternative therapies for gentamicin in patients with pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the quantified risk of ototoxicity when administering gentamicin to a patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "gentamicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Incidence rates or risk multipliers for gentamicin-induced ototoxicity in MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What are the target therapeutic plasma concentrations for gentamicin, and how are they affected by MT-RNR1 status?",
                "answer": {
                    "Drug Name": "gentamicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Therapeutic drug monitoring ranges for gentamicin and any specific considerations for MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
                "answer": {
                    "Drug Name": "gentamicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
                }
            },
            {
                "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to gentamicin-induced ototoxicity?",
                "answer": {
                    "Drug Name": "gentamicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Functional explanation of how MT-RNR1 variants interact with gentamicin to cause cellular damage."
                }
            },
            {
                "question": "What is the dosing recommendation for gentamicin in a pediatric patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "gentamicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Specific dosing guidance for gentamicin in pediatric populations carrying pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the recommended dosing for kanamycin in an individual with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "kanamycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Dosing recommendations or alternative therapies for kanamycin in patients with pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the quantified risk of ototoxicity when administering kanamycin to a patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "kanamycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Incidence rates or risk multipliers for kanamycin-induced ototoxicity in MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What are the target therapeutic plasma concentrations for kanamycin, and how are they affected by MT-RNR1 status?",
                "answer": {
                    "Drug Name": "kanamycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Therapeutic drug monitoring ranges for kanamycin and any specific considerations for MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
                "answer": {
                    "Drug Name": "kanamycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
                }
            },
            {
                "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to kanamycin-induced ototoxicity?",
                "answer": {
                    "Drug Name": "kanamycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Functional explanation of how MT-RNR1 variants interact with kanamycin to cause cellular damage."
                }
            },
            {
                "question": "What is the dosing recommendation for kanamycin in a pediatric patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "kanamycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Specific dosing guidance for kanamycin in pediatric populations carrying pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the recommended dosing for neomycin in an individual with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "neomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Dosing recommendations or alternative therapies for neomycin in patients with pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the quantified risk of ototoxicity when administering neomycin to a patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "neomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Incidence rates or risk multipliers for neomycin-induced ototoxicity in MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What are the target therapeutic plasma concentrations for neomycin, and how are they affected by MT-RNR1 status?",
                "answer": {
                    "Drug Name": "neomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Therapeutic drug monitoring ranges for neomycin and any specific considerations for MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
                "answer": {
                    "Drug Name": "neomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
                }
            },
            {
                "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to neomycin-induced ototoxicity?",
                "answer": {
                    "Drug Name": "neomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Functional explanation of how MT-RNR1 variants interact with neomycin to cause cellular damage."
                }
            },
            {
                "question": "What is the dosing recommendation for neomycin in a pediatric patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "neomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Specific dosing guidance for neomycin in pediatric populations carrying pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the recommended dosing for netilmicin in an individual with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "netilmicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Dosing recommendations or alternative therapies for netilmicin in patients with pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the quantified risk of ototoxicity when administering netilmicin to a patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "netilmicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Incidence rates or risk multipliers for netilmicin-induced ototoxicity in MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What are the target therapeutic plasma concentrations for netilmicin, and how are they affected by MT-RNR1 status?",
                "answer": {
                    "Drug Name": "netilmicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Therapeutic drug monitoring ranges for netilmicin and any specific considerations for MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
                "answer": {
                    "Drug Name": "netilmicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
                }
            },
            {
                "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to netilmicin-induced ototoxicity?",
                "answer": {
                    "Drug Name": "netilmicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Functional explanation of how MT-RNR1 variants interact with netilmicin to cause cellular damage."
                }
            },
            {
                "question": "What is the dosing recommendation for netilmicin in a pediatric patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "netilmicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Specific dosing guidance for netilmicin in pediatric populations carrying pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the recommended dosing for paromomycin in an individual with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "paromomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Dosing recommendations or alternative therapies for paromomycin in patients with pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the quantified risk of ototoxicity when administering paromomycin to a patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "paromomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Incidence rates or risk multipliers for paromomycin-induced ototoxicity in MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What are the target therapeutic plasma concentrations for paromomycin, and how are they affected by MT-RNR1 status?",
                "answer": {
                    "Drug Name": "paromomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Therapeutic drug monitoring ranges for paromomycin and any specific considerations for MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
                "answer": {
                    "Drug Name": "paromomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
                }
            },
            {
                "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to paromomycin-induced ototoxicity?",
                "answer": {
                    "Drug Name": "paromomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Functional explanation of how MT-RNR1 variants interact with paromomycin to cause cellular damage."
                }
            },
            {
                "question": "What is the dosing recommendation for paromomycin in a pediatric patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "paromomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Specific dosing guidance for paromomycin in pediatric populations carrying pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the recommended dosing for plazomicin in an individual with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "plazomicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Dosing recommendations or alternative therapies for plazomicin in patients with pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the quantified risk of ototoxicity when administering plazomicin to a patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "plazomicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Incidence rates or risk multipliers for plazomicin-induced ototoxicity in MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What are the target therapeutic plasma concentrations for plazomicin, and how are they affected by MT-RNR1 status?",
                "answer": {
                    "Drug Name": "plazomicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Therapeutic drug monitoring ranges for plazomicin and any specific considerations for MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
                "answer": {
                    "Drug Name": "plazomicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
                }
            },
            {
                "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to plazomicin-induced ototoxicity?",
                "answer": {
                    "Drug Name": "plazomicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Functional explanation of how MT-RNR1 variants interact with plazomicin to cause cellular damage."
                }
            },
            {
                "question": "What is the dosing recommendation for plazomicin in a pediatric patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "plazomicin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Specific dosing guidance for plazomicin in pediatric populations carrying pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the recommended dosing for ribostamycin in an individual with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "ribostamycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Dosing recommendations or alternative therapies for ribostamycin in patients with pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the quantified risk of ototoxicity when administering ribostamycin to a patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "ribostamycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Incidence rates or risk multipliers for ribostamycin-induced ototoxicity in MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What are the target therapeutic plasma concentrations for ribostamycin, and how are they affected by MT-RNR1 status?",
                "answer": {
                    "Drug Name": "ribostamycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Therapeutic drug monitoring ranges for ribostamycin and any specific considerations for MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
                "answer": {
                    "Drug Name": "ribostamycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
                }
            },
            {
                "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to ribostamycin-induced ototoxicity?",
                "answer": {
                    "Drug Name": "ribostamycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Functional explanation of how MT-RNR1 variants interact with ribostamycin to cause cellular damage."
                }
            },
            {
                "question": "What is the dosing recommendation for ribostamycin in a pediatric patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "ribostamycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Specific dosing guidance for ribostamycin in pediatric populations carrying pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the recommended dosing for streptomycin in an individual with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "streptomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Dosing recommendations or alternative therapies for streptomycin in patients with pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the quantified risk of ototoxicity when administering streptomycin to a patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "streptomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Incidence rates or risk multipliers for streptomycin-induced ototoxicity in MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What are the target therapeutic plasma concentrations for streptomycin, and how are they affected by MT-RNR1 status?",
                "answer": {
                    "Drug Name": "streptomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Therapeutic drug monitoring ranges for streptomycin and any specific considerations for MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
                "answer": {
                    "Drug Name": "streptomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
                }
            },
            {
                "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to streptomycin-induced ototoxicity?",
                "answer": {
                    "Drug Name": "streptomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Functional explanation of how MT-RNR1 variants interact with streptomycin to cause cellular damage."
                }
            },
            {
                "question": "What is the dosing recommendation for streptomycin in a pediatric patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "streptomycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Specific dosing guidance for streptomycin in pediatric populations carrying pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the recommended dosing for tobramycin in an individual with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "tobramycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Dosing recommendations or alternative therapies for tobramycin in patients with pathogenic MT-RNR1 variants."
                }
            },
            {
                "question": "What is the quantified risk of ototoxicity when administering tobramycin to a patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "tobramycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Incidence rates or risk multipliers for tobramycin-induced ototoxicity in MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What are the target therapeutic plasma concentrations for tobramycin, and how are they affected by MT-RNR1 status?",
                "answer": {
                    "Drug Name": "tobramycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Therapeutic drug monitoring ranges for tobramycin and any specific considerations for MT-RNR1 variant carriers."
                }
            },
            {
                "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
                "answer": {
                    "Drug Name": "tobramycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
                }
            },
            {
                "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to tobramycin-induced ototoxicity?",
                "answer": {
                    "Drug Name": "tobramycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Functional explanation of how MT-RNR1 variants interact with tobramycin to cause cellular damage."
                }
            },
            {
                "question": "What is the dosing recommendation for tobramycin in a pediatric patient with a pathogenic MT-RNR1 variant?",
                "answer": {
                    "Drug Name": "tobramycin",
                    "Gene Name": "MT-RNR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
                    "Content to Search": "Specific dosing guidance for tobramycin in pediatric populations carrying pathogenic MT-RNR1 variants."
                }
            }
        ]
    },
    {
        "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf": [
            {
                "question": "What is the recommended dosing for desflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "desflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for desflurane in patients with RYR1-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering desflurane to a patient with a pathogenic RYR1 variant?",
                "answer": {
                    "Drug Name": "desflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for desflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for desflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "desflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for desflurane in the context of RYR1-MHS."
                }
            },
            {
                "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "desflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the RYR1 gene in the mechanism of desflurane-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "desflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of desflurane-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "desflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
                }
            },
            {
                "question": "What is the recommended dosing for desflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "desflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for desflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering desflurane to a patient with a pathogenic CACNA1S variant?",
                "answer": {
                    "Drug Name": "desflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for desflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for desflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "desflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for desflurane in the context of CACNA1S-MHS."
                }
            },
            {
                "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "desflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the CACNA1S gene in the mechanism of desflurane-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "desflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of desflurane-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "desflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
                }
            },
            {
                "question": "What is the recommended dosing for enflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "enflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for enflurane in patients with RYR1-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering enflurane to a patient with a pathogenic RYR1 variant?",
                "answer": {
                    "Drug Name": "enflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for enflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for enflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "enflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for enflurane in the context of RYR1-MHS."
                }
            },
            {
                "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "enflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the RYR1 gene in the mechanism of enflurane-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "enflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of enflurane-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "enflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
                }
            },
            {
                "question": "What is the recommended dosing for enflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "enflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for enflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering enflurane to a patient with a pathogenic CACNA1S variant?",
                "answer": {
                    "Drug Name": "enflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for enflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for enflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "enflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for enflurane in the context of CACNA1S-MHS."
                }
            },
            {
                "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "enflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the CACNA1S gene in the mechanism of enflurane-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "enflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of enflurane-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "enflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
                }
            },
            {
                "question": "What is the recommended dosing for halothane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "halothane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for halothane in patients with RYR1-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering halothane to a patient with a pathogenic RYR1 variant?",
                "answer": {
                    "Drug Name": "halothane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for halothane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for halothane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "halothane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for halothane in the context of RYR1-MHS."
                }
            },
            {
                "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "halothane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the RYR1 gene in the mechanism of halothane-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "halothane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of halothane-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "halothane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
                }
            },
            {
                "question": "What is the recommended dosing for halothane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "halothane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for halothane in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering halothane to a patient with a pathogenic CACNA1S variant?",
                "answer": {
                    "Drug Name": "halothane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for halothane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for halothane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "halothane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for halothane in the context of CACNA1S-MHS."
                }
            },
            {
                "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "halothane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the CACNA1S gene in the mechanism of halothane-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "halothane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of halothane-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "halothane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
                }
            },
            {
                "question": "What is the recommended dosing for isoflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "isoflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for isoflurane in patients with RYR1-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering isoflurane to a patient with a pathogenic RYR1 variant?",
                "answer": {
                    "Drug Name": "isoflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for isoflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for isoflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "isoflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for isoflurane in the context of RYR1-MHS."
                }
            },
            {
                "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "isoflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the RYR1 gene in the mechanism of isoflurane-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "isoflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of isoflurane-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "isoflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
                }
            },
            {
                "question": "What is the recommended dosing for isoflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "isoflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for isoflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering isoflurane to a patient with a pathogenic CACNA1S variant?",
                "answer": {
                    "Drug Name": "isoflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for isoflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for isoflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "isoflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for isoflurane in the context of CACNA1S-MHS."
                }
            },
            {
                "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "isoflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the CACNA1S gene in the mechanism of isoflurane-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "isoflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of isoflurane-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "isoflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
                }
            },
            {
                "question": "What is the recommended dosing for methoxyflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "methoxyflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for methoxyflurane in patients with RYR1-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering methoxyflurane to a patient with a pathogenic RYR1 variant?",
                "answer": {
                    "Drug Name": "methoxyflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for methoxyflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for methoxyflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "methoxyflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for methoxyflurane in the context of RYR1-MHS."
                }
            },
            {
                "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "methoxyflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the RYR1 gene in the mechanism of methoxyflurane-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "methoxyflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of methoxyflurane-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "methoxyflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
                }
            },
            {
                "question": "What is the recommended dosing for methoxyflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "methoxyflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for methoxyflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering methoxyflurane to a patient with a pathogenic CACNA1S variant?",
                "answer": {
                    "Drug Name": "methoxyflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for methoxyflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for methoxyflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "methoxyflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for methoxyflurane in the context of CACNA1S-MHS."
                }
            },
            {
                "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "methoxyflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the CACNA1S gene in the mechanism of methoxyflurane-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "methoxyflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of methoxyflurane-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "methoxyflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
                }
            },
            {
                "question": "What is the recommended dosing for sevoflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "sevoflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for sevoflurane in patients with RYR1-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering sevoflurane to a patient with a pathogenic RYR1 variant?",
                "answer": {
                    "Drug Name": "sevoflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for sevoflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for sevoflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "sevoflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for sevoflurane in the context of RYR1-MHS."
                }
            },
            {
                "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "sevoflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the RYR1 gene in the mechanism of sevoflurane-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "sevoflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of sevoflurane-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "sevoflurane",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
                }
            },
            {
                "question": "What is the recommended dosing for sevoflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "sevoflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for sevoflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering sevoflurane to a patient with a pathogenic CACNA1S variant?",
                "answer": {
                    "Drug Name": "sevoflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for sevoflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for sevoflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "sevoflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for sevoflurane in the context of CACNA1S-MHS."
                }
            },
            {
                "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "sevoflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the CACNA1S gene in the mechanism of sevoflurane-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "sevoflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of sevoflurane-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "sevoflurane",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
                }
            },
            {
                "question": "What is the recommended dosing for succinylcholine in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "succinylcholine",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for succinylcholine in patients with RYR1-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering succinylcholine to a patient with a pathogenic RYR1 variant?",
                "answer": {
                    "Drug Name": "succinylcholine",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for succinylcholine-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for succinylcholine in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "succinylcholine",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for succinylcholine in the context of RYR1-MHS."
                }
            },
            {
                "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "succinylcholine",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the RYR1 gene in the mechanism of succinylcholine-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "succinylcholine",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of succinylcholine-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "succinylcholine",
                    "Gene Name": "RYR1",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
                }
            },
            {
                "question": "What is the recommended dosing for succinylcholine in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "succinylcholine",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Dosing protocol or avoidance recommendation for succinylcholine in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
                }
            },
            {
                "question": "What is the quantified risk of malignant hyperthermia when administering succinylcholine to a patient with a pathogenic CACNA1S variant?",
                "answer": {
                    "Drug Name": "succinylcholine",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Incidence rates or risk data for succinylcholine-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
                }
            },
            {
                "question": "Are there specific PK/PD parameters to monitor for succinylcholine in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "succinylcholine",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for succinylcholine in the context of CACNA1S-MHS."
                }
            },
            {
                "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "succinylcholine",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
                }
            },
            {
                "question": "What is the role of the CACNA1S gene in the mechanism of succinylcholine-triggered malignant hyperthermia?",
                "answer": {
                    "Drug Name": "succinylcholine",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of succinylcholine-induced malignant hyperthermia."
                }
            },
            {
                "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
                "answer": {
                    "Drug Name": "succinylcholine",
                    "Gene Name": "CACNA1S",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
                    "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
                }
            }
        ]
    },
        {
        "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf": [
            {
                "question": "Does the recommended dosing of peginterferon alfa-2a change for a patient with a favorable IFNL3 genotype (e.g., rs12979860 CC)?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2a",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Dose adjustment protocol or clinical recommendation for peginterferon alfa-2a based on IFNL3 favorable response genotype"
                }
            },
            {
                "question": "What is the probability of achieving sustained virologic response (SVR) with peginterferon alfa-2a in a patient with an unfavorable IFNL3 genotype?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2a",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Quantified SVR rates for peginterferon alfa-2a therapy in patients with unfavorable IFNL3 genotypes"
                }
            },
            {
                "question": "How does the IFNL3 genotype affect the viral kinetics during treatment with peginterferon alfa-2a?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2a",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Pharmacodynamic data on viral load reduction based on IFNL3 genotype during peginterferon alfa-2a treatment"
                }
            },
            {
                "question": "Which genotypes for the IFNL3 SNP rs12979860 define a favorable response phenotype to peginterferon alfa-2a therapy?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2a",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Genotype definitions for the IFNL3 favorable response phenotype"
                }
            },
            {
                "question": "What is the function of the IFNL3 gene that influences the efficacy of peginterferon alfa-2a in treating Hepatitis C?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2a",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Role of the IFNL3 gene product in the immune response to HCV and interferon-based therapy"
                }
            },
            {
                "question": "Are there different treatment recommendations with peginterferon alfa-2a for patients with HIV/HCV coinfection based on their IFNL3 genotype?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2a",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Specific recommendations for peginterferon alfa-2a in HIV/HCV coinfected patients stratified by IFNL3 genotype"
                }
            },
            {
                "question": "Is the dosing of peginterferon alfa-2a modified based on the IFNL4-ΔG/TT genotype (rs368234815)?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2a",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Dose adjustment protocol for peginterferon alfa-2a based on IFNL4 genotype"
                }
            },
            {
                "question": "What is the likelihood of treatment failure with peginterferon alfa-2a for a patient with the unfavorable IFNL4-ΔG allele?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2a",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Quantified risk of non-response or relapse in patients with the IFNL4-ΔG allele treated with peginterferon alfa-2a"
                }
            },
            {
                "question": "Is there a correlation between IFNL4 genotype and interferon-stimulated gene (ISG) expression levels before peginterferon alfa-2a treatment?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2a",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Pharmacodynamic data linking IFNL4 genotype to baseline ISG expression levels"
                }
            },
            {
                "question": "Which IFNL4 genotype (rs368234815) corresponds to a favorable response to peginterferon alfa-2a?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2a",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Genotype definition (e.g., TT/TT) for the IFNL4 favorable response phenotype"
                }
            },
            {
                "question": "What is the function of the IFNL4-ΔG variant that leads to impaired viral clearance during peginterferon alfa-2a therapy?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2a",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Mechanism of the IFNL4-ΔG variant and its impact on interferon signaling or response"
                }
            },
            {
                "question": "Are there specific peginterferon alfa-2a treatment duration guidelines for African-American patients based on their IFNL4 genotype?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2a",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Treatment duration recommendations for peginterferon alfa-2a in African-American patients stratified by IFNL4 genotype"
                }
            },
            {
                "question": "Is the dose of peginterferon alfa-2b adjusted based on a patient's IFNL3 genotype?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2b",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Dosing recommendations for peginterferon alfa-2b based on IFNL3 genotype"
                }
            },
            {
                "question": "What is the relative chance of achieving SVR with peginterferon alfa-2b for a patient with IFNL3 rs12979860 CC versus CT/TT genotypes?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2b",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Odds ratio or comparative SVR rates for peginterferon alfa-2b based on IFNL3 rs12979860 genotypes"
                }
            },
            {
                "question": "How does IFNL3 genotype influence the rapid virologic response (RVR) to peginterferon alfa-2b therapy?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2b",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Pharmacodynamic data on RVR rates stratified by IFNL3 genotype for patients on peginterferon alfa-2b"
                }
            },
            {
                "question": "What IFNL3 genotype is considered to predict an unfavorable response to peginterferon alfa-2b?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2b",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Genotype definitions (e.g., rs12979860 CT or TT) for the IFNL3 unfavorable response phenotype"
                }
            },
            {
                "question": "How does peginterferon alfa-2b's mechanism of action interact with the IFNL3-mediated immune pathway?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2b",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Interaction between peginterferon alfa-2b's antiviral effect and the IFNL3 signaling pathway"
                }
            },
            {
                "question": "Are there specific recommendations for peginterferon alfa-2b treatment duration in HCV genotype 1 patients based on IFNL3 status?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2b",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Guidance on peginterferon alfa-2b treatment duration for HCV genotype 1 patients stratified by IFNL3 genotype"
                }
            },
            {
                "question": "Should the dose of peginterferon alfa-2b be altered for a patient with the IFNL4-ΔG/TT genotype?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2b",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Dose adjustment protocol for peginterferon alfa-2b based on IFNL4 genotype"
                }
            },
            {
                "question": "What is the SVR rate for patients with the favorable IFNL4 TT/TT genotype when treated with peginterferon alfa-2b?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2b",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Quantified SVR rates for peginterferon alfa-2b therapy in patients with the favorable IFNL4 genotype"
                }
            },
            {
                "question": "Is there a difference in the clearance of peginterferon alfa-2b based on a patient's IFNL4 genotype?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2b",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Pharmacokinetic data on peginterferon alfa-2b clearance stratified by IFNL4 genotype"
                }
            },
            {
                "question": "Which IFNL4 genotypes are linked to a poor response to peginterferon alfa-2b therapy?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2b",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Genotype definitions (e.g., containing the ΔG allele) for the IFNL4 unfavorable response phenotype"
                }
            },
            {
                "question": "What is the biological function of the protein encoded by IFNL4 that impacts peginterferon alfa-2b treatment outcome?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2b",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Function of the IFNL4 gene product and its role in interferon signaling"
                }
            },
            {
                "question": "Are there specific guidelines for using peginterferon alfa-2b in patients of Asian descent based on their IFNL4 genotype?",
                "answer": {
                    "Drug Name": "peginterferon alfa-2b",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Treatment recommendations for peginterferon alfa-2b in Asian patients stratified by IFNL4 genotype"
                }
            },
            {
                "question": "Is the dose of ribavirin adjusted based on a patient's IFNL3 genotype when used in combination with peginterferon?",
                "answer": {
                    "Drug Name": "ribavirin",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Ribavirin dose adjustment protocol based on IFNL3 genotype"
                }
            },
            {
                "question": "What is the likelihood of achieving SVR with a peginterferon/ribavirin regimen in a patient with a favorable IFNL3 genotype?",
                "answer": {
                    "Drug Name": "ribavirin",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Quantified SVR rates for combination therapy with ribavirin in patients with favorable IFNL3 genotypes"
                }
            },
            {
                "question": "Does IFNL3 genotype influence the risk of ribavirin-induced anemia?",
                "answer": {
                    "Drug Name": "ribavirin",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Pharmacodynamic or safety data linking IFNL3 genotype to the incidence of ribavirin-induced anemia"
                }
            },
            {
                "question": "How is the IFNL3 genotype used to define the overall response phenotype for peginterferon/ribavirin combination therapy?",
                "answer": {
                    "Drug Name": "ribavirin",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Definition of response phenotypes for combination therapy based on IFNL3 genotype"
                }
            },
            {
                "question": "What is the mechanism of action of ribavirin and how does it synergize with the IFNL3-related interferon response?",
                "answer": {
                    "Drug Name": "ribavirin",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Interaction between ribavirin's mechanism and the IFNL3-mediated immune pathway"
                }
            },
            {
                "question": "Are there specific ribavirin dosing guidelines for pediatric patients based on their IFNL3 genotype?",
                "answer": {
                    "Drug Name": "ribavirin",
                    "Gene Name": "IFNL3",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Pediatric dosing recommendations for ribavirin stratified by IFNL3 genotype"
                }
            },
            {
                "question": "Should ribavirin dosing be modified in a peginterferon regimen based on the patient's IFNL4 genotype?",
                "answer": {
                    "Drug Name": "ribavirin",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Ribavirin dose adjustment protocol based on IFNL4 genotype"
                }
            },
            {
                "question": "What is the SVR probability for a peginterferon/ribavirin regimen in a patient with the unfavorable IFNL4-ΔG allele?",
                "answer": {
                    "Drug Name": "ribavirin",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Quantified SVR rates for combination therapy with ribavirin in patients with the unfavorable IFNL4 genotype"
                }
            },
            {
                "question": "Is there a correlation between IFNL4 genotype and the therapeutic plasma concentration of ribavirin?",
                "answer": {
                    "Drug Name": "ribavirin",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Pharmacokinetic data on ribavirin concentrations stratified by IFNL4 genotype"
                }
            },
            {
                "question": "How does the IFNL4 genotype contribute to the overall response prediction for peginterferon/ribavirin therapy?",
                "answer": {
                    "Drug Name": "ribavirin",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Definition of response phenotypes for combination therapy based on IFNL4 genotype"
                }
            },
            {
                "question": "How does the IFNL4-ΔG variant, which produces a disruptive protein, affect the antiviral activity of ribavirin?",
                "answer": {
                    "Drug Name": "ribavirin",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Interaction between the IFNL4-ΔG gene product and the mechanism of action of ribavirin"
                }
            },
            {
                "question": "Are there specific recommendations for ribavirin use in patients with liver transplants based on their IFNL4 genotype?",
                "answer": {
                    "Drug Name": "ribavirin",
                    "Gene Name": "IFNL4",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
                    "Content to Search": "Guidance for ribavirin use in liver transplant recipients stratified by IFNL4 genotype"
                }
            }
        ]
    },
    {
        "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf": [
            {
                "question": "What is the recommended starting dose of azathioprine for a NUDT15 intermediate metabolizer?",
                "answer": {
                    "Drug Name": "azathioprine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Dose adjustment protocol or percentage reduction for azathioprine in NUDT15 intermediate metabolizers"
                }
            },
            {
                "question": "What is the risk of severe hematologic toxicity for a NUDT15 poor metabolizer taking a standard dose of azathioprine?",
                "answer": {
                    "Drug Name": "azathioprine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Quantified risk or incidence rate of severe myelosuppression in NUDT15 poor metabolizers using azathioprine"
                }
            },
            {
                "question": "How does NUDT15 poor metabolizer status affect the accumulation of active thioguanine nucleotide (TGN) metabolites from azathioprine?",
                "answer": {
                    "Drug Name": "azathioprine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Pharmacokinetic data on TGN concentrations in NUDT15 poor metabolizers after azathioprine administration"
                }
            },
            {
                "question": "Which diplotypes define a NUDT15 poor metabolizer?",
                "answer": {
                    "Drug Name": "azathioprine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Diplotype definitions for the NUDT15 poor metabolizer phenotype"
                }
            },
            {
                "question": "What is the function of the NUDT15 enzyme in the metabolic pathway of azathioprine?",
                "answer": {
                    "Drug Name": "azathioprine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Role of the NUDT15 enzyme in deactivating thiopurine metabolites"
                }
            },
            {
                "question": "What is the recommended azathioprine dosing for a pediatric patient with acute lymphoblastic leukemia (ALL) who is a NUDT15 intermediate metabolizer?",
                "answer": {
                    "Drug Name": "azathioprine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Pediatric dosing guidance for azathioprine in ALL patients with NUDT15 intermediate metabolizer status"
                }
            },
            {
                "question": "How should azathioprine dosing be adjusted for a TPMT intermediate metabolizer?",
                "answer": {
                    "Drug Name": "azathioprine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Dose adjustment protocol or percentage reduction for azathioprine in TPMT intermediate metabolizers"
                }
            },
            {
                "question": "What is the quantified risk of myelosuppression in a TPMT poor metabolizer treated with a standard dose of azathioprine?",
                "answer": {
                    "Drug Name": "azathioprine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Incidence rate or risk multiplier for myelosuppression in TPMT poor metabolizers using azathioprine"
                }
            },
            {
                "question": "What is the target therapeutic range for 6-thioguanine nucleotide (6-TGN) concentrations when treating inflammatory bowel disease with azathioprine?",
                "answer": {
                    "Drug Name": "azathioprine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Therapeutic window or target concentration range for 6-TGN metabolites"
                }
            },
            {
                "question": "Which diplotypes define a TPMT intermediate metabolizer?",
                "answer": {
                    "Drug Name": "azathioprine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Diplotype definitions for the TPMT intermediate metabolizer phenotype"
                }
            },
            {
                "question": "What is the function of the TPMT enzyme in shunting azathioprine metabolites away from the active cytotoxic pathway?",
                "answer": {
                    "Drug Name": "azathioprine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Role of the TPMT enzyme in the inactivation pathway of azathioprine metabolites"
                }
            },
            {
                "question": "What is the azathioprine dosing recommendation for a patient who is a TPMT intermediate metabolizer AND a NUDT15 intermediate metabolizer?",
                "answer": {
                    "Drug Name": "azathioprine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Dosing guidance for azathioprine in patients with combined TPMT and NUDT15 intermediate metabolizer status"
                }
            },
            {
                "question": "What is the recommended starting dose of mercaptopurine for a NUDT15 poor metabolizer?",
                "answer": {
                    "Drug Name": "mercaptopurine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Specific dose reduction or alternative therapy recommendation for mercaptopurine in NUDT15 poor metabolizers"
                }
            },
            {
                "question": "What is the incidence of leukopenia in Asian patients with the NUDT15 risk allele when treated with mercaptopurine?",
                "answer": {
                    "Drug Name": "mercaptopurine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Incidence rates of leukopenia in Asian populations with NUDT15 variants taking mercaptopurine"
                }
            },
            {
                "question": "How does NUDT15 deficiency impact the ratio of 6-TGN to 6-MMPN metabolites during mercaptopurine therapy?",
                "answer": {
                    "Drug Name": "mercaptopurine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Pharmacokinetic data on the ratio of active to inactive metabolites in NUDT15 deficient individuals on mercaptopurine"
                }
            },
            {
                "question": "Which NUDT15 alleles are most commonly associated with an intermediate metabolizer phenotype?",
                "answer": {
                    "Drug Name": "mercaptopurine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Allele definitions for the NUDT15 intermediate metabolizer phenotype"
                }
            },
            {
                "question": "How does mercaptopurine exert its cytotoxic effect, and how does NUDT15 activity mitigate this?",
                "answer": {
                    "Drug Name": "mercaptopurine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Mechanism of action of mercaptopurine and the protective role of the NUDT15 enzyme"
                }
            },
            {
                "question": "What is the mercaptopurine dosing recommendation for a pediatric ALL patient who is a NUDT15 poor metabolizer?",
                "answer": {
                    "Drug Name": "mercaptopurine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Pediatric dosing guidance for mercaptopurine in ALL patients with NUDT15 poor metabolizer status"
                }
            },
            {
                "question": "What is the recommended dose reduction of mercaptopurine for a TPMT poor metabolizer?",
                "answer": {
                    "Drug Name": "mercaptopurine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Specific dose reduction (e.g., percentage) for mercaptopurine in TPMT poor metabolizers"
                }
            },
            {
                "question": "What is the threshold for 6-TGN concentration that is associated with an increased risk of toxicity from mercaptopurine?",
                "answer": {
                    "Drug Name": "mercaptopurine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Toxicity threshold for 6-thioguanine nucleotide concentrations"
                }
            },
            {
                "question": "What are the expected 6-TGN levels in a TPMT intermediate metabolizer on a standard mercaptopurine dose compared to a normal metabolizer?",
                "answer": {
                    "Drug Name": "mercaptopurine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Comparative pharmacokinetic data on 6-TGN levels between TPMT intermediate and normal metabolizers"
                }
            },
            {
                "question": "Which TPMT alleles are combined to define a poor metabolizer phenotype?",
                "answer": {
                    "Drug Name": "mercaptopurine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Allele or diplotype definitions for the TPMT poor metabolizer phenotype"
                }
            },
            {
                "question": "What is the primary metabolic pathway for mercaptopurine inactivation that is catalyzed by TPMT?",
                "answer": {
                    "Drug Name": "mercaptopurine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Biochemical reaction catalyzed by TPMT in the metabolism of mercaptopurine"
                }
            },
            {
                "question": "What is the mercaptopurine dosing recommendation for a patient with Crohn's disease who is a TPMT intermediate metabolizer?",
                "answer": {
                    "Drug Name": "mercaptopurine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Dosing guidance for mercaptopurine in Crohn's disease patients with TPMT intermediate metabolizer status"
                }
            },
            {
                "question": "What is the recommended starting dose of thioguanine for a patient who is a NUDT15 intermediate metabolizer?",
                "answer": {
                    "Drug Name": "thioguanine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Dose adjustment protocol for thioguanine in NUDT15 intermediate metabolizers"
                }
            },
            {
                "question": "What is the risk of life-threatening myelosuppression when administering standard-dose thioguanine to a NUDT15 poor metabolizer?",
                "answer": {
                    "Drug Name": "thioguanine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Quantified risk data for severe toxicity in NUDT15 poor metabolizers using thioguanine"
                }
            },
            {
                "question": "How does NUDT15 genotype affect the intracellular concentration of thioguanine triphosphate (TGTP)?",
                "answer": {
                    "Drug Name": "thioguanine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Pharmacokinetic data on TGTP levels in relation to NUDT15 metabolizer status"
                }
            },
            {
                "question": "What is the phenotype assignment for a patient with one normal function and one no function NUDT15 allele?",
                "answer": {
                    "Drug Name": "thioguanine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Phenotype category for a heterozygous NUDT15 no function allele carrier"
                }
            },
            {
                "question": "What is the specific biochemical reaction catalyzed by NUDT15 that deactivates thioguanine's active metabolites?",
                "answer": {
                    "Drug Name": "thioguanine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Mechanism of NUDT15 enzyme in hydrolyzing active thioguanine metabolites"
                }
            },
            {
                "question": "Are there specific thioguanine dosing recommendations for patients of East Asian ancestry due to higher prevalence of NUDT15 variants?",
                "answer": {
                    "Drug Name": "thioguanine",
                    "Gene Name": "NUDT15",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Dosing guidance for thioguanine in East Asian populations considering NUDT15 genotype"
                }
            },
            {
                "question": "What is the recommended dose adjustment for thioguanine in a patient who is a TPMT intermediate metabolizer?",
                "answer": {
                    "Drug Name": "thioguanine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Dose reduction protocol for thioguanine in TPMT intermediate metabolizers"
                }
            },
            {
                "question": "What is the risk of developing hepatotoxicity (nodular regenerative hyperplasia) in a TPMT normal metabolizer on long-term thioguanine therapy?",
                "answer": {
                    "Drug Name": "thioguanine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Risk data for thioguanine-induced hepatotoxicity in TPMT normal metabolizers"
                }
            },
            {
                "question": "What is the expected level of 6-methylmercaptopurine (6-MMP) metabolites in a TPMT normal metabolizer taking thioguanine?",
                "answer": {
                    "Drug Name": "thioguanine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Pharmacokinetic data on 6-MMP levels in TPMT normal metabolizers on thioguanine"
                }
            },
            {
                "question": "What is the phenotype assignment for a patient with a TPMT*1/*3A diplotype?",
                "answer": {
                    "Drug Name": "thioguanine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Phenotype category (intermediate metabolizer) for the TPMT*1/*3A diplotype"
                }
            },
            {
                "question": "How does the metabolic pathway of thioguanine differ from azathioprine and mercaptopurine with respect to TPMT's role?",
                "answer": {
                    "Drug Name": "thioguanine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Comparison of thiopurine metabolic pathways and the specific role of TPMT for thioguanine"
                }
            },
            {
                "question": "What is the thioguanine dosing recommendation for a patient with IBD who is a TPMT poor metabolizer?",
                "answer": {
                    "Drug Name": "thioguanine",
                    "Gene Name": "TPMT",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
                    "Content to Search": "Dosing guidance or contraindication for thioguanine in IBD patients with TPMT poor metabolizer status"
                }
            }
        ]
    },
        {
        "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf": [
            {
                "question": "What is the recommended dosing adjustment for amitriptyline in a CYP2C19 ultrarapid metabolizer?",
                "answer": {
                    "Drug Name": "amitriptyline",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dose adjustment protocol for amitriptyline in CYP2C19 ultrarapid metabolizers"
                }
            },
            {
                "question": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking amitriptyline?",
                "answer": {
                    "Drug Name": "amitriptyline",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using amitriptyline"
                }
            },
            {
                "question": "What is the expected plasma concentration of amitriptyline in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
                "answer": {
                    "Drug Name": "amitriptyline",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Pharmacokinetic data comparing amitriptyline plasma concentrations between CYP2C19 poor and normal metabolizers"
                }
            },
            {
                "question": "Which diplotypes define a CYP2C19 ultrarapid metabolizer?",
                "answer": {
                    "Drug Name": "amitriptyline",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2C19 ultrarapid metabolizer phenotype"
                }
            },
            {
                "question": "What is the role of the CYP2C19 enzyme in the metabolism of amitriptyline?",
                "answer": {
                    "Drug Name": "amitriptyline",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Function of CYP2C19 enzyme in the metabolic pathway of amitriptyline"
                }
            },
            {
                "question": "Are there specific amitriptyline dosing recommendations for pediatric patients who are CYP2C19 poor metabolizers?",
                "answer": {
                    "Drug Name": "amitriptyline",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Pediatric dosing guidance for amitriptyline in CYP2C19 poor metabolizers"
                }
            },
            {
                "question": "What is the recommended starting dose of amitriptyline for a CYP2D6 poor metabolizer?",
                "answer": {
                    "Drug Name": "amitriptyline",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Recommended starting dose and titration protocol for amitriptyline in CYP2D6 poor metabolizers"
                }
            },
            {
                "question": "What is the risk of cardiotoxicity for a CYP2D6 poor metabolizer taking amitriptyline?",
                "answer": {
                    "Drug Name": "amitriptyline",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk of cardiotoxicity or QTc prolongation in CYP2D6 poor metabolizers on amitriptyline"
                }
            },
            {
                "question": "What is the suggested therapeutic range for the sum of amitriptyline and nortriptyline concentrations, and how is it affected by CYP2D6 status?",
                "answer": {
                    "Drug Name": "amitriptyline",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Therapeutic drug monitoring range for amitriptyline plus nortriptyline and its relation to CYP2D6 phenotype"
                }
            },
            {
                "question": "What diplotypes define a CYP2D6 poor metabolizer?",
                "answer": {
                    "Drug Name": "amitriptyline",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2D6 poor metabolizer phenotype"
                }
            },
            {
                "question": "How does the CYP2D6 enzyme metabolize amitriptyline to its active metabolite, nortriptyline?",
                "answer": {
                    "Drug Name": "amitriptyline",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Mechanism of CYP2D6-mediated metabolism of amitriptyline to nortriptyline"
                }
            },
            {
                "question": "What is the amitriptyline dosing recommendation for an elderly patient who is a CYP2D6 poor metabolizer?",
                "answer": {
                    "Drug Name": "amitriptyline",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Geriatric dosing recommendations for amitriptyline in CYP2D6 poor metabolizers"
                }
            },
            {
                "question": "What is the recommended dose adjustment for clomipramine in a patient who is a CYP2C19 poor metabolizer?",
                "answer": {
                    "Drug Name": "clomipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dose adjustment protocol for clomipramine in CYP2C19 poor metabolizers"
                }
            },
            {
                "question": "What is the increased risk of anticholinergic side effects in a CYP2C19 poor metabolizer taking clomipramine?",
                "answer": {
                    "Drug Name": "clomipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk of anticholinergic effects in CYP2C19 poor metabolizers on clomipramine"
                }
            },
            {
                "question": "How does CYP2C19 ultrarapid metabolizer status affect the plasma concentration of clomipramine?",
                "answer": {
                    "Drug Name": "clomipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Pharmacokinetic data on clomipramine plasma concentrations in CYP2C19 ultrarapid metabolizers"
                }
            },
            {
                "question": "Which diplotypes define a CYP2C19 intermediate metabolizer?",
                "answer": {
                    "Drug Name": "clomipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2C19 intermediate metabolizer phenotype"
                }
            },
            {
                "question": "What is the role of the CYP2C19 enzyme in the demethylation of clomipramine?",
                "answer": {
                    "Drug Name": "clomipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Function of CYP2C19 in the metabolic pathway of clomipramine"
                }
            },
            {
                "question": "Are there specific clomipramine dosing guidelines for adolescents with OCD who are CYP2C19 ultrarapid metabolizers?",
                "answer": {
                    "Drug Name": "clomipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Adolescent dosing recommendations for clomipramine in CYP2C19 ultrarapid metabolizers"
                }
            },
            {
                "question": "What is the recommended clomipramine dose for a patient who is a CYP2D6 ultrarapid metabolizer?",
                "answer": {
                    "Drug Name": "clomipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dosing recommendation for clomipramine in CYP2D6 ultrarapid metabolizers"
                }
            },
            {
                "question": "What is the risk of therapeutic failure for a CYP2D6 ultrarapid metabolizer on a standard dose of clomipramine?",
                "answer": {
                    "Drug Name": "clomipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk of non-response or therapeutic failure in CYP2D6 ultrarapid metabolizers taking clomipramine"
                }
            },
            {
                "question": "What is the target plasma concentration for the sum of clomipramine and desmethylclomipramine, and how is it influenced by CYP2D6 phenotype?",
                "answer": {
                    "Drug Name": "clomipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Therapeutic drug monitoring range for clomipramine plus its metabolite and its relation to CYP2D6 status"
                }
            },
            {
                "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
                "answer": {
                    "Drug Name": "clomipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2D6 ultrarapid metabolizer phenotype"
                }
            },
            {
                "question": "What is the function of the CYP2D6 enzyme in the hydroxylation of clomipramine?",
                "answer": {
                    "Drug Name": "clomipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Role of CYP2D6 in the metabolic pathway of clomipramine"
                }
            },
            {
                "question": "What is the clomipramine dosing recommendation for a patient who is both a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer?",
                "answer": {
                    "Drug Name": "clomipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dosing guidance for clomipramine in patients with combined CYP2D6 and CYP2C19 poor metabolizer status"
                }
            },
            {
                "question": "Is there any recommended dosing adjustment for desipramine based on CYP2C19 genotype?",
                "answer": {
                    "Drug Name": "desipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dose adjustment protocol for desipramine based on CYP2C19 status"
                }
            },
            {
                "question": "Is there a documented increased risk of adverse effects from desipramine in CYP2C19 poor metabolizers?",
                "answer": {
                    "Drug Name": "desipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using desipramine"
                }
            },
            {
                "question": "Does CYP2C19 genotype significantly alter the plasma concentrations of desipramine?",
                "answer": {
                    "Drug Name": "desipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Pharmacokinetic data on the impact of CYP2C19 genotype on desipramine plasma levels"
                }
            },
            {
                "question": "What diplotypes define a CYP2C19 poor metabolizer?",
                "answer": {
                    "Drug Name": "desipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2C19 poor metabolizer phenotype"
                }
            },
            {
                "question": "What is the role, if any, of the CYP2C19 enzyme in the metabolism of desipramine?",
                "answer": {
                    "Drug Name": "desipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Function of CYP2C19 enzyme in the metabolic pathway of desipramine"
                }
            },
            {
                "question": "Are there any special considerations for pediatric patients on desipramine with a known CYP2C19 variant?",
                "answer": {
                    "Drug Name": "desipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Pediatric dosing or safety considerations for desipramine related to CYP2C19 status"
                }
            },
            {
                "question": "What is the recommended dose reduction for desipramine in a CYP2D6 poor metabolizer?",
                "answer": {
                    "Drug Name": "desipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Specific dose reduction percentage for desipramine in CYP2D6 poor metabolizers"
                }
            },
            {
                "question": "What is the increased risk of QTc prolongation for a CYP2D6 poor metabolizer taking desipramine?",
                "answer": {
                    "Drug Name": "desipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk of QTc prolongation in CYP2D6 poor metabolizers on desipramine"
                }
            },
            {
                "question": "What is the target plasma concentration range for desipramine, and how is it affected by CYP2D6 ultrarapid metabolizer status?",
                "answer": {
                    "Drug Name": "desipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Therapeutic drug monitoring range for desipramine and its relation to CYP2D6 ultrarapid metabolizer status"
                }
            },
            {
                "question": "Which diplotypes define a CYP2D6 intermediate metabolizer?",
                "answer": {
                    "Drug Name": "desipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2D6 intermediate metabolizer phenotype"
                }
            },
            {
                "question": "What is the primary metabolic pathway for desipramine clearance involving the CYP2D6 enzyme?",
                "answer": {
                    "Drug Name": "desipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Role of CYP2D6-mediated hydroxylation in desipramine metabolism"
                }
            },
            {
                "question": "Are there specific desipramine dosing guidelines for geriatric patients who are CYP2D6 intermediate metabolizers?",
                "answer": {
                    "Drug Name": "desipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Geriatric dosing recommendations for desipramine in CYP2D6 intermediate metabolizers"
                }
            },
            {
                "question": "How should doxepin dosing be adjusted for a CYP2C19 poor metabolizer?",
                "answer": {
                    "Drug Name": "doxepin",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dose adjustment protocol for doxepin in CYP2C19 poor metabolizers"
                }
            },
            {
                "question": "What is the risk of excessive sedation in a CYP2C19 poor metabolizer taking doxepin?",
                "answer": {
                    "Drug Name": "doxepin",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk of sedation or other CNS effects in CYP2C19 poor metabolizers on doxepin"
                }
            },
            {
                "question": "What is the expected plasma concentration of doxepin in a CYP2C19 ultrarapid metabolizer?",
                "answer": {
                    "Drug Name": "doxepin",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Pharmacokinetic data on doxepin plasma concentrations in CYP2C19 ultrarapid metabolizers"
                }
            },
            {
                "question": "Which genotypes correspond to the CYP2C19 normal metabolizer phenotype?",
                "answer": {
                    "Drug Name": "doxepin",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Genotype or diplotype definitions for the CYP2C19 normal metabolizer phenotype"
                }
            },
            {
                "question": "What is the role of CYP2C19 in the metabolism of doxepin to nordoxepin?",
                "answer": {
                    "Drug Name": "doxepin",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Function of CYP2C19 in the N-demethylation of doxepin"
                }
            },
            {
                "question": "Are there specific doxepin dosing recommendations for patients with comorbid anxiety who are CYP2C19 poor metabolizers?",
                "answer": {
                    "Drug Name": "doxepin",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dosing guidance for doxepin in patients with anxiety and CYP2C19 poor metabolizer status"
                }
            },
            {
                "question": "What is the recommended starting dose of doxepin for a CYP2D6 poor metabolizer?",
                "answer": {
                    "Drug Name": "doxepin",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Recommended starting dose for doxepin in CYP2D6 poor metabolizers"
                }
            },
            {
                "question": "What is the increased risk of adverse events in a CYP2D6 poor metabolizer taking doxepin?",
                "answer": {
                    "Drug Name": "doxepin",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk of adverse events in CYP2D6 poor metabolizers on doxepin"
                }
            },
            {
                "question": "What is the therapeutic range for the sum of doxepin and nordoxepin concentrations?",
                "answer": {
                    "Drug Name": "doxepin",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Therapeutic drug monitoring range for doxepin plus its active metabolite"
                }
            },
            {
                "question": "Which diplotypes define a CYP2D6 poor metabolizer?",
                "answer": {
                    "Drug Name": "doxepin",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2D6 poor metabolizer phenotype"
                }
            },
            {
                "question": "What is the function of the CYP2D6 enzyme in the metabolism of doxepin?",
                "answer": {
                    "Drug Name": "doxepin",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Role of CYP2D6 in the metabolic clearance of doxepin"
                }
            },
            {
                "question": "What is the doxepin dosing recommendation for a patient who is both a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer?",
                "answer": {
                    "Drug Name": "doxepin",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dosing guidance for doxepin in patients with combined CYP2D6 and CYP2C19 ultrarapid metabolizer status"
                }
            },
            {
                "question": "What is the recommended dosing adjustment for imipramine in a CYP2C19 ultrarapid metabolizer?",
                "answer": {
                    "Drug Name": "imipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dose adjustment protocol for imipramine in CYP2C19 ultrarapid metabolizers"
                }
            },
            {
                "question": "What is the risk of therapeutic failure for a CYP2C19 ultrarapid metabolizer on a standard dose of imipramine?",
                "answer": {
                    "Drug Name": "imipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk of non-response in CYP2C19 ultrarapid metabolizers taking imipramine"
                }
            },
            {
                "question": "How does CYP2C19 poor metabolizer status affect the plasma concentration of imipramine?",
                "answer": {
                    "Drug Name": "imipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Pharmacokinetic data on imipramine plasma concentrations in CYP2C19 poor metabolizers"
                }
            },
            {
                "question": "Which diplotypes define a CYP2C19 poor metabolizer?",
                "answer": {
                    "Drug Name": "imipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2C19 poor metabolizer phenotype"
                }
            },
            {
                "question": "What is the role of the CYP2C19 enzyme in the N-demethylation of imipramine to desipramine?",
                "answer": {
                    "Drug Name": "imipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Function of CYP2C19 in the metabolic conversion of imipramine to desipramine"
                }
            },
            {
                "question": "Are there specific imipramine dosing recommendations for pediatric patients with enuresis who are CYP2C19 poor metabolizers?",
                "answer": {
                    "Drug Name": "imipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Pediatric dosing guidance for imipramine in CYP2C19 poor metabolizers with enuresis"
                }
            },
            {
                "question": "What is the recommended starting dose of imipramine for a CYP2D6 poor metabolizer?",
                "answer": {
                    "Drug Name": "imipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Recommended starting dose for imipramine in CYP2D6 poor metabolizers"
                }
            },
            {
                "question": "What is the increased risk of toxicity in a CYP2D6 poor metabolizer taking imipramine?",
                "answer": {
                    "Drug Name": "imipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk of toxicity in CYP2D6 poor metabolizers on imipramine"
                }
            },
            {
                "question": "What is the therapeutic range for the sum of imipramine and desipramine concentrations?",
                "answer": {
                    "Drug Name": "imipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Therapeutic drug monitoring range for imipramine plus its active metabolite, desipramine"
                }
            },
            {
                "question": "Which diplotypes define a CYP2D6 ultrarapid metabolizer?",
                "answer": {
                    "Drug Name": "imipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2D6 ultrarapid metabolizer phenotype"
                }
            },
            {
                "question": "What is the function of the CYP2D6 enzyme in the hydroxylation of imipramine?",
                "answer": {
                    "Drug Name": "imipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Role of CYP2D6 in the metabolic clearance of imipramine"
                }
            },
            {
                "question": "What is the imipramine dosing recommendation for a patient who is a CYP2D6 poor metabolizer and also has renal impairment?",
                "answer": {
                    "Drug Name": "imipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dosing guidance for imipramine in patients with both CYP2D6 poor metabolizer status and renal impairment"
                }
            },
            {
                "question": "Is there a recommended dosing adjustment for nortriptyline based on CYP2C19 genotype?",
                "answer": {
                    "Drug Name": "nortriptyline",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dose adjustment protocol for nortriptyline based on CYP2C19 status"
                }
            },
            {
                "question": "Is there a documented increased risk of adverse effects from nortriptyline in CYP2C19 poor metabolizers?",
                "answer": {
                    "Drug Name": "nortriptyline",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using nortriptyline"
                }
            },
            {
                "question": "Does CYP2C19 genotype significantly alter the plasma concentrations of nortriptyline?",
                "answer": {
                    "Drug Name": "nortriptyline",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Pharmacokinetic data on the impact of CYP2C19 genotype on nortriptyline plasma levels"
                }
            },
            {
                "question": "What diplotypes define a CYP2C19 normal metabolizer?",
                "answer": {
                    "Drug Name": "nortriptyline",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2C19 normal metabolizer phenotype"
                }
            },
            {
                "question": "What is the role, if any, of the CYP2C19 enzyme in the metabolism of nortriptyline?",
                "answer": {
                    "Drug Name": "nortriptyline",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Function of CYP2C19 enzyme in the metabolic pathway of nortriptyline"
                }
            },
            {
                "question": "Are there any special considerations for using nortriptyline for smoking cessation in patients with known CYP2C19 variants?",
                "answer": {
                    "Drug Name": "nortriptyline",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dosing or safety considerations for nortriptyline in smoking cessation related to CYP2C19 status"
                }
            },
            {
                "question": "What is the recommended dose reduction for nortriptyline in a CYP2D6 poor metabolizer?",
                "answer": {
                    "Drug Name": "nortriptyline",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Specific dose reduction percentage for nortriptyline in CYP2D6 poor metabolizers"
                }
            },
            {
                "question": "What is the increased risk of adverse events for a CYP2D6 poor metabolizer taking nortriptyline?",
                "answer": {
                    "Drug Name": "nortriptyline",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk of adverse events in CYP2D6 poor metabolizers on nortriptyline"
                }
            },
            {
                "question": "What is the target plasma concentration range for nortriptyline?",
                "answer": {
                    "Drug Name": "nortriptyline",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Therapeutic drug monitoring range for nortriptyline"
                }
            },
            {
                "question": "Which diplotypes define a CYP2D6 poor metabolizer?",
                "answer": {
                    "Drug Name": "nortriptyline",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2D6 poor metabolizer phenotype"
                }
            },
            {
                "question": "What is the primary metabolic pathway for nortriptyline clearance involving the CYP2D6 enzyme?",
                "answer": {
                    "Drug Name": "nortriptyline",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Role of CYP2D6-mediated hydroxylation in nortriptyline metabolism"
                }
            },
            {
                "question": "Are there specific nortriptyline dosing guidelines for geriatric patients who are CYP2D6 ultrarapid metabolizers?",
                "answer": {
                    "Drug Name": "nortriptyline",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Geriatric dosing recommendations for nortriptyline in CYP2D6 ultrarapid metabolizers"
                }
            },
            {
                "question": "How should trimipramine dosing be adjusted for a CYP2C19 poor metabolizer?",
                "answer": {
                    "Drug Name": "trimipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dose adjustment protocol for trimipramine in CYP2C19 poor metabolizers"
                }
            },
            {
                "question": "What is the risk of toxicity in a CYP2C19 poor metabolizer taking trimipramine?",
                "answer": {
                    "Drug Name": "trimipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk of toxicity in CYP2C19 poor metabolizers on trimipramine"
                }
            },
            {
                "question": "How does CYP2C19 ultrarapid metabolizer status affect the plasma concentration of trimipramine?",
                "answer": {
                    "Drug Name": "trimipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Pharmacokinetic data on trimipramine plasma concentrations in CYP2C19 ultrarapid metabolizers"
                }
            },
            {
                "question": "Which genotypes correspond to the CYP2C19 intermediate metabolizer phenotype?",
                "answer": {
                    "Drug Name": "trimipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Genotype or diplotype definitions for the CYP2C19 intermediate metabolizer phenotype"
                }
            },
            {
                "question": "What is the role of CYP2C19 in the metabolism of trimipramine?",
                "answer": {
                    "Drug Name": "trimipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Function of CYP2C19 in the metabolic pathway of trimipramine"
                }
            },
            {
                "question": "Are there specific trimipramine dosing recommendations for pregnant patients who are CYP2C19 poor metabolizers?",
                "answer": {
                    "Drug Name": "trimipramine",
                    "Gene Name": "CYP2C19",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dosing guidance for trimipramine during pregnancy for CYP2C19 poor metabolizers"
                }
            },
            {
                "question": "What is the recommended starting dose of trimipramine for a CYP2D6 poor metabolizer?",
                "answer": {
                    "Drug Name": "trimipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Recommended starting dose for trimipramine in CYP2D6 poor metabolizers"
                }
            },
            {
                "question": "What is the increased risk of adverse events in a CYP2D6 poor metabolizer taking trimipramine?",
                "answer": {
                    "Drug Name": "trimipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Quantified risk of adverse events in CYP2D6 poor metabolizers on trimipramine"
                }
            },
            {
                "question": "Is there a recommended therapeutic range for trimipramine concentrations?",
                "answer": {
                    "Drug Name": "trimipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Therapeutic drug monitoring range for trimipramine"
                }
            },
            {
                "question": "Which diplotypes define a CYP2D6 normal metabolizer?",
                "answer": {
                    "Drug Name": "trimipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Diplotype definitions for the CYP2D6 normal metabolizer phenotype"
                }
            },
            {
                "question": "What is the function of the CYP2D6 enzyme in the metabolism of trimipramine?",
                "answer": {
                    "Drug Name": "trimipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Role of CYP2D6 in the metabolic clearance of trimipramine"
                }
            },
            {
                "question": "What is the trimipramine dosing recommendation for a patient who is a CYP2D6 poor metabolizer and is taking a concurrent CYP2D6 inhibitor?",
                "answer": {
                    "Drug Name": "trimipramine",
                    "Gene Name": "CYP2D6",
                    "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
                    "Content to Search": "Dosing guidance for trimipramine in CYP2D6 poor metabolizers with a drug-drug interaction involving a CYP2D6 inhibitor"
                }
            }
        ]
    },
        {
    "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf": [
        {
        "question": "What is the recommended alfentanil dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for alfentanil in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking alfentanil?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for alfentanil in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma alfentanil concentrations in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for alfentanil stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'low-activity' phenotype?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to alfentanil?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and alfentanil's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for alfentanil in pediatric patients with a COMT high-activity genotype?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for alfentanil adjusted for COMT high-activity genotype."
        }
        },
        {
        "question": "How should alfentanil dosing be adjusted for a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for alfentanil in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking alfentanil?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using alfentanil."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma alfentanil concentrations in a CYP2D6 intermediate metabolizer?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration ranges for alfentanil in CYP2D6 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of alfentanil?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in alfentanil metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for alfentanil in children with a CYP2D6 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing adjustments for alfentanil in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "How should alfentanil dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for alfentanil based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking alfentanil?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of alfentanil in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma alfentanil concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for alfentanil stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered opioid response or dose requirements?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on opioid response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of alfentanil therapy?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for alfentanil."
        }
        },
        {
        "question": "What is the dosing recommendation for alfentanil in patients with cancer pain and an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "alfentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for alfentanil in cancer patients, adjusted for OPRM1 genotype."
        }
        },
        {
        "question": "What is the recommended buprenorphine dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for buprenorphine in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking buprenorphine?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for buprenorphine in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma buprenorphine concentrations in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for buprenorphine stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'high-activity' phenotype?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT high-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to buprenorphine?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and buprenorphine's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for buprenorphine in pediatric patients with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for buprenorphine adjusted for COMT low-activity genotype."
        }
        },
        {
        "question": "How should buprenorphine dosing be adjusted for a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for buprenorphine in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking buprenorphine?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using buprenorphine."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma buprenorphine concentrations in a CYP2D6 intermediate metabolizer?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration ranges for buprenorphine in CYP2D6 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of buprenorphine?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in buprenorphine metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for buprenorphine in children with a CYP2D6 ultrarapid metabolizer phenotype?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing adjustments for buprenorphine in CYP2D6 ultrarapid metabolizers."
        }
        },
        {
        "question": "How should buprenorphine dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for buprenorphine based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking buprenorphine?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of buprenorphine in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma buprenorphine concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for buprenorphine stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered buprenorphine response?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on buprenorphine response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of buprenorphine therapy?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, a primary target for buprenorphine."
        }
        },
        {
        "question": "What is the dosing recommendation for buprenorphine in patients with opioid use disorder and an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "buprenorphine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for buprenorphine in opioid use disorder patients, adjusted for OPRM1 genotype."
        }
        },
        {
        "question": "What is the recommended codeine dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for codeine in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking codeine?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for codeine in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma morphine concentrations (from codeine) in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for morphine (active metabolite of codeine) stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'normal-activity' phenotype?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to codeine?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and codeine's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for codeine in pediatric patients with a COMT high-activity genotype?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for codeine adjusted for COMT high-activity genotype."
        }
        },
        {
        "question": "What is the recommended codeine dose for a CYP2D6 ultrarapid metabolizer?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Specific dosing recommendation or contraindication for codeine in CYP2D6 ultrarapid metabolizers."
        }
        },
        {
        "question": "What is the increased risk of morphine toxicity for a CYP2D6 ultrarapid metabolizer taking codeine?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk, incidence rate, or odds ratio for morphine toxicity in CYP2D6 UMs using codeine."
        }
        },
        {
        "question": "What are the expected plasma concentrations of morphine in a CYP2D6 poor metabolizer after a standard dose of codeine?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration data for morphine (the active metabolite of codeine) in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and corresponding activity scores for the CYP2D6 poor metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of codeine?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in converting codeine to its active metabolite, morphine."
        }
        },
        {
        "question": "What is the dosing recommendation for codeine in breastfeeding mothers who are CYP2D6 ultrarapid metabolizers?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing recommendations or contraindications for codeine in lactating mothers with a CYP2D6 UM phenotype."
        }
        },
        {
        "question": "How should codeine dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for codeine based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking codeine?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of codeine in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma morphine concentrations (from codeine) in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for morphine (active metabolite of codeine) stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered codeine response?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on codeine response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of codeine therapy?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for codeine's active metabolite, morphine."
        }
        },
        {
        "question": "What is the dosing recommendation for codeine in pediatric patients post-tonsillectomy with an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "codeine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for codeine in pediatric post-tonsillectomy patients, adjusted for OPRM1 genotype."
        }
        },
        {
        "question": "What is the recommended fentanyl dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for fentanyl in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking fentanyl?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for fentanyl in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma fentanyl concentrations in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for fentanyl stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'low-activity' phenotype?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to fentanyl?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and fentanyl's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for fentanyl in pediatric patients with a COMT high-activity genotype?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for fentanyl adjusted for COMT high-activity genotype."
        }
        },
        {
        "question": "How should fentanyl dosing be adjusted for a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for fentanyl in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking fentanyl?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using fentanyl."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma fentanyl concentrations in a CYP2D6 intermediate metabolizer?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration ranges for fentanyl in CYP2D6 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 normal metabolizer?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of fentanyl?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in fentanyl metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for fentanyl in children with a CYP2D6 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing adjustments for fentanyl in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "How should fentanyl dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for fentanyl based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking fentanyl?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of fentanyl in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma fentanyl concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for fentanyl stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered fentanyl response?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on fentanyl response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of fentanyl therapy?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for fentanyl."
        }
        },
        {
        "question": "What is the dosing recommendation for fentanyl in patients with cancer pain and an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "fentanyl",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for fentanyl in cancer patients, adjusted for OPRM1 genotype."
        }
        },
        {
        "question": "What is the recommended hydrocodone dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for hydrocodone in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking hydrocodone?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for hydrocodone in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma hydromorphone concentrations (from hydrocodone) in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for hydromorphone (active metabolite of hydrocodone) stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'normal-activity' phenotype?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to hydrocodone?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and hydrocodone's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for hydrocodone in pediatric patients with a COMT high-activity genotype?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for hydrocodone adjusted for COMT high-activity genotype."
        }
        },
        {
        "question": "What is the recommended hydrocodone dose for a CYP2D6 ultrarapid metabolizer?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Specific dosing recommendation or contraindication for hydrocodone in CYP2D6 ultrarapid metabolizers."
        }
        },
        {
        "question": "What is the increased risk of hydromorphone toxicity for a CYP2D6 ultrarapid metabolizer taking hydrocodone?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk, incidence rate, or odds ratio for hydromorphone toxicity in CYP2D6 UMs using hydrocodone."
        }
        },
        {
        "question": "What are the expected plasma concentrations of hydromorphone in a CYP2D6 poor metabolizer after a standard dose of hydrocodone?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration data for hydromorphone (the active metabolite of hydrocodone) in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and corresponding activity scores for the CYP2D6 poor metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of hydrocodone?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in converting hydrocodone to its active metabolite, hydromorphone."
        }
        },
        {
        "question": "What is the dosing recommendation for hydrocodone in breastfeeding mothers who are CYP2D6 ultrarapid metabolizers?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing recommendations or contraindications for hydrocodone in lactating mothers with a CYP2D6 UM phenotype."
        }
        },
        {
        "question": "How should hydrocodone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for hydrocodone based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking hydrocodone?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of hydrocodone in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma hydromorphone concentrations (from hydrocodone) in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for hydromorphone (active metabolite of hydrocodone) stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered hydrocodone response?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on hydrocodone response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of hydrocodone therapy?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for hydrocodone's active metabolite, hydromorphone."
        }
        },
        {
        "question": "What is the dosing recommendation for hydrocodone in pediatric patients with an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "hydrocodone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for hydrocodone in pediatric patients, adjusted for OPRM1 genotype."
        }
        },
        {
        "question": "What is the recommended hydromorphone dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for hydromorphone in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking hydromorphone?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for hydromorphone in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma hydromorphone concentrations in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for hydromorphone stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'high-activity' phenotype?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT high-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to hydromorphone?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and hydromorphone's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for hydromorphone in pediatric patients with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for hydromorphone adjusted for COMT low-activity genotype."
        }
        },
        {
        "question": "How should hydromorphone dosing be adjusted for a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for hydromorphone in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking hydromorphone?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using hydromorphone."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma hydromorphone concentrations in a CYP2D6 intermediate metabolizer?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration ranges for hydromorphone in CYP2D6 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of hydromorphone?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in hydromorphone metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for hydromorphone in children with a CYP2D6 ultrarapid metabolizer phenotype?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing adjustments for hydromorphone in CYP2D6 ultrarapid metabolizers."
        }
        },
        {
        "question": "How should hydromorphone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for hydromorphone based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking hydromorphone?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of hydromorphone in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma hydromorphone concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for hydromorphone stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered hydromorphone response?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on hydromorphone response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of hydromorphone therapy?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for hydromorphone."
        }
        },
        {
        "question": "What is the dosing recommendation for hydromorphone in patients with cancer pain and an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "hydromorphone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for hydromorphone in cancer patients, adjusted for OPRM1 genotype."
        }
        },
        {
        "question": "What is the recommended levomethadone dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for levomethadone in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking levomethadone?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for levomethadone in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma levomethadone concentrations in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for levomethadone stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'low-activity' phenotype?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to levomethadone?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and levomethadone's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for levomethadone in pediatric patients with a COMT high-activity genotype?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for levomethadone adjusted for COMT high-activity genotype."
        }
        },
        {
        "question": "How should levomethadone dosing be adjusted for a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for levomethadone in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking levomethadone?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using levomethadone."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma levomethadone concentrations in a CYP2D6 intermediate metabolizer?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration ranges for levomethadone in CYP2D6 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of levomethadone?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in levomethadone metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for levomethadone in children with a CYP2D6 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing adjustments for levomethadone in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "How should levomethadone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for levomethadone based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking levomethadone?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of levomethadone in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma levomethadone concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for levomethadone stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered levomethadone response?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on levomethadone response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of levomethadone therapy?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for levomethadone."
        }
        },
        {
        "question": "What is the dosing recommendation for levomethadone in patients with opioid use disorder and an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "levomethadone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for levomethadone in opioid use disorder patients, adjusted for OPRM1 genotype."
        }
        },
        {
        "question": "What is the recommended methadone dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for methadone in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking methadone?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for methadone in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma methadone concentrations in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for methadone stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'normal-activity' phenotype?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to methadone?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and methadone's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for methadone in pediatric patients with a COMT high-activity genotype?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for methadone adjusted for COMT high-activity genotype."
        }
        },
        {
        "question": "How should methadone dosing be adjusted for a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for methadone in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking methadone?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using methadone."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma methadone concentrations in a CYP2D6 intermediate metabolizer?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration ranges for methadone in CYP2D6 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 normal metabolizer?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of methadone?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in methadone metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for methadone in children with a CYP2D6 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing adjustments for methadone in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "How should methadone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for methadone based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking methadone?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of methadone in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma methadone concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for methadone stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered methadone response?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on methadone response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of methadone therapy?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for methadone."
        }
        },
        {
        "question": "What is the dosing recommendation for methadone in patients with opioid use disorder and an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "methadone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for methadone in opioid use disorder patients, adjusted for OPRM1 genotype."
        }
        },
        {
        "question": "What is the recommended morphine dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for morphine in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking morphine?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for morphine in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma morphine concentrations in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for morphine stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'high-activity' phenotype?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT high-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to morphine?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and morphine's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for morphine in pediatric patients with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for morphine adjusted for COMT low-activity genotype."
        }
        },
        {
        "question": "How should morphine dosing be adjusted for a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for morphine in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking morphine?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using morphine."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma morphine concentrations in a CYP2D6 intermediate metabolizer?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration ranges for morphine in CYP2D6 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of morphine?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in morphine metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for morphine in children with a CYP2D6 ultrarapid metabolizer phenotype?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing adjustments for morphine in CYP2D6 ultrarapid metabolizers."
        }
        },
        {
        "question": "How should morphine dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for morphine based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking morphine?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of morphine in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma morphine concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for morphine stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered morphine response?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on morphine response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of morphine therapy?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for morphine."
        }
        },
        {
        "question": "What is the dosing recommendation for morphine in patients with cancer pain and an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "morphine",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for morphine in cancer patients, adjusted for OPRM1 genotype."
        }
        },
        {
        "question": "What is the recommended naltrexone dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for naltrexone in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking naltrexone?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for naltrexone in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma naltrexone concentrations in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for naltrexone stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'low-activity' phenotype?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to naltrexone?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and naltrexone's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for naltrexone in pediatric patients with a COMT high-activity genotype?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for naltrexone adjusted for COMT high-activity genotype."
        }
        },
        {
        "question": "How should naltrexone dosing be adjusted for a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for naltrexone in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking naltrexone?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using naltrexone."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma naltrexone concentrations in a CYP2D6 intermediate metabolizer?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration ranges for naltrexone in CYP2D6 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of naltrexone?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in naltrexone metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for naltrexone in children with a CYP2D6 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing adjustments for naltrexone in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "How should naltrexone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for naltrexone based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of altered therapeutic effect for individuals with the OPRM1 A118G variant when taking naltrexone?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for altered therapeutic efficacy of naltrexone in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma naltrexone concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for naltrexone stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered naltrexone response?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on naltrexone response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of naltrexone therapy?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for naltrexone."
        }
        },
        {
        "question": "What is the dosing recommendation for naltrexone in patients with alcohol use disorder and an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "naltrexone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for naltrexone in alcohol use disorder patients, adjusted for OPRM1 genotype."
        }
        },
        {
        "question": "What is the recommended oxycodone dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for oxycodone in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking oxycodone?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for oxycodone in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma oxymorphone concentrations (from oxycodone) in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for oxymorphone (active metabolite of oxycodone) stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'normal-activity' phenotype?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to oxycodone?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and oxycodone's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for oxycodone in pediatric patients with a COMT high-activity genotype?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for oxycodone adjusted for COMT high-activity genotype."
        }
        },
        {
        "question": "What is the recommended oxycodone dose for a CYP2D6 ultrarapid metabolizer?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Specific dosing recommendation or contraindication for oxycodone in CYP2D6 ultrarapid metabolizers."
        }
        },
        {
        "question": "What is the increased risk of oxymorphone toxicity for a CYP2D6 ultrarapid metabolizer taking oxycodone?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk, incidence rate, or odds ratio for oxymorphone toxicity in CYP2D6 UMs using oxycodone."
        }
        },
        {
        "question": "What are the expected plasma concentrations of oxymorphone in a CYP2D6 poor metabolizer after a standard dose of oxycodone?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration data for oxymorphone (the active metabolite of oxycodone) in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 normal metabolizer?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of oxycodone?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in converting oxycodone to its active metabolite, oxymorphone."
        }
        },
        {
        "question": "What is the dosing recommendation for oxycodone in breastfeeding mothers who are CYP2D6 ultrarapid metabolizers?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing recommendations or contraindications for oxycodone in lactating mothers with a CYP2D6 UM phenotype."
        }
        },
        {
        "question": "How should oxycodone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for oxycodone based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking oxycodone?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of oxycodone in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma oxymorphone concentrations (from oxycodone) in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for oxymorphone (active metabolite of oxycodone) stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered oxycodone response?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on oxycodone response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of oxycodone therapy?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for oxycodone's active metabolite, oxymorphone."
        }
        },
        {
        "question": "What is the dosing recommendation for oxycodone in pediatric patients with an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "oxycodone",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for oxycodone in pediatric patients, adjusted for OPRM1 genotype."
        }
        },
        {
        "question": "What is the recommended remifentanil dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for remifentanil in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking remifentanil?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for remifentanil in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma remifentanil concentrations in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for remifentanil stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'high-activity' phenotype?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT high-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to remifentanil?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and remifentanil's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for remifentanil in pediatric patients with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for remifentanil adjusted for COMT low-activity genotype."
        }
        },
        {
        "question": "How should remifentanil dosing be adjusted for a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for remifentanil in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking remifentanil?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using remifentanil."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma remifentanil concentrations in a CYP2D6 intermediate metabolizer?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration ranges for remifentanil in CYP2D6 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of remifentanil?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in remifentanil metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for remifentanil in children with a CYP2D6 ultrarapid metabolizer phenotype?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing adjustments for remifentanil in CYP2D6 ultrarapid metabolizers."
        }
        },
        {
        "question": "How should remifentanil dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for remifentanil based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking remifentanil?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of remifentanil in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma remifentanil concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for remifentanil stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered remifentanil response?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on remifentanil response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of remifentanil therapy?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for remifentanil."
        }
        },
        {
        "question": "What is the dosing recommendation for remifentanil in patients undergoing surgery with an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "remifentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for remifentanil in surgical patients, adjusted for OPRM1 genotype."
        }
        },
        {
        "question": "What is the recommended sufentanil dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for sufentanil in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking sufentanil?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for sufentanil in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma sufentanil concentrations in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for sufentanil stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'normal-activity' phenotype?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to sufentanil?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and sufentanil's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for sufentanil in pediatric patients with a COMT high-activity genotype?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for sufentanil adjusted for COMT high-activity genotype."
        }
        },
        {
        "question": "How should sufentanil dosing be adjusted for a CYP2D6 poor metabolizer?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for sufentanil in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking sufentanil?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using sufentanil."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma sufentanil concentrations in a CYP2D6 intermediate metabolizer?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration ranges for sufentanil in CYP2D6 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of sufentanil?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in sufentanil metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for sufentanil in children with a CYP2D6 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing adjustments for sufentanil in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "How should sufentanil dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for sufentanil based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking sufentanil?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of sufentanil in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma sufentanil concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for sufentanil stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered sufentanil response?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on sufentanil response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of sufentanil therapy?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for sufentanil."
        }
        },
        {
        "question": "What is the dosing recommendation for sufentanil in patients undergoing surgery with an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "sufentanil",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for sufentanil in surgical patients, adjusted for OPRM1 genotype."
        }
        },
        {
        "question": "What is the recommended tramadol dose for an individual with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for tramadol in individuals with a COMT low-activity genotype."
        }
        },
        {
        "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking tramadol?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Risk multipliers or incidence rates of adverse effects for tramadol in patients with COMT high-activity genotype."
        }
        },
        {
        "question": "What are the expected plasma O-desmethyltramadol concentrations (from tramadol) in a patient with a COMT low-activity genotype?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic range or plasma concentration data for O-desmethyltramadol (active metabolite of tramadol) stratified by COMT genotype."
        }
        },
        {
        "question": "What genotypes define the COMT 'low-activity' phenotype?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype."
        }
        },
        {
        "question": "What is the role of the COMT enzyme in the pharmacological response to tramadol?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Mechanism of interaction between COMT enzyme activity and tramadol's effects."
        }
        },
        {
        "question": "What is the dosing recommendation for tramadol in pediatric patients with a COMT high-activity genotype?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "COMT",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Pediatric dosing guidelines for tramadol adjusted for COMT high-activity genotype."
        }
        },
        {
        "question": "What is the recommended tramadol dose for a CYP2D6 ultrarapid metabolizer?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Specific dosing recommendation or contraindication for tramadol in CYP2D6 ultrarapid metabolizers."
        }
        },
        {
        "question": "What is the increased risk of O-desmethyltramadol toxicity for a CYP2D6 ultrarapid metabolizer taking tramadol?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk, incidence rate, or odds ratio for O-desmethyltramadol toxicity in CYP2D6 UMs using tramadol."
        }
        },
        {
        "question": "What are the expected plasma concentrations of O-desmethyltramadol in a CYP2D6 poor metabolizer after a standard dose of tramadol?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Plasma concentration data for O-desmethyltramadol (the active metabolite of tramadol) in CYP2D6 poor metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2D6 enzyme in the metabolism of tramadol?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Description of CYP2D6's role in converting tramadol to its active metabolite, O-desmethyltramadol."
        }
        },
        {
        "question": "What is the dosing recommendation for tramadol in breastfeeding mothers who are CYP2D6 ultrarapid metabolizers?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "CYP2D6",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing recommendations or contraindications for tramadol in lactating mothers with a CYP2D6 UM phenotype."
        }
        },
        {
        "question": "How should tramadol dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dose adjustment protocol for tramadol based on OPRM1 variants affecting receptor function."
        }
        },
        {
        "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking tramadol?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of tramadol in patients with the OPRM1 A118G variant."
        }
        },
        {
        "question": "What is the suggested therapeutic range for plasma O-desmethyltramadol concentrations (from tramadol) in a patient with an OPRM1 variant leading to increased receptor expression?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Therapeutic drug monitoring values for O-desmethyltramadol (active metabolite of tramadol) stratified by OPRM1 genotype."
        }
        },
        {
        "question": "What OPRM1 variants are associated with altered tramadol response?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on tramadol response."
        }
        },
        {
        "question": "What is the function of the OPRM1 gene product in the context of tramadol therapy?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for tramadol's active metabolite, O-desmethyltramadol."
        }
        },
        {
        "question": "What is the dosing recommendation for tramadol in pediatric patients post-tonsillectomy with an OPRM1 variant associated with decreased receptor function?",
        "answer": {
            "Drug Name": "tramadol",
            "Gene Name": "OPRM1",
            "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
            "Content to Search": "Dosing guidelines for tramadol in pediatric post-tonsillectomy patients, adjusted for OPRM1 genotype."
        }
        }
    ]
    },
    {
    "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf": [
        {
        "question": "What is the recommended atorvastatin dose for an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for atorvastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What is the increased risk of statin-associated musculoskeletal symptoms (SAMS) for an individual with ABCG2 decreased function taking atorvastatin?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking atorvastatin."
        }
        },
        {
        "question": "What are the expected plasma atorvastatin concentrations in an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for atorvastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What genotypes define ABCG2 decreased function?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Genotype or diplotype definitions for the ABCG2 decreased function phenotype."
        }
        },
        {
        "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of atorvastatin?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of ABCG2's role as an efflux transporter affecting atorvastatin disposition."
        }
        },
        {
        "question": "What is the dosing recommendation for atorvastatin in pediatric patients with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for atorvastatin adjusted for ABCG2 decreased function."
        }
        },
        {
        "question": "What is the recommended atorvastatin dose for a CYP2C9 poor metabolizer?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for atorvastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking atorvastatin?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using atorvastatin."
        }
        },
        {
        "question": "What are the expected plasma atorvastatin concentrations in a CYP2C9 intermediate metabolizer?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for atorvastatin in CYP2C9 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2C9 poor metabolizer?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 poor metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2C9 enzyme in the metabolism of atorvastatin?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP2C9's role in atorvastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for atorvastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for atorvastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended atorvastatin dose for a CYP3A4 poor metabolizer?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for atorvastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking atorvastatin?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using atorvastatin."
        }
        },
        {
        "question": "What are the expected plasma atorvastatin concentrations in a CYP3A4 intermediate metabolizer?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for atorvastatin in CYP3A4 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A4 poor metabolizer?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 poor metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A4 enzyme in the metabolism of atorvastatin?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A4's role in atorvastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for atorvastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for atorvastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended atorvastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for atorvastatin in CYP3A5 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking atorvastatin?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using atorvastatin."
        }
        },
        {
        "question": "What are the expected plasma atorvastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for atorvastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A5 normal metabolizer (expresser)?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions for the CYP3A5 normal metabolizer (expresser) phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A5 enzyme in the metabolism of atorvastatin?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A5's role in atorvastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for atorvastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for atorvastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What is the recommended atorvastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for atorvastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking atorvastatin?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking atorvastatin."
        }
        },
        {
        "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking atorvastatin?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pharmacodynamic data (LDL-C reduction) for atorvastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What HMGCR variants are associated with altered statin response?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
        }
        },
        {
        "question": "What is the function of HMGCR in the mechanism of action of atorvastatin?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of HMGCR as the pharmacological target of atorvastatin."
        }
        },
        {
        "question": "What is the dosing recommendation for atorvastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for atorvastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the recommended atorvastatin dose for an individual with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for atorvastatin in individuals with SLCO1B1 low function."
        }
        },
        {
        "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking atorvastatin?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking atorvastatin."
        }
        },
        {
        "question": "What are the expected plasma atorvastatin concentrations in an individual with SLCO1B1 intermediate function?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for atorvastatin in individuals with SLCO1B1 intermediate function."
        }
        },
        {
        "question": "What diplotypes define SLCO1B1 low function?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 low function phenotype."
        }
        },
        {
        "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of atorvastatin?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting atorvastatin clearance."
        }
        },
        {
        "question": "What is the dosing recommendation for atorvastatin in pediatric patients with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "atorvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for atorvastatin adjusted for SLCO1B1 low function."
        }
        },
        {
        "question": "What is the recommended fluvastatin dose for an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for fluvastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking fluvastatin?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking fluvastatin."
        }
        },
        {
        "question": "What are the expected plasma fluvastatin concentrations in an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for fluvastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What genotypes define ABCG2 normal function?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Genotype or diplotype definitions for the ABCG2 normal function phenotype."
        }
        },
        {
        "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of fluvastatin?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of ABCG2's role as an efflux transporter affecting fluvastatin disposition."
        }
        },
        {
        "question": "What is the dosing recommendation for fluvastatin in pediatric patients with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for fluvastatin adjusted for ABCG2 decreased function."
        }
        },
        {
        "question": "What is the recommended fluvastatin dose for a CYP2C9 poor metabolizer?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for fluvastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking fluvastatin?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using fluvastatin."
        }
        },
        {
        "question": "What are the expected plasma fluvastatin concentrations in a CYP2C9 intermediate metabolizer?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for fluvastatin in CYP2C9 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2C9 intermediate metabolizer?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 intermediate metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2C9 enzyme in the metabolism of fluvastatin?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP2C9's role in fluvastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for fluvastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for fluvastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended fluvastatin dose for a CYP3A4 poor metabolizer?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for fluvastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking fluvastatin?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using fluvastatin."
        }
        },
        {
        "question": "What are the expected plasma fluvastatin concentrations in a CYP3A4 intermediate metabolizer?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for fluvastatin in CYP3A4 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A4 normal metabolizer?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 normal metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A4 enzyme in the metabolism of fluvastatin?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A4's role in fluvastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for fluvastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for fluvastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended fluvastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for fluvastatin in CYP3A5 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking fluvastatin?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using fluvastatin."
        }
        },
        {
        "question": "What are the expected plasma fluvastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for fluvastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A5 poor metabolizer (non-expresser)?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions for the CYP3A5 poor metabolizer (non-expresser) phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A5 enzyme in the metabolism of fluvastatin?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A5's role in fluvastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for fluvastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for fluvastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What is the recommended fluvastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for fluvastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking fluvastatin?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking fluvastatin."
        }
        },
        {
        "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking fluvastatin?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pharmacodynamic data (LDL-C reduction) for fluvastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What HMGCR variants are associated with altered statin response?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
        }
        },
        {
        "question": "What is the function of HMGCR in the mechanism of action of fluvastatin?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of HMGCR as the pharmacological target of fluvastatin."
        }
        },
        {
        "question": "What is the dosing recommendation for fluvastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for fluvastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the recommended fluvastatin dose for an individual with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for fluvastatin in individuals with SLCO1B1 low function."
        }
        },
        {
        "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking fluvastatin?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking fluvastatin."
        }
        },
        {
        "question": "What are the expected plasma fluvastatin concentrations in an individual with SLCO1B1 intermediate function?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for fluvastatin in individuals with SLCO1B1 intermediate function."
        }
        },
        {
        "question": "What diplotypes define SLCO1B1 normal function?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 normal function phenotype."
        }
        },
        {
        "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of fluvastatin?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting fluvastatin clearance."
        }
        },
        {
        "question": "What is the dosing recommendation for fluvastatin in pediatric patients with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "fluvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for fluvastatin adjusted for SLCO1B1 low function."
        }
        },
        {
        "question": "What is the recommended lovastatin dose for an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for lovastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking lovastatin?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking lovastatin."
        }
        },
        {
        "question": "What are the expected plasma lovastatin concentrations in an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for lovastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What genotypes define ABCG2 decreased function?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Genotype or diplotype definitions for the ABCG2 decreased function phenotype."
        }
        },
        {
        "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of lovastatin?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of ABCG2's role as an efflux transporter affecting lovastatin disposition."
        }
        },
        {
        "question": "What is the dosing recommendation for lovastatin in pediatric patients with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for lovastatin adjusted for ABCG2 decreased function."
        }
        },
        {
        "question": "What is the recommended lovastatin dose for a CYP2C9 poor metabolizer?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for lovastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking lovastatin?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using lovastatin."
        }
        },
        {
        "question": "What are the expected plasma lovastatin concentrations in a CYP2C9 intermediate metabolizer?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for lovastatin in CYP2C9 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2C9 poor metabolizer?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 poor metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2C9 enzyme in the metabolism of lovastatin?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP2C9's role in lovastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for lovastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for lovastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended lovastatin dose for a CYP3A4 poor metabolizer?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for lovastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking lovastatin?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using lovastatin."
        }
        },
        {
        "question": "What are the expected plasma lovastatin concentrations in a CYP3A4 intermediate metabolizer?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for lovastatin in CYP3A4 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A4 poor metabolizer?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 poor metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A4 enzyme in the metabolism of lovastatin?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A4's role in lovastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for lovastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for lovastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended lovastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for lovastatin in CYP3A5 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking lovastatin?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using lovastatin."
        }
        },
        {
        "question": "What are the expected plasma lovastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for lovastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A5 normal metabolizer (expresser)?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions for the CYP3A5 normal metabolizer (expresser) phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A5 enzyme in the metabolism of lovastatin?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A5's role in lovastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for lovastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for lovastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What is the recommended lovastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for lovastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking lovastatin?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking lovastatin."
        }
        },
        {
        "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking lovastatin?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pharmacodynamic data (LDL-C reduction) for lovastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What HMGCR variants are associated with altered statin response?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
        }
        },
        {
        "question": "What is the function of HMGCR in the mechanism of action of lovastatin?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of HMGCR as the pharmacological target of lovastatin."
        }
        },
        {
        "question": "What is the dosing recommendation for lovastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for lovastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the recommended lovastatin dose for an individual with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for lovastatin in individuals with SLCO1B1 low function."
        }
        },
        {
        "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking lovastatin?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking lovastatin."
        }
        },
        {
        "question": "What are the expected plasma lovastatin concentrations in an individual with SLCO1B1 intermediate function?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for lovastatin in individuals with SLCO1B1 intermediate function."
        }
        },
        {
        "question": "What diplotypes define SLCO1B1 intermediate function?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 intermediate function phenotype."
        }
        },
        {
        "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of lovastatin?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting lovastatin clearance."
        }
        },
        {
        "question": "What is the dosing recommendation for lovastatin in pediatric patients with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "lovastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for lovastatin adjusted for SLCO1B1 low function."
        }
        },
        {
        "question": "What is the recommended pitavastatin dose for an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for pitavastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking pitavastatin?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking pitavastatin."
        }
        },
        {
        "question": "What are the expected plasma pitavastatin concentrations in an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for pitavastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What genotypes define ABCG2 normal function?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Genotype or diplotype definitions for the ABCG2 normal function phenotype."
        }
        },
        {
        "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of pitavastatin?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of ABCG2's role as an efflux transporter affecting pitavastatin disposition."
        }
        },
        {
        "question": "What is the dosing recommendation for pitavastatin in pediatric patients with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for pitavastatin adjusted for ABCG2 decreased function."
        }
        },
        {
        "question": "What is the recommended pitavastatin dose for a CYP2C9 poor metabolizer?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for pitavastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking pitavastatin?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using pitavastatin."
        }
        },
        {
        "question": "What are the expected plasma pitavastatin concentrations in a CYP2C9 intermediate metabolizer?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for pitavastatin in CYP2C9 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2C9 normal metabolizer?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 normal metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2C9 enzyme in the metabolism of pitavastatin?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP2C9's role in pitavastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for pitavastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for pitavastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended pitavastatin dose for a CYP3A4 poor metabolizer?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for pitavastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking pitavastatin?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using pitavastatin."
        }
        },
        {
        "question": "What are the expected plasma pitavastatin concentrations in a CYP3A4 intermediate metabolizer?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for pitavastatin in CYP3A4 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A4 normal metabolizer?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 normal metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A4 enzyme in the metabolism of pitavastatin?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A4's role in pitavastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for pitavastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for pitavastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended pitavastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for pitavastatin in CYP3A5 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking pitavastatin?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using pitavastatin."
        }
        },
        {
        "question": "What are the expected plasma pitavastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for pitavastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A5 poor metabolizer (non-expresser)?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions for the CYP3A5 poor metabolizer (non-expresser) phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A5 enzyme in the metabolism of pitavastatin?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A5's role in pitavastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for pitavastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for pitavastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What is the recommended pitavastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for pitavastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking pitavastatin?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking pitavastatin."
        }
        },
        {
        "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking pitavastatin?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pharmacodynamic data (LDL-C reduction) for pitavastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What HMGCR variants are associated with altered statin response?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
        }
        },
        {
        "question": "What is the function of HMGCR in the mechanism of action of pitavastatin?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of HMGCR as the pharmacological target of pitavastatin."
        }
        },
        {
        "question": "What is the dosing recommendation for pitavastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for pitavastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the recommended pitavastatin dose for an individual with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for pitavastatin in individuals with SLCO1B1 low function."
        }
        },
        {
        "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking pitavastatin?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking pitavastatin."
        }
        },
        {
        "question": "What are the expected plasma pitavastatin concentrations in an individual with SLCO1B1 intermediate function?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for pitavastatin in individuals with SLCO1B1 intermediate function."
        }
        },
        {
        "question": "What diplotypes define SLCO1B1 low function?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 low function phenotype."
        }
        },
        {
        "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of pitavastatin?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting pitavastatin clearance."
        }
        },
        {
        "question": "What is the dosing recommendation for pitavastatin in pediatric patients with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "pitavastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for pitavastatin adjusted for SLCO1B1 low function."
        }
        },
        {
        "question": "What is the recommended pravastatin dose for an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for pravastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking pravastatin?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking pravastatin."
        }
        },
        {
        "question": "What are the expected plasma pravastatin concentrations in an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for pravastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What genotypes define ABCG2 decreased function?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Genotype or diplotype definitions for the ABCG2 decreased function phenotype."
        }
        },
        {
        "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of pravastatin?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of ABCG2's role as an efflux transporter affecting pravastatin disposition."
        }
        },
        {
        "question": "What is the dosing recommendation for pravastatin in pediatric patients with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for pravastatin adjusted for ABCG2 decreased function."
        }
        },
        {
        "question": "What is the recommended pravastatin dose for a CYP2C9 poor metabolizer?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for pravastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking pravastatin?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using pravastatin."
        }
        },
        {
        "question": "What are the expected plasma pravastatin concentrations in a CYP2C9 intermediate metabolizer?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for pravastatin in CYP2C9 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2C9 poor metabolizer?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 poor metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2C9 enzyme in the metabolism of pravastatin?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP2C9's role in pravastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for pravastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for pravastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended pravastatin dose for a CYP3A4 poor metabolizer?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for pravastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking pravastatin?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using pravastatin."
        }
        },
        {
        "question": "What are the expected plasma pravastatin concentrations in a CYP3A4 intermediate metabolizer?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for pravastatin in CYP3A4 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A4 poor metabolizer?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 poor metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A4 enzyme in the metabolism of pravastatin?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A4's role in pravastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for pravastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for pravastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended pravastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for pravastatin in CYP3A5 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking pravastatin?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using pravastatin."
        }
        },
        {
        "question": "What are the expected plasma pravastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for pravastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A5 normal metabolizer (expresser)?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions for the CYP3A5 normal metabolizer (expresser) phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A5 enzyme in the metabolism of pravastatin?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A5's role in pravastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for pravastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for pravastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What is the recommended pravastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for pravastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking pravastatin?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking pravastatin."
        }
        },
        {
        "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking pravastatin?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pharmacodynamic data (LDL-C reduction) for pravastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What HMGCR variants are associated with altered statin response?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
        }
        },
        {
        "question": "What is the function of HMGCR in the mechanism of action of pravastatin?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of HMGCR as the pharmacological target of pravastatin."
        }
        },
        {
        "question": "What is the dosing recommendation for pravastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for pravastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the recommended pravastatin dose for an individual with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for pravastatin in individuals with SLCO1B1 low function."
        }
        },
        {
        "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking pravastatin?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking pravastatin."
        }
        },
        {
        "question": "What are the expected plasma pravastatin concentrations in an individual with SLCO1B1 intermediate function?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for pravastatin in individuals with SLCO1B1 intermediate function."
        }
        },
        {
        "question": "What diplotypes define SLCO1B1 normal function?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 normal function phenotype."
        }
        },
        {
        "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of pravastatin?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting pravastatin clearance."
        }
        },
        {
        "question": "What is the dosing recommendation for pravastatin in pediatric patients with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "pravastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for pravastatin adjusted for SLCO1B1 low function."
        }
        },
        {
        "question": "What is the recommended rosuvastatin dose for an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for rosuvastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking rosuvastatin?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking rosuvastatin."
        }
        },
        {
        "question": "What are the expected plasma rosuvastatin concentrations in an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for rosuvastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What genotypes define ABCG2 normal function?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Genotype or diplotype definitions for the ABCG2 normal function phenotype."
        }
        },
        {
        "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of rosuvastatin?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of ABCG2's role as an efflux transporter affecting rosuvastatin disposition."
        }
        },
        {
        "question": "What is the dosing recommendation for rosuvastatin in pediatric patients with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for rosuvastatin adjusted for ABCG2 decreased function."
        }
        },
        {
        "question": "What is the recommended rosuvastatin dose for a CYP2C9 poor metabolizer?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for rosuvastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking rosuvastatin?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using rosuvastatin."
        }
        },
        {
        "question": "What are the expected plasma rosuvastatin concentrations in a CYP2C9 intermediate metabolizer?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for rosuvastatin in CYP2C9 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2C9 intermediate metabolizer?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 intermediate metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2C9 enzyme in the metabolism of rosuvastatin?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP2C9's role in rosuvastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for rosuvastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for rosuvastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended rosuvastatin dose for a CYP3A4 poor metabolizer?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for rosuvastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking rosuvastatin?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using rosuvastatin."
        }
        },
        {
        "question": "What are the expected plasma rosuvastatin concentrations in a CYP3A4 intermediate metabolizer?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for rosuvastatin in CYP3A4 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A4 normal metabolizer?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 normal metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A4 enzyme in the metabolism of rosuvastatin?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A4's role in rosuvastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for rosuvastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for rosuvastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended rosuvastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for rosuvastatin in CYP3A5 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking rosuvastatin?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using rosuvastatin."
        }
        },
        {
        "question": "What are the expected plasma rosuvastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for rosuvastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A5 poor metabolizer (non-expresser)?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions for the CYP3A5 poor metabolizer (non-expresser) phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A5 enzyme in the metabolism of rosuvastatin?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A5's role in rosuvastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for rosuvastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for rosuvastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What is the recommended rosuvastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for rosuvastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking rosuvastatin?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking rosuvastatin."
        }
        },
        {
        "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking rosuvastatin?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pharmacodynamic data (LDL-C reduction) for rosuvastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What HMGCR variants are associated with altered statin response?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
        }
        },
        {
        "question": "What is the function of HMGCR in the mechanism of action of rosuvastatin?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of HMGCR as the pharmacological target of rosuvastatin."
        }
        },
        {
        "question": "What is the dosing recommendation for rosuvastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for rosuvastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the recommended rosuvastatin dose for an individual with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for rosuvastatin in individuals with SLCO1B1 low function."
        }
        },
        {
        "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking rosuvastatin?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking rosuvastatin."
        }
        },
        {
        "question": "What are the expected plasma rosuvastatin concentrations in an individual with SLCO1B1 intermediate function?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for rosuvastatin in individuals with SLCO1B1 intermediate function."
        }
        },
        {
        "question": "What diplotypes define SLCO1B1 intermediate function?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 intermediate function phenotype."
        }
        },
        {
        "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of rosuvastatin?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting rosuvastatin clearance."
        }
        },
        {
        "question": "What is the dosing recommendation for rosuvastatin in pediatric patients with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "rosuvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for rosuvastatin adjusted for SLCO1B1 low function."
        }
        },
        {
        "question": "What is the recommended simvastatin dose for an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for simvastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking simvastatin?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking simvastatin."
        }
        },
        {
        "question": "What are the expected plasma simvastatin concentrations in an individual with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for simvastatin in individuals with ABCG2 decreased function."
        }
        },
        {
        "question": "What genotypes define ABCG2 decreased function?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Genotype or diplotype definitions for the ABCG2 decreased function phenotype."
        }
        },
        {
        "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of simvastatin?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of ABCG2's role as an efflux transporter affecting simvastatin disposition."
        }
        },
        {
        "question": "What is the dosing recommendation for simvastatin in pediatric patients with ABCG2 decreased function?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "ABCG2",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for simvastatin adjusted for ABCG2 decreased function."
        }
        },
        {
        "question": "What is the recommended simvastatin dose for a CYP2C9 poor metabolizer?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for simvastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking simvastatin?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using simvastatin."
        }
        },
        {
        "question": "What are the expected plasma simvastatin concentrations in a CYP2C9 intermediate metabolizer?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for simvastatin in CYP2C9 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP2C9 normal metabolizer?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 normal metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP2C9 enzyme in the metabolism of simvastatin?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP2C9's role in simvastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for simvastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP2C9",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for simvastatin in CYP2C9 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended simvastatin dose for a CYP3A4 poor metabolizer?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for simvastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking simvastatin?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using simvastatin."
        }
        },
        {
        "question": "What are the expected plasma simvastatin concentrations in a CYP3A4 intermediate metabolizer?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for simvastatin in CYP3A4 intermediate metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A4 poor metabolizer?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 poor metabolizer phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A4 enzyme in the metabolism of simvastatin?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A4's role in simvastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for simvastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP3A4",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for simvastatin in CYP3A4 poor metabolizers."
        }
        },
        {
        "question": "What is the recommended simvastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for simvastatin in CYP3A5 poor metabolizers."
        }
        },
        {
        "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking simvastatin?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using simvastatin."
        }
        },
        {
        "question": "What are the expected plasma simvastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for simvastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What diplotypes define a CYP3A5 normal metabolizer (expresser)?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions for the CYP3A5 normal metabolizer (expresser) phenotype."
        }
        },
        {
        "question": "What is the function of the CYP3A5 enzyme in the metabolism of simvastatin?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of CYP3A5's role in simvastatin metabolism."
        }
        },
        {
        "question": "What is the dosing recommendation for simvastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "CYP3A5",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for simvastatin in CYP3A5 normal metabolizers."
        }
        },
        {
        "question": "What is the recommended simvastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for simvastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking simvastatin?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking simvastatin."
        }
        },
        {
        "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking simvastatin?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pharmacodynamic data (LDL-C reduction) for simvastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What HMGCR variants are associated with altered statin response?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
        }
        },
        {
        "question": "What is the function of HMGCR in the mechanism of action of simvastatin?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of HMGCR as the pharmacological target of simvastatin."
        }
        },
        {
        "question": "What is the dosing recommendation for simvastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "HMGCR",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing adjustments for simvastatin based on HMGCR genotype."
        }
        },
        {
        "question": "What is the recommended simvastatin dose for an individual with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Dose adjustment protocol for simvastatin in individuals with SLCO1B1 low function."
        }
        },
        {
        "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking simvastatin?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking simvastatin."
        }
        },
        {
        "question": "What are the expected plasma simvastatin concentrations in an individual with SLCO1B1 intermediate function?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Plasma concentration ranges or AUC data for simvastatin in individuals with SLCO1B1 intermediate function."
        }
        },
        {
        "question": "What diplotypes define SLCO1B1 low function?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 low function phenotype."
        }
        },
        {
        "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of simvastatin?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting simvastatin clearance."
        }
        },
        {
        "question": "What is the dosing recommendation for simvastatin in pediatric patients with SLCO1B1 low function?",
        "answer": {
            "Drug Name": "simvastatin",
            "Gene Name": "SLCO1B1",
            "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
            "Content to Search": "Pediatric dosing guidelines for simvastatin adjusted for SLCO1B1 low function."
        }
        }
    ]
    },
    {
    "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf": [
        {
        "question": "What is the dosing recommendation for aminosalicylic acid in a G6PD deficient individual?",
        "answer": {
            "Drug Name": "aminosalicylic acid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for aminosalicylic acid in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking aminosalicylic acid?",
        "answer": {
            "Drug Name": "aminosalicylic acid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with aminosalicylic acid use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes, such as hemoglobin drop, in a G6PD deficient individual exposed to aminosalicylic acid?",
        "answer": {
            "Drug Name": "aminosalicylic acid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters (hemoglobin, reticulocyte count) in G6PD deficient individuals after aminosalicylic acid administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "aminosalicylic acid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which aminosalicylic acid causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "aminosalicylic acid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of aminosalicylic acid-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for aminosalicylic acid in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "aminosalicylic acid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines or contraindications for aminosalicylic acid in G6PD deficient children."
        }
        },
        {
        "question": "What is the recommended aspirin dose for a G6PD deficient individual, particularly regarding high vs. low doses?",
        "answer": {
            "Drug Name": "aspirin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dose-specific recommendations for aspirin use (e.g., analgesic vs. antiplatelet doses) in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking high-dose aspirin?",
        "answer": {
            "Drug Name": "aspirin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with high-dose aspirin use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes, such as hemoglobin drop, in a G6PD deficient individual exposed to high-dose aspirin?",
        "answer": {
            "Drug Name": "aspirin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after high-dose aspirin administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "aspirin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which aspirin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "aspirin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of aspirin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for aspirin in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "aspirin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for aspirin in G6PD deficient children, considering risks of both hemolysis and Reye's syndrome."
        }
        },
        {
        "question": "Is chloramphenicol contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "chloramphenicol",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for chloramphenicol in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking chloramphenicol?",
        "answer": {
            "Drug Name": "chloramphenicol",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with chloramphenicol use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to chloramphenicol?",
        "answer": {
            "Drug Name": "chloramphenicol",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters (hemoglobin, reticulocyte count) in G6PD deficient individuals after chloramphenicol administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "chloramphenicol",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which chloramphenicol causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "chloramphenicol",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of chloramphenicol-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for chloramphenicol in a neonate with G6PD deficiency?",
        "answer": {
            "Drug Name": "chloramphenicol",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Neonate-specific dosing guidelines for chloramphenicol in G6PD deficient infants, considering risks of both hemolysis and gray baby syndrome."
        }
        },
        {
        "question": "What is the recommended chloroquine dose for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "chloroquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for chloroquine in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking chloroquine?",
        "answer": {
            "Drug Name": "chloroquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with chloroquine use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to chloroquine?",
        "answer": {
            "Drug Name": "chloroquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after chloroquine administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "chloroquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which chloroquine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "chloroquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of chloroquine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for chloroquine in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "chloroquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for chloroquine in G6PD deficient children."
        }
        },
        {
        "question": "Is chlorpropamide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "chlorpropamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for chlorpropamide in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking chlorpropamide?",
        "answer": {
            "Drug Name": "chlorpropamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with chlorpropamide use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to chlorpropamide?",
        "answer": {
            "Drug Name": "chlorpropamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after chlorpropamide administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "chlorpropamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which chlorpropamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "chlorpropamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of chlorpropamide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for chlorpropamide in an elderly patient with G6PD deficiency and renal impairment?",
        "answer": {
            "Drug Name": "chlorpropamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for chlorpropamide in elderly G6PD deficient patients with comorbidities like renal impairment."
        }
        },
        {
        "question": "What is the dosing recommendation for ciprofloxacin in a G6PD deficient individual?",
        "answer": {
            "Drug Name": "ciprofloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for ciprofloxacin in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking ciprofloxacin?",
        "answer": {
            "Drug Name": "ciprofloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with ciprofloxacin use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to ciprofloxacin?",
        "answer": {
            "Drug Name": "ciprofloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after ciprofloxacin administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "ciprofloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which ciprofloxacin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "ciprofloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of ciprofloxacin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for ciprofloxacin in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "ciprofloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for ciprofloxacin in G6PD deficient children."
        }
        },
        {
        "question": "Is dabrafenib contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "dabrafenib",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for dabrafenib in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking dabrafenib?",
        "answer": {
            "Drug Name": "dabrafenib",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with dabrafenib use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to dabrafenib?",
        "answer": {
            "Drug Name": "dabrafenib",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after dabrafenib administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "dabrafenib",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which dabrafenib causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "dabrafenib",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of dabrafenib-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for dabrafenib in a cancer patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "dabrafenib",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for dabrafenib in G6PD deficient cancer patients, considering the specific indication (e.g., melanoma)."
        }
        },
        {
        "question": "Is dapsone contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "dapsone",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for dapsone in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking dapsone?",
        "answer": {
            "Drug Name": "dapsone",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with dapsone use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to dapsone?",
        "answer": {
            "Drug Name": "dapsone",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after dapsone administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "dapsone",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which dapsone causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "dapsone",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of dapsone-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for dapsone in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "dapsone",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for dapsone in G6PD deficient children."
        }
        },
        {
        "question": "Is dimercaprol contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "dimercaprol",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for dimercaprol in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking dimercaprol?",
        "answer": {
            "Drug Name": "dimercaprol",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with dimercaprol use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to dimercaprol?",
        "answer": {
            "Drug Name": "dimercaprol",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after dimercaprol administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "dimercaprol",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which dimercaprol causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "dimercaprol",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of dimercaprol-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for dimercaprol in a G6PD deficient patient being treated for heavy metal poisoning?",
        "answer": {
            "Drug Name": "dimercaprol",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for dimercaprol in G6PD deficient patients with heavy metal poisoning."
        }
        },
        {
        "question": "Is doxorubicin contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "doxorubicin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for doxorubicin in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking doxorubicin?",
        "answer": {
            "Drug Name": "doxorubicin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with doxorubicin use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to doxorubicin?",
        "answer": {
            "Drug Name": "doxorubicin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after doxorubicin administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "doxorubicin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which doxorubicin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "doxorubicin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of doxorubicin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for doxorubicin in a pediatric cancer patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "doxorubicin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for doxorubicin in G6PD deficient children undergoing chemotherapy."
        }
        },
        {
        "question": "Is furazolidone contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "furazolidone",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for furazolidone in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking furazolidone?",
        "answer": {
            "Drug Name": "furazolidone",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with furazolidone use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to furazolidone?",
        "answer": {
            "Drug Name": "furazolidone",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after furazolidone administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "furazolidone",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which furazolidone causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "furazolidone",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of furazolidone-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for furazolidone in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "furazolidone",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for furazolidone in G6PD deficient children."
        }
        },
        {
        "question": "Is gliclazide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "gliclazide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for gliclazide in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking gliclazide?",
        "answer": {
            "Drug Name": "gliclazide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with gliclazide use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to gliclazide?",
        "answer": {
            "Drug Name": "gliclazide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after gliclazide administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "gliclazide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which gliclazide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "gliclazide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of gliclazide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for gliclazide in a diabetic patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "gliclazide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for gliclazide in G6PD deficient patients with type 2 diabetes."
        }
        },
        {
        "question": "Is glimepiride contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "glimepiride",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for glimepiride in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking glimepiride?",
        "answer": {
            "Drug Name": "glimepiride",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with glimepiride use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to glimepiride?",
        "answer": {
            "Drug Name": "glimepiride",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after glimepiride administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "glimepiride",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which glimepiride causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "glimepiride",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of glimepiride-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for glimepiride in a diabetic patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "glimepiride",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for glimepiride in G6PD deficient patients with type 2 diabetes."
        }
        },
        {
        "question": "Is glipizide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "glipizide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for glipizide in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking glipizide?",
        "answer": {
            "Drug Name": "glipizide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with glipizide use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to glipizide?",
        "answer": {
            "Drug Name": "glipizide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after glipizide administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "glipizide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which glipizide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "glipizide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of glipizide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for glipizide in a diabetic patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "glipizide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for glipizide in G6PD deficient patients with type 2 diabetes."
        }
        },
        {
        "question": "Is glyburide (glibenclamide) contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "glyburide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for glyburide in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking glyburide?",
        "answer": {
            "Drug Name": "glyburide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with glyburide use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to glyburide?",
        "answer": {
            "Drug Name": "glyburide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after glyburide administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "glyburide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which glyburide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "glyburide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of glyburide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for glyburide in a diabetic patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "glyburide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for glyburide in G6PD deficient patients with type 2 diabetes."
        }
        },
        {
        "question": "What is the recommended hydroxychloroquine dose for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "hydroxychloroquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for hydroxychloroquine in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking hydroxychloroquine?",
        "answer": {
            "Drug Name": "hydroxychloroquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with hydroxychloroquine use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to hydroxychloroquine?",
        "answer": {
            "Drug Name": "hydroxychloroquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after hydroxychloroquine administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "hydroxychloroquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which hydroxychloroquine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "hydroxychloroquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of hydroxychloroquine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for hydroxychloroquine in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "hydroxychloroquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for hydroxychloroquine in G6PD deficient children."
        }
        },
        {
        "question": "Is mafenide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "mafenide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for mafenide in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking mafenide?",
        "answer": {
            "Drug Name": "mafenide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with mafenide use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to mafenide?",
        "answer": {
            "Drug Name": "mafenide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after mafenide administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "mafenide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which mafenide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "mafenide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of mafenide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the recommendation for using topical mafenide on a burn patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "mafenide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Guidelines for topical mafenide use in G6PD deficient burn patients, considering systemic absorption."
        }
        },
        {
        "question": "Is mepacrine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "mepacrine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for mepacrine in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking mepacrine?",
        "answer": {
            "Drug Name": "mepacrine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with mepacrine use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to mepacrine?",
        "answer": {
            "Drug Name": "mepacrine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after mepacrine administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "mepacrine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which mepacrine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "mepacrine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of mepacrine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for mepacrine in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "mepacrine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for mepacrine in G6PD deficient children."
        }
        },
        {
        "question": "Is mesalazine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "mesalazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for mesalazine in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking mesalazine?",
        "answer": {
            "Drug Name": "mesalazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with mesalazine use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to mesalazine?",
        "answer": {
            "Drug Name": "mesalazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after mesalazine administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "mesalazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which mesalazine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "mesalazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of mesalazine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for mesalazine in a patient with inflammatory bowel disease and G6PD deficiency?",
        "answer": {
            "Drug Name": "mesalazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for mesalazine in G6PD deficient patients with IBD."
        }
        },
        {
        "question": "Is methylene blue contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "methylene blue",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for methylene blue in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking methylene blue?",
        "answer": {
            "Drug Name": "methylene blue",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with methylene blue use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to methylene blue?",
        "answer": {
            "Drug Name": "methylene blue",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after methylene blue administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "methylene blue",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which methylene blue causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "methylene blue",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of methylene blue-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the recommendation for using methylene blue to treat methemoglobinemia in a G6PD deficient patient?",
        "answer": {
            "Drug Name": "methylene blue",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Guidelines for methylene blue use for methemoglobinemia in G6PD deficient patients, including potential for paradoxical worsening."
        }
        },
        {
        "question": "Is moxifloxacin contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "moxifloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for moxifloxacin in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking moxifloxacin?",
        "answer": {
            "Drug Name": "moxifloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with moxifloxacin use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to moxifloxacin?",
        "answer": {
            "Drug Name": "moxifloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after moxifloxacin administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "moxifloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which moxifloxacin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "moxifloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of moxifloxacin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for moxifloxacin in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "moxifloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for moxifloxacin in G6PD deficient children."
        }
        },
        {
        "question": "Is nalidixic acid contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "nalidixic acid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for nalidixic acid in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking nalidixic acid?",
        "answer": {
            "Drug Name": "nalidixic acid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with nalidixic acid use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to nalidixic acid?",
        "answer": {
            "Drug Name": "nalidixic acid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after nalidixic acid administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "nalidixic acid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which nalidixic acid causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "nalidixic acid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of nalidixic acid-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for nalidixic acid in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "nalidixic acid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for nalidixic acid in G6PD deficient children."
        }
        },
        {
        "question": "Is nicorandil contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "nicorandil",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for nicorandil in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking nicorandil?",
        "answer": {
            "Drug Name": "nicorandil",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with nicorandil use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to nicorandil?",
        "answer": {
            "Drug Name": "nicorandil",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after nicorandil administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "nicorandil",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which nicorandil causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "nicorandil",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of nicorandil-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for nicorandil in a cardiac patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "nicorandil",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for nicorandil in G6PD deficient patients with angina."
        }
        },
        {
        "question": "Is nitrofural (nitrofurazone) contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "nitrofural",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for nitrofural in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking nitrofural?",
        "answer": {
            "Drug Name": "nitrofural",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with nitrofural use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to nitrofural?",
        "answer": {
            "Drug Name": "nitrofural",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after nitrofural administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "nitrofural",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which nitrofural causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "nitrofural",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of nitrofural-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the recommendation for using topical nitrofural in a G6PD deficient patient?",
        "answer": {
            "Drug Name": "nitrofural",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Guidelines for topical nitrofural use in G6PD deficient patients."
        }
        },
        {
        "question": "Is nitrofurantoin contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "nitrofurantoin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for nitrofurantoin in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking nitrofurantoin?",
        "answer": {
            "Drug Name": "nitrofurantoin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with nitrofurantoin use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to nitrofurantoin?",
        "answer": {
            "Drug Name": "nitrofurantoin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after nitrofurantoin administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "nitrofurantoin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which nitrofurantoin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "nitrofurantoin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of nitrofurantoin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for nitrofurantoin in a pregnant patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "nitrofurantoin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for nitrofurantoin in pregnant G6PD deficient patients, especially near term."
        }
        },
        {
        "question": "Is norfloxacin contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "norfloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for norfloxacin in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking norfloxacin?",
        "answer": {
            "Drug Name": "norfloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with norfloxacin use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to norfloxacin?",
        "answer": {
            "Drug Name": "norfloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after norfloxacin administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "norfloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which norfloxacin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "norfloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of norfloxacin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for norfloxacin in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "norfloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for norfloxacin in G6PD deficient children."
        }
        },
        {
        "question": "Is ofloxacin contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "ofloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for ofloxacin in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking ofloxacin?",
        "answer": {
            "Drug Name": "ofloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with ofloxacin use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to ofloxacin?",
        "answer": {
            "Drug Name": "ofloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after ofloxacin administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "ofloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which ofloxacin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "ofloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of ofloxacin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for ofloxacin in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "ofloxacin",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for ofloxacin in G6PD deficient children."
        }
        },
        {
        "question": "Is pegloticase contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "pegloticase",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for pegloticase in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking pegloticase?",
        "answer": {
            "Drug Name": "pegloticase",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with pegloticase use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to pegloticase?",
        "answer": {
            "Drug Name": "pegloticase",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after pegloticase administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "pegloticase",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which pegloticase causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "pegloticase",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of pegloticase-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for pegloticase in a patient with chronic gout and G6PD deficiency?",
        "answer": {
            "Drug Name": "pegloticase",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for pegloticase in G6PD deficient patients with chronic gout."
        }
        },
        {
        "question": "Is phenazopyridine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "phenazopyridine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for phenazopyridine in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking phenazopyridine?",
        "answer": {
            "Drug Name": "phenazopyridine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with phenazopyridine use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to phenazopyridine?",
        "answer": {
            "Drug Name": "phenazopyridine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after phenazopyridine administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "phenazopyridine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which phenazopyridine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "phenazopyridine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of phenazopyridine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for phenazopyridine in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "phenazopyridine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for phenazopyridine in G6PD deficient children."
        }
        },
        {
        "question": "Is primaquine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "primaquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for primaquine in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking primaquine?",
        "answer": {
            "Drug Name": "primaquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with primaquine use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to primaquine?",
        "answer": {
            "Drug Name": "primaquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after primaquine administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "primaquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which primaquine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "primaquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of primaquine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for primaquine for malaria prophylaxis in a G6PD deficient child?",
        "answer": {
            "Drug Name": "primaquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for primaquine in G6PD deficient children for malaria treatment or prophylaxis."
        }
        },
        {
        "question": "Is probenecid contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "probenecid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for probenecid in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking probenecid?",
        "answer": {
            "Drug Name": "probenecid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with probenecid use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to probenecid?",
        "answer": {
            "Drug Name": "probenecid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after probenecid administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "probenecid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which probenecid causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "probenecid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of probenecid-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for probenecid in a patient with gout and G6PD deficiency?",
        "answer": {
            "Drug Name": "probenecid",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for probenecid in G6PD deficient patients with gout."
        }
        },
        {
        "question": "Is quinine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "quinine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for quinine in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking quinine?",
        "answer": {
            "Drug Name": "quinine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with quinine use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to quinine?",
        "answer": {
            "Drug Name": "quinine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after quinine administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "quinine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which quinine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "quinine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of quinine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for quinine for malaria treatment in a G6PD deficient child?",
        "answer": {
            "Drug Name": "quinine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for quinine in G6PD deficient children for malaria treatment."
        }
        },
        {
        "question": "Is rasburicase contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "rasburicase",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for rasburicase in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking rasburicase?",
        "answer": {
            "Drug Name": "rasburicase",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with rasburicase use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to rasburicase?",
        "answer": {
            "Drug Name": "rasburicase",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after rasburicase administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "rasburicase",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which rasburicase causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "rasburicase",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of rasburicase-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for rasburicase for tumor lysis syndrome in a G6PD deficient cancer patient?",
        "answer": {
            "Drug Name": "rasburicase",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for rasburicase in G6PD deficient patients with tumor lysis syndrome."
        }
        },
        {
        "question": "Is sodium nitrite contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "sodium nitrite",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for sodium nitrite in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sodium nitrite?",
        "answer": {
            "Drug Name": "sodium nitrite",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sodium nitrite use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sodium nitrite?",
        "answer": {
            "Drug Name": "sodium nitrite",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sodium nitrite administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "sodium nitrite",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which sodium nitrite causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "sodium nitrite",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of sodium nitrite-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the recommendation for using sodium nitrite for cyanide poisoning in a G6PD deficient patient?",
        "answer": {
            "Drug Name": "sodium nitrite",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Guidelines for using sodium nitrite as a cyanide antidote in G6PD deficient patients."
        }
        },
        {
        "question": "Is sulfacetamide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "sulfacetamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for sulfacetamide in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfacetamide?",
        "answer": {
            "Drug Name": "sulfacetamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfacetamide use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfacetamide?",
        "answer": {
            "Drug Name": "sulfacetamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfacetamide administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "sulfacetamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which sulfacetamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "sulfacetamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of sulfacetamide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the recommendation for using topical sulfacetamide in a G6PD deficient patient?",
        "answer": {
            "Drug Name": "sulfacetamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Guidelines for topical sulfacetamide use in G6PD deficient patients."
        }
        },
        {
        "question": "Is sulfadiazine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "sulfadiazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for sulfadiazine in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfadiazine?",
        "answer": {
            "Drug Name": "sulfadiazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfadiazine use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfadiazine?",
        "answer": {
            "Drug Name": "sulfadiazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfadiazine administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "sulfadiazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which sulfadiazine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "sulfadiazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of sulfadiazine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for sulfadiazine in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "sulfadiazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for sulfadiazine in G6PD deficient children."
        }
        },
        {
        "question": "Is sulfadimidine (sulfamethazine) contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "sulfadimidine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for sulfadimidine in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfadimidine?",
        "answer": {
            "Drug Name": "sulfadimidine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfadimidine use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfadimidine?",
        "answer": {
            "Drug Name": "sulfadimidine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfadimidine administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "sulfadimidine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which sulfadimidine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "sulfadimidine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of sulfadimidine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for sulfadimidine in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "sulfadimidine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for sulfadimidine in G6PD deficient children."
        }
        },
        {
        "question": "Is sulfamethoxazole / trimethoprim contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "sulfamethoxazole / trimethoprim",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for sulfamethoxazole / trimethoprim in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfamethoxazole / trimethoprim?",
        "answer": {
            "Drug Name": "sulfamethoxazole / trimethoprim",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfamethoxazole / trimethoprim use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfamethoxazole / trimethoprim?",
        "answer": {
            "Drug Name": "sulfamethoxazole / trimethoprim",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfamethoxazole / trimethoprim administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "sulfamethoxazole / trimethoprim",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which sulfamethoxazole causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "sulfamethoxazole / trimethoprim",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of sulfamethoxazole-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for sulfamethoxazole / trimethoprim in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "sulfamethoxazole / trimethoprim",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for sulfamethoxazole / trimethoprim in G6PD deficient children."
        }
        },
        {
        "question": "Is sulfanilamide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "sulfanilamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for sulfanilamide in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfanilamide?",
        "answer": {
            "Drug Name": "sulfanilamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfanilamide use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfanilamide?",
        "answer": {
            "Drug Name": "sulfanilamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfanilamide administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "sulfanilamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which sulfanilamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "sulfanilamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of sulfanilamide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the recommendation for using topical sulfanilamide in a G6PD deficient patient?",
        "answer": {
            "Drug Name": "sulfanilamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Guidelines for topical sulfanilamide use in G6PD deficient patients."
        }
        },
        {
        "question": "Is sulfasalazine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "sulfasalazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for sulfasalazine in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfasalazine?",
        "answer": {
            "Drug Name": "sulfasalazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfasalazine use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfasalazine?",
        "answer": {
            "Drug Name": "sulfasalazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfasalazine administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "sulfasalazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which sulfasalazine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "sulfasalazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of sulfasalazine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for sulfasalazine in a patient with rheumatoid arthritis and G6PD deficiency?",
        "answer": {
            "Drug Name": "sulfasalazine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for sulfasalazine in G6PD deficient patients with rheumatoid arthritis."
        }
        },
        {
        "question": "Is sulfisoxazole contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "sulfisoxazole",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for sulfisoxazole in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfisoxazole?",
        "answer": {
            "Drug Name": "sulfisoxazole",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfisoxazole use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfisoxazole?",
        "answer": {
            "Drug Name": "sulfisoxazole",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfisoxazole administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "sulfisoxazole",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which sulfisoxazole causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "sulfisoxazole",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of sulfisoxazole-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for sulfisoxazole in a pediatric patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "sulfisoxazole",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for sulfisoxazole in G6PD deficient children."
        }
        },
        {
        "question": "Is tafenoquine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "tafenoquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for tafenoquine in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking tafenoquine?",
        "answer": {
            "Drug Name": "tafenoquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with tafenoquine use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to tafenoquine?",
        "answer": {
            "Drug Name": "tafenoquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after tafenoquine administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "tafenoquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which tafenoquine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "tafenoquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of tafenoquine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for tafenoquine for malaria prophylaxis in a G6PD deficient child?",
        "answer": {
            "Drug Name": "tafenoquine",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Pediatric-specific dosing guidelines for tafenoquine in G6PD deficient children for malaria prophylaxis."
        }
        },
        {
        "question": "Is tolazamide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "tolazamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for tolazamide in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking tolazamide?",
        "answer": {
            "Drug Name": "tolazamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with tolazamide use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to tolazamide?",
        "answer": {
            "Drug Name": "tolazamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after tolazamide administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "tolazamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which tolazamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "tolazamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of tolazamide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for tolazamide in a diabetic patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "tolazamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for tolazamide in G6PD deficient patients with type 2 diabetes."
        }
        },
        {
        "question": "Is tolbutamide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "tolbutamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for tolbutamide in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking tolbutamide?",
        "answer": {
            "Drug Name": "tolbutamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with tolbutamide use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to tolbutamide?",
        "answer": {
            "Drug Name": "tolbutamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after tolbutamide administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "tolbutamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which tolbutamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "tolbutamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of tolbutamide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for tolbutamide in a diabetic patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "tolbutamide",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for tolbutamide in G6PD deficient patients with type 2 diabetes."
        }
        },
        {
        "question": "Is toluidine blue contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "toluidine blue",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for toluidine blue in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking toluidine blue?",
        "answer": {
            "Drug Name": "toluidine blue",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with toluidine blue use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to toluidine blue?",
        "answer": {
            "Drug Name": "toluidine blue",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after toluidine blue administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "toluidine blue",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which toluidine blue causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "toluidine blue",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of toluidine blue-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the recommendation for using toluidine blue as a diagnostic dye in a G6PD deficient patient?",
        "answer": {
            "Drug Name": "toluidine blue",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Guidelines for using toluidine blue as a dye in G6PD deficient patients."
        }
        },
        {
        "question": "Is trametinib contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "trametinib",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for trametinib in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking trametinib?",
        "answer": {
            "Drug Name": "trametinib",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with trametinib use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to trametinib?",
        "answer": {
            "Drug Name": "trametinib",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after trametinib administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "trametinib",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which trametinib causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "trametinib",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of trametinib-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for trametinib in a cancer patient with G6PD deficiency?",
        "answer": {
            "Drug Name": "trametinib",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for trametinib in G6PD deficient cancer patients."
        }
        },
        {
        "question": "Is high-dose vitamin C contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "vitamin c",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for high-dose vitamin C in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking high-dose vitamin C?",
        "answer": {
            "Drug Name": "vitamin c",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with high-dose vitamin C use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to high-dose vitamin C?",
        "answer": {
            "Drug Name": "vitamin c",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after high-dose vitamin C administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "vitamin c",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which high-dose vitamin C causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "vitamin c",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of high-dose vitamin C-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the recommendation for intravenous vitamin C administration in a G6PD deficient patient?",
        "answer": {
            "Drug Name": "vitamin c",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Guidelines for IV vitamin C use in G6PD deficient patients, particularly in the context of sepsis or cancer therapy."
        }
        },
        {
        "question": "Is vitamin K contraindicated or should dosing be adjusted for a G6PD deficient individual?",
        "answer": {
            "Drug Name": "vitamin k",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing protocol or contraindication for vitamin K in G6PD deficient individuals."
        }
        },
        {
        "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking vitamin K?",
        "answer": {
            "Drug Name": "vitamin k",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with vitamin K use in G6PD deficient patients."
        }
        },
        {
        "question": "What are the expected hematological changes in a G6PD deficient individual exposed to vitamin K?",
        "answer": {
            "Drug Name": "vitamin k",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Data on hematological parameters in G6PD deficient individuals after vitamin K administration."
        }
        },
        {
        "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
        "answer": {
            "Drug Name": "vitamin k",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
        }
        },
        {
        "question": "What is the mechanism by which vitamin K causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
        "answer": {
            "Drug Name": "vitamin k",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Biochemical mechanism of vitamin K-induced oxidative damage to red blood cells in the context of G6PD deficiency."
        }
        },
        {
        "question": "What is the dosing recommendation for vitamin K in a G6PD deficient neonate?",
        "answer": {
            "Drug Name": "vitamin k",
            "Gene Name": "G6PD",
            "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
            "Content to Search": "Dosing guidelines for vitamin K administration to G6PD deficient newborns."
        }
        }
    ]
    },
    {
  "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf": [
    {
      "question": "How should acebutolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for acebutolol based on ADRA2C genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking acebutolol?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking acebutolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking acebutolol?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for acebutolol stratified by ADRA2C genotype."
      }
    },
    {
      "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRA2C gene product in the context of acebutolol therapy?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with acebutolol."
      }
    },
    {
      "question": "What is the dosing recommendation for acebutolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for acebutolol in heart failure patients, adjusted for ADRA2C genotype."
      }
    },
    {
      "question": "How should acebutolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for acebutolol based on ADRB1 Arg389Gly genotype."
      }
    },
    {
      "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking acebutolol?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking acebutolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking acebutolol?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for acebutolol stratified by ADRB1 genotype."
      }
    },
    {
      "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB1 receptor in the mechanism of action of acebutolol?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for acebutolol."
      }
    },
    {
      "question": "What is the dosing recommendation for acebutolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pediatric dosing guidelines for acebutolol adjusted for ADRB1 genotype."
      }
    },
    {
      "question": "How should acebutolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for acebutolol based on ADRB2 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking acebutolol?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking acebutolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking acebutolol?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for acebutolol stratified by ADRB2 genotype."
      }
    },
    {
      "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB2 gene product in the context of acebutolol therapy?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with acebutolol."
      }
    },
    {
      "question": "What is the dosing recommendation for acebutolol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for acebutolol in asthmatic patients, adjusted for ADRB2 genotype."
      }
    },
    {
      "question": "How should acebutolol dosing be adjusted for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for acebutolol in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking acebutolol?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using acebutolol."
      }
    },
    {
      "question": "What are the expected plasma acebutolol concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for acebutolol in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of acebutolol?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Description of CYP2D6's role in acebutolol metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for acebutolol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing adjustments for acebutolol in elderly CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should acebutolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for acebutolol based on GRK4 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking acebutolol?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking acebutolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking acebutolol?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for acebutolol stratified by GRK4 genotype."
      }
    },
    {
      "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK4 gene product in the context of acebutolol therapy?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for acebutolol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for acebutolol in hypertensive patients, adjusted for GRK4 genotype."
      }
    },
    {
      "question": "How should acebutolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for acebutolol based on GRK5 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking acebutolol?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking acebutolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking acebutolol?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for acebutolol stratified by GRK5 genotype."
      }
    },
    {
      "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK5 gene product in the context of acebutolol therapy?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for acebutolol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "acebutolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for acebutolol in heart failure patients, adjusted for GRK5 genotype."
      }
    },
    {
      "question": "How should atenolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for atenolol based on ADRA2C genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking atenolol?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking atenolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking atenolol?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for atenolol stratified by ADRA2C genotype."
      }
    },
    {
      "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRA2C gene product in the context of atenolol therapy?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with atenolol."
      }
    },
    {
      "question": "What is the dosing recommendation for atenolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for atenolol in heart failure patients, adjusted for ADRA2C genotype."
      }
    },
    {
      "question": "How should atenolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for atenolol based on ADRB1 Arg389Gly genotype."
      }
    },
    {
      "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking atenolol?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking atenolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking atenolol?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for atenolol stratified by ADRB1 genotype."
      }
    },
    {
      "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB1 receptor in the mechanism of action of atenolol?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for atenolol."
      }
    },
    {
      "question": "What is the dosing recommendation for atenolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pediatric dosing guidelines for atenolol adjusted for ADRB1 genotype."
      }
    },
    {
      "question": "How should atenolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for atenolol based on ADRB2 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking atenolol?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking atenolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking atenolol?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for atenolol stratified by ADRB2 genotype."
      }
    },
    {
      "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB2 gene product in the context of atenolol therapy?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with atenolol."
      }
    },
    {
      "question": "What is the dosing recommendation for atenolol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for atenolol in asthmatic patients, adjusted for ADRB2 genotype."
      }
    },
    {
      "question": "How should atenolol dosing be adjusted for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for atenolol in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking atenolol?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using atenolol."
      }
    },
    {
      "question": "What are the expected plasma atenolol concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for atenolol in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of atenolol?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Description of CYP2D6's role in atenolol metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for atenolol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing adjustments for atenolol in elderly CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should atenolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for atenolol based on GRK4 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking atenolol?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking atenolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking atenolol?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for atenolol stratified by GRK4 genotype."
      }
    },
    {
      "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK4 gene product in the context of atenolol therapy?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for atenolol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for atenolol in hypertensive patients, adjusted for GRK4 genotype."
      }
    },
    {
      "question": "How should atenolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for atenolol based on GRK5 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking atenolol?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking atenolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking atenolol?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for atenolol stratified by GRK5 genotype."
      }
    },
    {
      "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK5 gene product in the context of atenolol therapy?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for atenolol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "atenolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for atenolol in heart failure patients, adjusted for GRK5 genotype."
      }
    },
    {
      "question": "How should betaxolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for betaxolol based on ADRA2C genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking betaxolol?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking betaxolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking betaxolol?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for betaxolol stratified by ADRA2C genotype."
      }
    },
    {
      "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRA2C gene product in the context of betaxolol therapy?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with betaxolol."
      }
    },
    {
      "question": "What is the dosing recommendation for betaxolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for betaxolol in heart failure patients, adjusted for ADRA2C genotype."
      }
    },
    {
      "question": "How should betaxolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for betaxolol based on ADRB1 Arg389Gly genotype."
      }
    },
    {
      "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking betaxolol?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking betaxolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking betaxolol?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for betaxolol stratified by ADRB1 genotype."
      }
    },
    {
      "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB1 receptor in the mechanism of action of betaxolol?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for betaxolol."
      }
    },
    {
      "question": "What is the dosing recommendation for betaxolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pediatric dosing guidelines for betaxolol adjusted for ADRB1 genotype."
      }
    },
    {
      "question": "How should betaxolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for betaxolol based on ADRB2 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking betaxolol?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking betaxolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking betaxolol?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for betaxolol stratified by ADRB2 genotype."
      }
    },
    {
      "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB2 gene product in the context of betaxolol therapy?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with betaxolol."
      }
    },
    {
      "question": "What is the dosing recommendation for betaxolol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for betaxolol in asthmatic patients, adjusted for ADRB2 genotype."
      }
    },
    {
      "question": "How should betaxolol dosing be adjusted for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for betaxolol in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking betaxolol?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using betaxolol."
      }
    },
    {
      "question": "What are the expected plasma betaxolol concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for betaxolol in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of betaxolol?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Description of CYP2D6's role in betaxolol metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for betaxolol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing adjustments for betaxolol in elderly CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should betaxolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for betaxolol based on GRK4 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking betaxolol?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking betaxolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking betaxolol?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for betaxolol stratified by GRK4 genotype."
      }
    },
    {
      "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK4 gene product in the context of betaxolol therapy?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for betaxolol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for betaxolol in hypertensive patients, adjusted for GRK4 genotype."
      }
    },
    {
      "question": "How should betaxolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for betaxolol based on GRK5 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking betaxolol?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking betaxolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking betaxolol?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for betaxolol stratified by GRK5 genotype."
      }
    },
    {
      "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK5 gene product in the context of betaxolol therapy?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for betaxolol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "betaxolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for betaxolol in heart failure patients, adjusted for GRK5 genotype."
      }
    },
    {
      "question": "How should bisoprolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for bisoprolol based on ADRA2C genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking bisoprolol?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking bisoprolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking bisoprolol?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for bisoprolol stratified by ADRA2C genotype."
      }
    },
    {
      "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRA2C gene product in the context of bisoprolol therapy?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with bisoprolol."
      }
    },
    {
      "question": "What is the dosing recommendation for bisoprolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for bisoprolol in heart failure patients, adjusted for ADRA2C genotype."
      }
    },
    {
      "question": "How should bisoprolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for bisoprolol based on ADRB1 Arg389Gly genotype."
      }
    },
    {
      "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking bisoprolol?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking bisoprolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking bisoprolol?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for bisoprolol stratified by ADRB1 genotype."
      }
    },
    {
      "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB1 receptor in the mechanism of action of bisoprolol?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for bisoprolol."
      }
    },
    {
      "question": "What is the dosing recommendation for bisoprolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pediatric dosing guidelines for bisoprolol adjusted for ADRB1 genotype."
      }
    },
    {
      "question": "How should bisoprolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for bisoprolol based on ADRB2 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking bisoprolol?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking bisoprolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking bisoprolol?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for bisoprolol stratified by ADRB2 genotype."
      }
    },
    {
      "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB2 gene product in the context of bisoprolol therapy?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with bisoprolol."
      }
    },
    {
      "question": "What is the dosing recommendation for bisoprolol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for bisoprolol in asthmatic patients, adjusted for ADRB2 genotype."
      }
    },
    {
      "question": "How should bisoprolol dosing be adjusted for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for bisoprolol in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking bisoprolol?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using bisoprolol."
      }
    },
    {
      "question": "What are the expected plasma bisoprolol concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for bisoprolol in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 normal metabolizer?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of bisoprolol?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Description of CYP2D6's role in bisoprolol metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for bisoprolol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing adjustments for bisoprolol in elderly CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should bisoprolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for bisoprolol based on GRK4 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking bisoprolol?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking bisoprolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking bisoprolol?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for bisoprolol stratified by GRK4 genotype."
      }
    },
    {
      "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK4 gene product in the context of bisoprolol therapy?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for bisoprolol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for bisoprolol in hypertensive patients, adjusted for GRK4 genotype."
      }
    },
    {
      "question": "How should bisoprolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for bisoprolol based on GRK5 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking bisoprolol?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking bisoprolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking bisoprolol?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for bisoprolol stratified by GRK5 genotype."
      }
    },
    {
      "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK5 gene product in the context of bisoprolol therapy?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for bisoprolol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "bisoprolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for bisoprolol in heart failure patients, adjusted for GRK5 genotype."
      }
    },
    {
      "question": "How should carvedilol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for carvedilol based on ADRA2C genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking carvedilol?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking carvedilol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking carvedilol?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for carvedilol stratified by ADRA2C genotype."
      }
    },
    {
      "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRA2C gene product in the context of carvedilol therapy?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with carvedilol."
      }
    },
    {
      "question": "What is the dosing recommendation for carvedilol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for carvedilol in heart failure patients, adjusted for ADRA2C genotype."
      }
    },
    {
      "question": "How should carvedilol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for carvedilol based on ADRB1 Arg389Gly genotype."
      }
    },
    {
      "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking carvedilol?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking carvedilol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking carvedilol?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for carvedilol stratified by ADRB1 genotype."
      }
    },
    {
      "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB1 receptor in the mechanism of action of carvedilol?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for carvedilol."
      }
    },
    {
      "question": "What is the dosing recommendation for carvedilol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pediatric dosing guidelines for carvedilol adjusted for ADRB1 genotype."
      }
    },
    {
      "question": "How should carvedilol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for carvedilol based on ADRB2 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking carvedilol?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking carvedilol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking carvedilol?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for carvedilol stratified by ADRB2 genotype."
      }
    },
    {
      "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB2 gene product in the context of carvedilol therapy?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with carvedilol."
      }
    },
    {
      "question": "What is the dosing recommendation for carvedilol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for carvedilol in asthmatic patients, adjusted for ADRB2 genotype."
      }
    },
    {
      "question": "How should carvedilol dosing be adjusted for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for carvedilol in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking carvedilol?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using carvedilol."
      }
    },
    {
      "question": "What are the expected plasma carvedilol concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for carvedilol in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of carvedilol?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Description of CYP2D6's role in carvedilol metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for carvedilol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing adjustments for carvedilol in elderly CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should carvedilol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for carvedilol based on GRK4 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking carvedilol?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking carvedilol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking carvedilol?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for carvedilol stratified by GRK4 genotype."
      }
    },
    {
      "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK4 gene product in the context of carvedilol therapy?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for carvedilol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for carvedilol in hypertensive patients, adjusted for GRK4 genotype."
      }
    },
    {
      "question": "How should carvedilol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for carvedilol based on GRK5 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking carvedilol?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking carvedilol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking carvedilol?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for carvedilol stratified by GRK5 genotype."
      }
    },
    {
      "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK5 gene product in the context of carvedilol therapy?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for carvedilol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "carvedilol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for carvedilol in heart failure patients, adjusted for GRK5 genotype."
      }
    },
    {
      "question": "How should esmolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for esmolol based on ADRA2C genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking esmolol?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking esmolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking esmolol?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for esmolol stratified by ADRA2C genotype."
      }
    },
    {
      "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRA2C gene product in the context of esmolol therapy?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with esmolol."
      }
    },
    {
      "question": "What is the dosing recommendation for esmolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for esmolol in heart failure patients, adjusted for ADRA2C genotype."
      }
    },
    {
      "question": "How should esmolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for esmolol based on ADRB1 Arg389Gly genotype."
      }
    },
    {
      "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking esmolol?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking esmolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking esmolol?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for esmolol stratified by ADRB1 genotype."
      }
    },
    {
      "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB1 receptor in the mechanism of action of esmolol?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for esmolol."
      }
    },
    {
      "question": "What is the dosing recommendation for esmolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pediatric dosing guidelines for esmolol adjusted for ADRB1 genotype."
      }
    },
    {
      "question": "How should esmolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for esmolol based on ADRB2 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking esmolol?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking esmolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking esmolol?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for esmolol stratified by ADRB2 genotype."
      }
    },
    {
      "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB2 gene product in the context of esmolol therapy?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with esmolol."
      }
    },
    {
      "question": "What is the dosing recommendation for esmolol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for esmolol in asthmatic patients, adjusted for ADRB2 genotype."
      }
    },
    {
      "question": "How should esmolol dosing be adjusted for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for esmolol in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking esmolol?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using esmolol."
      }
    },
    {
      "question": "What are the expected plasma esmolol concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for esmolol in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 normal metabolizer?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of esmolol?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Description of CYP2D6's role in esmolol metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for esmolol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing adjustments for esmolol in elderly CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should esmolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for esmolol based on GRK4 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking esmolol?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking esmolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking esmolol?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for esmolol stratified by GRK4 genotype."
      }
    },
    {
      "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK4 gene product in the context of esmolol therapy?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for esmolol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for esmolol in hypertensive patients, adjusted for GRK4 genotype."
      }
    },
    {
      "question": "How should esmolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for esmolol based on GRK5 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking esmolol?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking esmolol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking esmolol?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for esmolol stratified by GRK5 genotype."
      }
    },
    {
      "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK5 gene product in the context of esmolol therapy?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for esmolol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "esmolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for esmolol in heart failure patients, adjusted for GRK5 genotype."
      }
    },
    {
      "question": "How should labetalol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for labetalol based on ADRA2C genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking labetalol?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking labetalol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking labetalol?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for labetalol stratified by ADRA2C genotype."
      }
    },
    {
      "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRA2C gene product in the context of labetalol therapy?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with labetalol."
      }
    },
    {
      "question": "What is the dosing recommendation for labetalol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for labetalol in heart failure patients, adjusted for ADRA2C genotype."
      }
    },
    {
      "question": "How should labetalol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for labetalol based on ADRB1 Arg389Gly genotype."
      }
    },
    {
      "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking labetalol?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking labetalol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking labetalol?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for labetalol stratified by ADRB1 genotype."
      }
    },
    {
      "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB1 receptor in the mechanism of action of labetalol?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for labetalol."
      }
    },
    {
      "question": "What is the dosing recommendation for labetalol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pediatric dosing guidelines for labetalol adjusted for ADRB1 genotype."
      }
    },
    {
      "question": "How should labetalol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for labetalol based on ADRB2 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking labetalol?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking labetalol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking labetalol?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for labetalol stratified by ADRB2 genotype."
      }
    },
    {
      "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the ADRB2 gene product in the context of labetalol therapy?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with labetalol."
      }
    },
    {
      "question": "What is the dosing recommendation for labetalol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for labetalol in asthmatic patients, adjusted for ADRB2 genotype."
      }
    },
    {
      "question": "How should labetalol dosing be adjusted for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for labetalol in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking labetalol?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using labetalol."
      }
    },
    {
      "question": "What are the expected plasma labetalol concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for labetalol in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of labetalol?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Description of CYP2D6's role in labetalol metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for labetalol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing adjustments for labetalol in elderly CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should labetalol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for labetalol based on GRK4 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking labetalol?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking labetalol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking labetalol?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for labetalol stratified by GRK4 genotype."
      }
    },
    {
      "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK4 gene product in the context of labetalol therapy?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for labetalol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for labetalol in hypertensive patients, adjusted for GRK4 genotype."
      }
    },
    {
      "question": "How should labetalol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for labetalol based on GRK5 genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking labetalol?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking labetalol."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking labetalol?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for labetalol stratified by GRK5 genotype."
      }
    },
    {
      "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
      }
    },
    {
      "question": "What is the function of the GRK5 gene product in the context of labetalol therapy?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
      }
    },
    {
      "question": "What is the dosing recommendation for labetalol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
      "answer": {
        "Drug Name": "labetalol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for labetalol in heart failure patients, adjusted for GRK5 genotype."
      }
    },
    {
      "question": "What is the recommended metoprolol dose for an individual with the ADRA2C Ins/Del polymorphism associated with decreased response?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for metoprolol based on ADRA2C Ins/Del polymorphism."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking metoprolol?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on reduced efficacy of metoprolol in patients with the ADRA2C Ins/Del polymorphism."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking metoprolol?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data, such as heart rate or blood pressure changes, for metoprolol stratified by ADRA2C genotype."
      }
    },
    {
      "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRA2C gene product in the context of metoprolol therapy?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on the sympathetic nervous system and beta-blocker effects."
      }
    },
    {
      "question": "What is the dosing recommendation for metoprolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for metoprolol in heart failure patients, adjusted for ADRA2C genotype."
      }
    },
    {
      "question": "What is the recommended metoprolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for metoprolol based on ADRB1 Arg389Gly genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking metoprolol?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on the efficacy of metoprolol in patients with the ADRB1 Arg389Arg genotype."
      }
    },
    {
      "question": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking metoprolol?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data, such as heart rate changes, for metoprolol stratified by ADRB1 Ser49Gly genotype."
      }
    },
    {
      "question": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRB1 gene product in the context of metoprolol therapy?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, the primary target for metoprolol."
      }
    },
    {
      "question": "What is the dosing recommendation for metoprolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pediatric dosing guidelines for metoprolol adjusted for ADRB1 genotype."
      }
    },
    {
      "question": "What is the recommended metoprolol dose for an individual with the ADRB2 Gly16Arg polymorphism?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for metoprolol based on ADRB2 Gly16Arg genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking metoprolol?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on the efficacy of metoprolol in patients with the ADRB2 Gln27Glu polymorphism."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking metoprolol?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data, such as blood pressure changes, for metoprolol stratified by ADRB2 genotype."
      }
    },
    {
      "question": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRB2 gene product in the context of metoprolol therapy?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to beta-blocker side effects and efficacy."
      }
    },
    {
      "question": "What is the dosing recommendation for metoprolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for metoprolol in asthmatic patients, adjusted for ADRB2 genotype."
      }
    },
    {
      "question": "What is the recommended metoprolol dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for metoprolol in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of bradycardia for a CYP2D6 poor metabolizer taking metoprolol?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for bradycardia or other adverse effects in CYP2D6 poor metabolizers using metoprolol."
      }
    },
    {
      "question": "What are the expected plasma metoprolol concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for metoprolol in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of metoprolol?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Description of CYP2D6's role as the primary metabolizing enzyme for metoprolol."
      }
    },
    {
      "question": "What is the dosing recommendation for metoprolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing adjustments for metoprolol in elderly CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended metoprolol dose for an individual with a GRK4 variant associated with altered response?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for metoprolol based on GRK4 genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking metoprolol?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on reduced efficacy of metoprolol in patients with high-activity GRK4 variants."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking metoprolol?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data, such as blood pressure changes, for metoprolol stratified by GRK4 genotype."
      }
    },
    {
      "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the GRK4 enzyme in the context of metoprolol therapy?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on beta-blocker efficacy."
      }
    },
    {
      "question": "What is the dosing recommendation for metoprolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for metoprolol in patients of African ancestry, adjusted for GRK4 genotype."
      }
    },
    {
      "question": "What is the recommended metoprolol dose for an individual with the GRK5 Gln41Leu polymorphism?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for metoprolol based on GRK5 Gln41Leu genotype."
      }
    },
    {
      "question": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking metoprolol?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on heart failure outcomes with metoprolol in patients with the GRK5 Leu41 variant."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking metoprolol?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data, such as changes in ejection fraction, for metoprolol stratified by GRK5 genotype."
      }
    },
    {
      "question": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the GRK5 enzyme in the context of metoprolol therapy?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on beta-blocker efficacy, particularly in heart failure."
      }
    },
    {
      "question": "What is the dosing recommendation for metoprolol in elderly patients with heart failure and the GRK5 Leu41 variant?",
      "answer": {
        "Drug Name": "metoprolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for metoprolol in elderly heart failure patients, adjusted for GRK5 genotype."
      }
    },
    {
      "question": "What is the recommended nadolol dose for an individual with the ADRA2C Ins/Del polymorphism?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for nadolol based on ADRA2C Ins/Del polymorphism."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking nadolol?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on reduced efficacy of nadolol in patients with the ADRA2C Ins/Del polymorphism."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking nadolol?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for nadolol stratified by ADRA2C genotype."
      }
    },
    {
      "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRA2C gene product in the context of nadolol therapy?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on nadolol effects."
      }
    },
    {
      "question": "What is the dosing recommendation for nadolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for nadolol in heart failure patients, adjusted for ADRA2C genotype."
      }
    },
    {
      "question": "What is the recommended nadolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for nadolol based on ADRB1 Arg389Gly genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking nadolol?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on the efficacy of nadolol in patients with the ADRB1 Arg389Arg genotype."
      }
    },
    {
      "question": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking nadolol?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for nadolol stratified by ADRB1 Ser49Gly genotype."
      }
    },
    {
      "question": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRB1 gene product in the context of nadolol therapy?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for nadolol."
      }
    },
    {
      "question": "What is the dosing recommendation for nadolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pediatric dosing guidelines for nadolol adjusted for ADRB1 genotype."
      }
    },
    {
      "question": "What is the recommended nadolol dose for an individual with the ADRB2 Gly16Arg polymorphism?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for nadolol based on ADRB2 Gly16Arg genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking nadolol?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on the efficacy of nadolol in patients with the ADRB2 Gln27Glu polymorphism."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking nadolol?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for nadolol stratified by ADRB2 genotype."
      }
    },
    {
      "question": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRB2 gene product in the context of nadolol therapy?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to nadolol therapy."
      }
    },
    {
      "question": "What is the dosing recommendation for nadolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for nadolol in asthmatic patients, adjusted for ADRB2 genotype."
      }
    },
    {
      "question": "What is the recommended nadolol dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for nadolol in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking nadolol?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using nadolol."
      }
    },
    {
      "question": "What are the expected plasma nadolol concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for nadolol in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of nadolol?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Description of CYP2D6's role in nadolol metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for nadolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing adjustments for nadolol in elderly CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended nadolol dose for an individual with a GRK4 variant associated with altered response?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for nadolol based on GRK4 genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking nadolol?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on reduced efficacy of nadolol in patients with high-activity GRK4 variants."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking nadolol?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for nadolol stratified by GRK4 genotype."
      }
    },
    {
      "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the GRK4 enzyme in the context of nadolol therapy?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on nadolol efficacy."
      }
    },
    {
      "question": "What is the dosing recommendation for nadolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for nadolol in patients of African ancestry, adjusted for GRK4 genotype."
      }
    },
    {
      "question": "What is the recommended nadolol dose for an individual with the GRK5 Gln41Leu polymorphism?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for nadolol based on GRK5 Gln41Leu genotype."
      }
    },
    {
      "question": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking nadolol?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on heart failure outcomes with nadolol in patients with the GRK5 Leu41 variant."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking nadolol?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for nadolol stratified by GRK5 genotype."
      }
    },
    {
      "question": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the GRK5 enzyme in the context of nadolol therapy?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on nadolol efficacy."
      }
    },
    {
      "question": "What is the dosing recommendation for nadolol in elderly patients with heart failure and the GRK5 Leu41 variant?",
      "answer": {
        "Drug Name": "nadolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for nadolol in elderly heart failure patients, adjusted for GRK5 genotype."
      }
    },
    {
      "question": "What is the recommended nebivolol dose for an individual with the ADRA2C Ins/Del polymorphism?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for nebivolol based on ADRA2C Ins/Del polymorphism."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking nebivolol?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on reduced efficacy of nebivolol in patients with the ADRA2C Ins/Del polymorphism."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking nebivolol?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for nebivolol stratified by ADRA2C genotype."
      }
    },
    {
      "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRA2C gene product in the context of nebivolol therapy?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on nebivolol effects."
      }
    },
    {
      "question": "What is the dosing recommendation for nebivolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for nebivolol in heart failure patients, adjusted for ADRA2C genotype."
      }
    },
    {
      "question": "What is the recommended nebivolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for nebivolol based on ADRB1 Arg389Gly genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking nebivolol?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on the efficacy of nebivolol in patients with the ADRB1 Arg389Arg genotype."
      }
    },
    {
      "question": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking nebivolol?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for nebivolol stratified by ADRB1 Ser49Gly genotype."
      }
    },
    {
      "question": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRB1 gene product in the context of nebivolol therapy?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for nebivolol."
      }
    },
    {
      "question": "What is the dosing recommendation for nebivolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pediatric dosing guidelines for nebivolol adjusted for ADRB1 genotype."
      }
    },
    {
      "question": "What is the recommended nebivolol dose for an individual with the ADRB2 Gly16Arg polymorphism?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for nebivolol based on ADRB2 Gly16Arg genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking nebivolol?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on the efficacy of nebivolol in patients with the ADRB2 Gln27Glu polymorphism."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking nebivolol?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for nebivolol stratified by ADRB2 genotype."
      }
    },
    {
      "question": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRB2 gene product in the context of nebivolol therapy?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to nebivolol therapy."
      }
    },
    {
      "question": "What is the dosing recommendation for nebivolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for nebivolol in asthmatic patients, adjusted for ADRB2 genotype."
      }
    },
    {
      "question": "What is the recommended nebivolol dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for nebivolol in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking nebivolol?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using nebivolol."
      }
    },
    {
      "question": "What are the expected plasma nebivolol concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for nebivolol in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of nebivolol?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Description of CYP2D6's role in nebivolol metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for nebivolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing adjustments for nebivolol in elderly CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended nebivolol dose for an individual with a GRK4 variant associated with altered response?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for nebivolol based on GRK4 genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking nebivolol?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on reduced efficacy of nebivolol in patients with high-activity GRK4 variants."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking nebivolol?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for nebivolol stratified by GRK4 genotype."
      }
    },
    {
      "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the GRK4 enzyme in the context of nebivolol therapy?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on nebivolol efficacy."
      }
    },
    {
      "question": "What is the dosing recommendation for nebivolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for nebivolol in patients of African ancestry, adjusted for GRK4 genotype."
      }
    },
    {
      "question": "What is the recommended nebivolol dose for an individual with the GRK5 Gln41Leu polymorphism?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for nebivolol based on GRK5 Gln41Leu genotype."
      }
    },
    {
      "question": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking nebivolol?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on heart failure outcomes with nebivolol in patients with the GRK5 Leu41 variant."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking nebivolol?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for nebivolol stratified by GRK5 genotype."
      }
    },
    {
      "question": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the GRK5 enzyme in the context of nebivolol therapy?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on nebivolol efficacy."
      }
    },
    {
      "question": "What is the dosing recommendation for nebivolol in elderly patients with heart failure and the GRK5 Leu41 variant?",
      "answer": {
        "Drug Name": "nebivolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for nebivolol in elderly heart failure patients, adjusted for GRK5 genotype."
      }
    },
    {
      "question": "What is the recommended pindolol dose for an individual with the ADRA2C Ins/Del polymorphism?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for pindolol based on ADRA2C Ins/Del polymorphism."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking pindolol?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on reduced efficacy of pindolol in patients with the ADRA2C Ins/Del polymorphism."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking pindolol?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for pindolol stratified by ADRA2C genotype."
      }
    },
    {
      "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRA2C gene product in the context of pindolol therapy?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on pindolol effects."
      }
    },
    {
      "question": "What is the dosing recommendation for pindolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for pindolol in heart failure patients, adjusted for ADRA2C genotype."
      }
    },
    {
      "question": "What is the recommended pindolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for pindolol based on ADRB1 Arg389Gly genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking pindolol?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on the efficacy of pindolol in patients with the ADRB1 Arg389Arg genotype."
      }
    },
    {
      "question": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking pindolol?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for pindolol stratified by ADRB1 Ser49Gly genotype."
      }
    },
    {
      "question": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRB1 gene product in the context of pindolol therapy?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for pindolol."
      }
    },
    {
      "question": "What is the dosing recommendation for pindolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pediatric dosing guidelines for pindolol adjusted for ADRB1 genotype."
      }
    },
    {
      "question": "What is the recommended pindolol dose for an individual with the ADRB2 Gly16Arg polymorphism?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for pindolol based on ADRB2 Gly16Arg genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking pindolol?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on the efficacy of pindolol in patients with the ADRB2 Gln27Glu polymorphism."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking pindolol?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for pindolol stratified by ADRB2 genotype."
      }
    },
    {
      "question": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRB2 gene product in the context of pindolol therapy?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to pindolol therapy."
      }
    },
    {
      "question": "What is the dosing recommendation for pindolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for pindolol in asthmatic patients, adjusted for ADRB2 genotype."
      }
    },
    {
      "question": "What is the recommended pindolol dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for pindolol in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking pindolol?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using pindolol."
      }
    },
    {
      "question": "What are the expected plasma pindolol concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for pindolol in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 normal metabolizer?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of pindolol?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Description of CYP2D6's role in pindolol metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for pindolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing adjustments for pindolol in elderly CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended pindolol dose for an individual with a GRK4 variant associated with altered response?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for pindolol based on GRK4 genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking pindolol?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on reduced efficacy of pindolol in patients with high-activity GRK4 variants."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking pindolol?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for pindolol stratified by GRK4 genotype."
      }
    },
    {
      "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the GRK4 enzyme in the context of pindolol therapy?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on pindolol efficacy."
      }
    },
    {
      "question": "What is the dosing recommendation for pindolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for pindolol in patients of African ancestry, adjusted for GRK4 genotype."
      }
    },
    {
      "question": "What is the recommended pindolol dose for an individual with the GRK5 Gln41Leu polymorphism?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for pindolol based on GRK5 Gln41Leu genotype."
      }
    },
    {
      "question": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking pindolol?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on heart failure outcomes with pindolol in patients with the GRK5 Leu41 variant."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking pindolol?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for pindolol stratified by GRK5 genotype."
      }
    },
    {
      "question": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the GRK5 enzyme in the context of pindolol therapy?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on pindolol efficacy."
      }
    },
    {
      "question": "What is the dosing recommendation for pindolol in elderly patients with heart failure and the GRK5 Leu41 variant?",
      "answer": {
        "Drug Name": "pindolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for pindolol in elderly heart failure patients, adjusted for GRK5 genotype."
      }
    },
    {
      "question": "What is the recommended propranolol dose for an individual with the ADRA2C Ins/Del polymorphism?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for propranolol based on ADRA2C Ins/Del polymorphism."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking propranolol?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on reduced efficacy of propranolol in patients with the ADRA2C Ins/Del polymorphism."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking propranolol?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for propranolol stratified by ADRA2C genotype."
      }
    },
    {
      "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRA2C gene product in the context of propranolol therapy?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on propranolol effects."
      }
    },
    {
      "question": "What is the dosing recommendation for propranolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for propranolol in heart failure patients, adjusted for ADRA2C genotype."
      }
    },
    {
      "question": "What is the recommended propranolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for propranolol based on ADRB1 Arg389Gly genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking propranolol?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on the efficacy of propranolol in patients with the ADRB1 Arg389Arg genotype."
      }
    },
    {
      "question": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking propranolol?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for propranolol stratified by ADRB1 Ser49Gly genotype."
      }
    },
    {
      "question": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRB1 gene product in the context of propranolol therapy?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for propranolol."
      }
    },
    {
      "question": "What is the dosing recommendation for propranolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pediatric dosing guidelines for propranolol adjusted for ADRB1 genotype."
      }
    },
    {
      "question": "What is the recommended propranolol dose for an individual with the ADRB2 Gly16Arg polymorphism?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for propranolol based on ADRB2 Gly16Arg genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking propranolol?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on the efficacy of propranolol in patients with the ADRB2 Gln27Glu polymorphism."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking propranolol?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for propranolol stratified by ADRB2 genotype."
      }
    },
    {
      "question": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRB2 gene product in the context of propranolol therapy?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to propranolol therapy."
      }
    },
    {
      "question": "What is the dosing recommendation for propranolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for propranolol in asthmatic patients, adjusted for ADRB2 genotype."
      }
    },
    {
      "question": "What is the recommended propranolol dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for propranolol in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking propranolol?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using propranolol."
      }
    },
    {
      "question": "What are the expected plasma propranolol concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for propranolol in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of propranolol?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Description of CYP2D6's role in propranolol metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for propranolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing adjustments for propranolol in elderly CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended propranolol dose for an individual with a GRK4 variant associated with altered response?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for propranolol based on GRK4 genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking propranolol?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on reduced efficacy of propranolol in patients with high-activity GRK4 variants."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking propranolol?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for propranolol stratified by GRK4 genotype."
      }
    },
    {
      "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the GRK4 enzyme in the context of propranolol therapy?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on propranolol efficacy."
      }
    },
    {
      "question": "What is the dosing recommendation for propranolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for propranolol in patients of African ancestry, adjusted for GRK4 genotype."
      }
    },
    {
      "question": "What is the recommended propranolol dose for an individual with the GRK5 Gln41Leu polymorphism?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for propranolol based on GRK5 Gln41Leu genotype."
      }
    },
    {
      "question": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking propranolol?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on heart failure outcomes with propranolol in patients with the GRK5 Leu41 variant."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking propranolol?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for propranolol stratified by GRK5 genotype."
      }
    },
    {
      "question": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the GRK5 enzyme in the context of propranolol therapy?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on propranolol efficacy."
      }
    },
    {
      "question": "What is the dosing recommendation for propranolol in elderly patients with heart failure and the GRK5 Leu41 variant?",
      "answer": {
        "Drug Name": "propranolol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for propranolol in elderly heart failure patients, adjusted for GRK5 genotype."
      }
    },
    {
      "question": "What is the recommended sotalol dose for an individual with the ADRA2C Ins/Del polymorphism?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for sotalol based on ADRA2C Ins/Del polymorphism."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking sotalol?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on reduced efficacy of sotalol in patients with the ADRA2C Ins/Del polymorphism."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking sotalol?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for sotalol stratified by ADRA2C genotype."
      }
    },
    {
      "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRA2C gene product in the context of sotalol therapy?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on sotalol effects."
      }
    },
    {
      "question": "What is the dosing recommendation for sotalol in patients with heart failure and the ADRA2C Ins/Del polymorphism?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRA2C",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for sotalol in heart failure patients, adjusted for ADRA2C genotype."
      }
    },
    {
      "question": "What is the recommended sotalol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for sotalol based on ADRB1 Arg389Gly genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking sotalol?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on the efficacy of sotalol in patients with the ADRB1 Arg389Arg genotype."
      }
    },
    {
      "question": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking sotalol?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for sotalol stratified by ADRB1 Ser49Gly genotype."
      }
    },
    {
      "question": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRB1 gene product in the context of sotalol therapy?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for sotalol."
      }
    },
    {
      "question": "What is the dosing recommendation for sotalol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRB1",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pediatric dosing guidelines for sotalol adjusted for ADRB1 genotype."
      }
    },
    {
      "question": "What is the recommended sotalol dose for an individual with the ADRB2 Gly16Arg polymorphism?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for sotalol based on ADRB2 Gly16Arg genotype."
      }
    },
    {
      "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking sotalol?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on the efficacy of sotalol in patients with the ADRB2 Gln27Glu polymorphism."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking sotalol?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for sotalol stratified by ADRB2 genotype."
      }
    },
    {
      "question": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the ADRB2 gene product in the context of sotalol therapy?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to sotalol therapy."
      }
    },
    {
      "question": "What is the dosing recommendation for sotalol in patients with asthma and the ADRB2 Gly16Arg polymorphism?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "ADRB2",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for sotalol in asthmatic patients, adjusted for ADRB2 genotype."
      }
    },
    {
      "question": "What is the recommended sotalol dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for sotalol in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking sotalol?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using sotalol."
      }
    },
    {
      "question": "What are the expected plasma sotalol concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for sotalol in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 normal metabolizer?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of sotalol?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Description of CYP2D6's role in sotalol metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for sotalol in elderly patients with hypertension who are CYP2D6 poor metabolizers?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing adjustments for sotalol in elderly CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended sotalol dose for an individual with a GRK4 variant associated with altered response?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for sotalol based on GRK4 genotype."
      }
    },
    {
      "question": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking sotalol?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on reduced efficacy of sotalol in patients with high-activity GRK4 variants."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking sotalol?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for sotalol stratified by GRK4 genotype."
      }
    },
    {
      "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the GRK4 enzyme in the context of sotalol therapy?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on sotalol efficacy."
      }
    },
    {
      "question": "What is the dosing recommendation for sotalol in patients of African ancestry with hypertension and a high-activity GRK4 variant?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "GRK4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for sotalol in patients of African ancestry, adjusted for GRK4 genotype."
      }
    },
    {
      "question": "What is the recommended sotalol dose for an individual with the GRK5 Gln41Leu polymorphism?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dose adjustment protocol for sotalol based on GRK5 Gln41Leu genotype."
      }
    },
    {
      "question": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking sotalol?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Risk multipliers or clinical data on heart failure outcomes with sotalol in patients with the GRK5 Leu41 variant."
      }
    },
    {
      "question": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking sotalol?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Pharmacodynamic data for sotalol stratified by GRK5 genotype."
      }
    },
    {
      "question": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy."
      }
    },
    {
      "question": "What is the function of the GRK5 enzyme in the context of sotalol therapy?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on sotalol efficacy."
      }
    },
    {
      "question": "What is the dosing recommendation for sotalol in elderly patients with heart failure and the GRK5 Leu41 variant?",
      "answer": {
        "Drug Name": "sotalol",
        "Gene Name": "GRK5",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
        "Content to Search": "Dosing guidelines for sotalol in elderly heart failure patients, adjusted for GRK5 genotype."
      }
    }
  ]
},
{
  "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf": [
    {
      "question": "What is the recommended citalopram dose for a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for citalopram in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2B6 ultrarapid metabolizer taking citalopram?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects or lack of efficacy in CYP2B6 ultrarapid metabolizers using citalopram."
      }
    },
    {
      "question": "What are the expected plasma concentrations of citalopram in a CYP2B6 intermediate metabolizer?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for citalopram in CYP2B6 intermediate metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2B6 enzyme in the metabolism of citalopram?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2B6's role in the metabolic pathway of citalopram."
      }
    },
    {
      "question": "What is the dosing recommendation for citalopram in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for citalopram in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended citalopram dose for a CYP2C19 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol or alternative medication recommendation for citalopram in CYP2C19 ultrarapid metabolizers."
      }
    },
    {
      "question": "What is the increased risk of failed therapy for a CYP2C19 ultrarapid metabolizer taking a standard dose of citalopram?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for lack of efficacy in CYP2C19 ultrarapid metabolizers using citalopram."
      }
    },
    {
      "question": "What are the expected plasma concentrations of citalopram in a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for citalopram in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2C19 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 ultrarapid metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2C19 enzyme in the metabolism of citalopram?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2C19's primary role in the metabolic pathway of citalopram."
      }
    },
    {
      "question": "What is the dosing recommendation for citalopram in pediatric patients with a CYP2C19 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for citalopram in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended citalopram dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for citalopram in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking citalopram?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using citalopram."
      }
    },
    {
      "question": "What are the expected plasma concentrations of citalopram in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for citalopram in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of citalopram?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2D6's role in the metabolic pathway of citalopram."
      }
    },
    {
      "question": "What is the dosing recommendation for citalopram in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for citalopram in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should citalopram dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for citalopram based on HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What is the risk of poor response to citalopram for individuals with the HTR2A rs7997012 A allele?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for altered citalopram efficacy in patients with the HTR2A rs7997012 A allele."
      }
    },
    {
      "question": "What is the expected clinical response to citalopram in a patient with the HTR2A rs7997012 G/G genotype?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for citalopram stratified by HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What HTR2A variants are associated with altered citalopram response?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of HTR2A variants and their corresponding impact on citalopram response."
      }
    },
    {
      "question": "What is the function of the HTR2A gene product in the context of citalopram therapy?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of citalopram."
      }
    },
    {
      "question": "What is the dosing recommendation for citalopram in adolescents with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for citalopram in adolescent patients, adjusted for HTR2A genotype."
      }
    },
    {
      "question": "How should citalopram dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for citalopram based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What is the risk of adverse effects to citalopram for individuals with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of citalopram in patients with the SLC6A4 S/S genotype."
      }
    },
    {
      "question": "What is the expected clinical response to citalopram in a patient with the SLC6A4 L/S genotype?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for citalopram stratified by SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered citalopram response?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on citalopram response."
      }
    },
    {
      "question": "What is the function of the SLC6A4 gene product in the mechanism of action of citalopram?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, the primary target of citalopram."
      }
    },
    {
      "question": "What is the dosing recommendation for citalopram in adolescents with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "citalopram",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for citalopram in adolescent patients, adjusted for SLC6A4 genotype."
      }
    },
    {
      "question": "What is the recommended desvenlafaxine dose for a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for desvenlafaxine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking desvenlafaxine?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using desvenlafaxine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of desvenlafaxine in a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for desvenlafaxine in CYP2B6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2B6 normal metabolizer?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 normal metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2B6 enzyme in the metabolism of desvenlafaxine?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2B6's role in the metabolic pathway of desvenlafaxine."
      }
    },
    {
      "question": "What is the dosing recommendation for desvenlafaxine in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for desvenlafaxine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended desvenlafaxine dose for a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for desvenlafaxine in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking desvenlafaxine?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using desvenlafaxine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of desvenlafaxine in a CYP2C19 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for desvenlafaxine in CYP2C19 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2C19 enzyme in the metabolism of desvenlafaxine?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2C19's role in the metabolic pathway of desvenlafaxine."
      }
    },
    {
      "question": "What is the dosing recommendation for desvenlafaxine in pediatric patients with a CYP2C19 ultrarapid metabolizer phenotype?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for desvenlafaxine in CYP2C19 ultrarapid metabolizers."
      }
    },
    {
      "question": "What is the recommended desvenlafaxine dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for desvenlafaxine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking desvenlafaxine?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using desvenlafaxine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of desvenlafaxine in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for desvenlafaxine in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of desvenlafaxine?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2D6's role in the metabolic pathway of desvenlafaxine."
      }
    },
    {
      "question": "What is the dosing recommendation for desvenlafaxine in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for desvenlafaxine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should desvenlafaxine dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for desvenlafaxine based on HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What is the risk of poor response to desvenlafaxine for individuals with the HTR2A rs7997012 A allele?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for altered desvenlafaxine efficacy in patients with the HTR2A rs7997012 A allele."
      }
    },
    {
      "question": "What is the expected clinical response to desvenlafaxine in a patient with the HTR2A rs7997012 G/G genotype?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for desvenlafaxine stratified by HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What HTR2A variants are associated with altered desvenlafaxine response?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of HTR2A variants and their corresponding impact on desvenlafaxine response."
      }
    },
    {
      "question": "What is the function of the HTR2A gene product in the context of desvenlafaxine therapy?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of desvenlafaxine."
      }
    },
    {
      "question": "What is the dosing recommendation for desvenlafaxine in adolescents with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for desvenlafaxine in adolescent patients, adjusted for HTR2A genotype."
      }
    },
    {
      "question": "How should desvenlafaxine dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for desvenlafaxine based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What is the risk of adverse effects to desvenlafaxine for individuals with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of desvenlafaxine in patients with the SLC6A4 S/S genotype."
      }
    },
    {
      "question": "What is the expected clinical response to desvenlafaxine in a patient with the SLC6A4 L/S genotype?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for desvenlafaxine stratified by SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered desvenlafaxine response?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on desvenlafaxine response."
      }
    },
    {
      "question": "What is the function of the SLC6A4 gene product in the mechanism of action of desvenlafaxine?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, a primary target of desvenlafaxine."
      }
    },
    {
      "question": "What is the dosing recommendation for desvenlafaxine in adolescents with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "desvenlafaxine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for desvenlafaxine in adolescent patients, adjusted for SLC6A4 genotype."
      }
    },
    {
      "question": "What is the recommended duloxetine dose for a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for duloxetine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking duloxetine?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using duloxetine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of duloxetine in a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for duloxetine in CYP2B6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2B6 intermediate metabolizer?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 intermediate metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2B6 enzyme in the metabolism of duloxetine?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2B6's role in the metabolic pathway of duloxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for duloxetine in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for duloxetine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended duloxetine dose for a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for duloxetine in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking duloxetine?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using duloxetine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of duloxetine in a CYP2C19 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for duloxetine in CYP2C19 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2C19 normal metabolizer?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 normal metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2C19 enzyme in the metabolism of duloxetine?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2C19's role in the metabolic pathway of duloxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for duloxetine in pediatric patients with a CYP2C19 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for duloxetine in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended duloxetine dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol or alternative medication recommendation for duloxetine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking a standard dose of duloxetine?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using duloxetine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of duloxetine in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for duloxetine in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of duloxetine?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2D6's primary role in the metabolic pathway of duloxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for duloxetine in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for duloxetine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should duloxetine dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for duloxetine based on HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What is the risk of poor response to duloxetine for individuals with the HTR2A rs7997012 A allele?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for altered duloxetine efficacy in patients with the HTR2A rs7997012 A allele."
      }
    },
    {
      "question": "What is the expected clinical response to duloxetine in a patient with the HTR2A rs7997012 G/G genotype?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for duloxetine stratified by HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What HTR2A variants are associated with altered duloxetine response?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of HTR2A variants and their corresponding impact on duloxetine response."
      }
    },
    {
      "question": "What is the function of the HTR2A gene product in the context of duloxetine therapy?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of duloxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for duloxetine in adolescents with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for duloxetine in adolescent patients, adjusted for HTR2A genotype."
      }
    },
    {
      "question": "How should duloxetine dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for duloxetine based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What is the risk of adverse effects to duloxetine for individuals with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of duloxetine in patients with the SLC6A4 S/S genotype."
      }
    },
    {
      "question": "What is the expected clinical response to duloxetine in a patient with the SLC6A4 L/S genotype?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for duloxetine stratified by SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered duloxetine response?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on duloxetine response."
      }
    },
    {
      "question": "What is the function of the SLC6A4 gene product in the mechanism of action of duloxetine?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, a primary target of duloxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for duloxetine in adolescents with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "duloxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for duloxetine in adolescent patients, adjusted for SLC6A4 genotype."
      }
    },
    {
      "question": "What is the recommended escitalopram dose for a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for escitalopram in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking escitalopram?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using escitalopram."
      }
    },
    {
      "question": "What are the expected plasma concentrations of escitalopram in a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for escitalopram in CYP2B6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2B6 enzyme in the metabolism of escitalopram?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2B6's role in the metabolic pathway of escitalopram."
      }
    },
    {
      "question": "What is the dosing recommendation for escitalopram in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for escitalopram in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended escitalopram dose for a CYP2C19 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol or alternative medication recommendation for escitalopram in CYP2C19 ultrarapid metabolizers."
      }
    },
    {
      "question": "What is the increased risk of failed therapy for a CYP2C19 ultrarapid metabolizer taking a standard dose of escitalopram?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for lack of efficacy in CYP2C19 ultrarapid metabolizers using escitalopram."
      }
    },
    {
      "question": "What are the expected plasma concentrations of escitalopram in a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for escitalopram in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2C19 intermediate metabolizer?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 intermediate metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2C19 enzyme in the metabolism of escitalopram?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2C19's primary role in the metabolic pathway of escitalopram."
      }
    },
    {
      "question": "What is the dosing recommendation for escitalopram in pediatric patients with a CYP2C19 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for escitalopram in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended escitalopram dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for escitalopram in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking escitalopram?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using escitalopram."
      }
    },
    {
      "question": "What are the expected plasma concentrations of escitalopram in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for escitalopram in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 normal metabolizer?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of escitalopram?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2D6's role in the metabolic pathway of escitalopram."
      }
    },
    {
      "question": "What is the dosing recommendation for escitalopram in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for escitalopram in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should escitalopram dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for escitalopram based on HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What is the risk of poor response to escitalopram for individuals with the HTR2A rs7997012 A allele?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for altered escitalopram efficacy in patients with the HTR2A rs7997012 A allele."
      }
    },
    {
      "question": "What is the expected clinical response to escitalopram in a patient with the HTR2A rs7997012 G/G genotype?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for escitalopram stratified by HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What HTR2A variants are associated with altered escitalopram response?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of HTR2A variants and their corresponding impact on escitalopram response."
      }
    },
    {
      "question": "What is the function of the HTR2A gene product in the context of escitalopram therapy?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of escitalopram."
      }
    },
    {
      "question": "What is the dosing recommendation for escitalopram in adolescents with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for escitalopram in adolescent patients, adjusted for HTR2A genotype."
      }
    },
    {
      "question": "How should escitalopram dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for escitalopram based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What is the risk of adverse effects to escitalopram for individuals with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of escitalopram in patients with the SLC6A4 S/S genotype."
      }
    },
    {
      "question": "What is the expected clinical response to escitalopram in a patient with the SLC6A4 L/S genotype?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for escitalopram stratified by SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered escitalopram response?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on escitalopram response."
      }
    },
    {
      "question": "What is the function of the SLC6A4 gene product in the mechanism of action of escitalopram?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, the primary target of escitalopram."
      }
    },
    {
      "question": "What is the dosing recommendation for escitalopram in adolescents with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "escitalopram",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for escitalopram in adolescent patients, adjusted for SLC6A4 genotype."
      }
    },
    {
      "question": "What is the recommended fluoxetine dose for a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for fluoxetine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking fluoxetine?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using fluoxetine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of fluoxetine in a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for fluoxetine in CYP2B6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 ultrarapid metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2B6 enzyme in the metabolism of fluoxetine?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2B6's role in the metabolic pathway of fluoxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for fluoxetine in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for fluoxetine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended fluoxetine dose for a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for fluoxetine in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking fluoxetine?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using fluoxetine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of fluoxetine in a CYP2C19 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for fluoxetine in CYP2C19 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2C19 enzyme in the metabolism of fluoxetine?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2C19's role in the metabolic pathway of fluoxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for fluoxetine in pediatric patients with a CYP2C19 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for fluoxetine in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended fluoxetine dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol or alternative medication recommendation for fluoxetine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking a standard dose of fluoxetine?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using fluoxetine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of fluoxetine in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for fluoxetine in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of fluoxetine?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2D6's primary role in the metabolic pathway of fluoxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for fluoxetine in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for fluoxetine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should fluoxetine dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for fluoxetine based on HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What is the risk of poor response to fluoxetine for individuals with the HTR2A rs7997012 A allele?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for altered fluoxetine efficacy in patients with the HTR2A rs7997012 A allele."
      }
    },
    {
      "question": "What is the expected clinical response to fluoxetine in a patient with the HTR2A rs7997012 G/G genotype?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for fluoxetine stratified by HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What HTR2A variants are associated with altered fluoxetine response?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of HTR2A variants and their corresponding impact on fluoxetine response."
      }
    },
    {
      "question": "What is the function of the HTR2A gene product in the context of fluoxetine therapy?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of fluoxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for fluoxetine in adolescents with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for fluoxetine in adolescent patients, adjusted for HTR2A genotype."
      }
    },
    {
      "question": "How should fluoxetine dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for fluoxetine based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What is the risk of adverse effects to fluoxetine for individuals with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of fluoxetine in patients with the SLC6A4 S/S genotype."
      }
    },
    {
      "question": "What is the expected clinical response to fluoxetine in a patient with the SLC6A4 L/S genotype?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for fluoxetine stratified by SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered fluoxetine response?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on fluoxetine response."
      }
    },
    {
      "question": "What is the function of the SLC6A4 gene product in the mechanism of action of fluoxetine?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, the primary target of fluoxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for fluoxetine in adolescents with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "fluoxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for fluoxetine in adolescent patients, adjusted for SLC6A4 genotype."
      }
    },
    {
      "question": "What is the recommended fluvoxamine dose for a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for fluvoxamine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking fluvoxamine?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using fluvoxamine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of fluvoxamine in a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for fluvoxamine in CYP2B6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2B6 normal metabolizer?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 normal metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2B6 enzyme in the metabolism of fluvoxamine?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2B6's role in the metabolic pathway of fluvoxamine."
      }
    },
    {
      "question": "What is the dosing recommendation for fluvoxamine in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for fluvoxamine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended fluvoxamine dose for a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for fluvoxamine in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking fluvoxamine?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using fluvoxamine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of fluvoxamine in a CYP2C19 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for fluvoxamine in CYP2C19 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2C19 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 ultrarapid metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2C19 enzyme in the metabolism of fluvoxamine?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2C19's role in the metabolic pathway of fluvoxamine."
      }
    },
    {
      "question": "What is the dosing recommendation for fluvoxamine in pediatric patients with a CYP2C19 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for fluvoxamine in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended fluvoxamine dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol or alternative medication recommendation for fluvoxamine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking a standard dose of fluvoxamine?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using fluvoxamine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of fluvoxamine in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for fluvoxamine in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of fluvoxamine?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2D6's primary role in the metabolic pathway of fluvoxamine."
      }
    },
    {
      "question": "What is the dosing recommendation for fluvoxamine in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for fluvoxamine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should fluvoxamine dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for fluvoxamine based on HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What is the risk of poor response to fluvoxamine for individuals with the HTR2A rs7997012 A allele?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for altered fluvoxamine efficacy in patients with the HTR2A rs7997012 A allele."
      }
    },
    {
      "question": "What is the expected clinical response to fluvoxamine in a patient with the HTR2A rs7997012 G/G genotype?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for fluvoxamine stratified by HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What HTR2A variants are associated with altered fluvoxamine response?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of HTR2A variants and their corresponding impact on fluvoxamine response."
      }
    },
    {
      "question": "What is the function of the HTR2A gene product in the context of fluvoxamine therapy?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of fluvoxamine."
      }
    },
    {
      "question": "What is the dosing recommendation for fluvoxamine in adolescents with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for fluvoxamine in adolescent patients, adjusted for HTR2A genotype."
      }
    },
    {
      "question": "How should fluvoxamine dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for fluvoxamine based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What is the risk of adverse effects to fluvoxamine for individuals with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of fluvoxamine in patients with the SLC6A4 S/S genotype."
      }
    },
    {
      "question": "What is the expected clinical response to fluvoxamine in a patient with the SLC6A4 L/S genotype?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for fluvoxamine stratified by SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered fluvoxamine response?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on fluvoxamine response."
      }
    },
    {
      "question": "What is the function of the SLC6A4 gene product in the mechanism of action of fluvoxamine?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, the primary target of fluvoxamine."
      }
    },
    {
      "question": "What is the dosing recommendation for fluvoxamine in adolescents with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "fluvoxamine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for fluvoxamine in adolescent patients, adjusted for SLC6A4 genotype."
      }
    },
    {
      "question": "What is the recommended levomilnacipran dose for a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for levomilnacipran in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking levomilnacipran?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using levomilnacipran."
      }
    },
    {
      "question": "What are the expected plasma concentrations of levomilnacipran in a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for levomilnacipran in CYP2B6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2B6 enzyme in the metabolism of levomilnacipran?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2B6's role in the metabolic pathway of levomilnacipran."
      }
    },
    {
      "question": "What is the dosing recommendation for levomilnacipran in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for levomilnacipran in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended levomilnacipran dose for a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for levomilnacipran in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking levomilnacipran?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using levomilnacipran."
      }
    },
    {
      "question": "What are the expected plasma concentrations of levomilnacipran in a CYP2C19 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for levomilnacipran in CYP2C19 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2C19 normal metabolizer?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 normal metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2C19 enzyme in the metabolism of levomilnacipran?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2C19's role in the metabolic pathway of levomilnacipran."
      }
    },
    {
      "question": "What is the dosing recommendation for levomilnacipran in pediatric patients with a CYP2C19 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for levomilnacipran in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended levomilnacipran dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for levomilnacipran in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking levomilnacipran?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using levomilnacipran."
      }
    },
    {
      "question": "What are the expected plasma concentrations of levomilnacipran in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for levomilnacipran in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of levomilnacipran?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2D6's role in the metabolic pathway of levomilnacipran."
      }
    },
    {
      "question": "What is the dosing recommendation for levomilnacipran in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for levomilnacipran in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should levomilnacipran dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for levomilnacipran based on HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What is the risk of poor response to levomilnacipran for individuals with the HTR2A rs7997012 A allele?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for altered levomilnacipran efficacy in patients with the HTR2A rs7997012 A allele."
      }
    },
    {
      "question": "What is the expected clinical response to levomilnacipran in a patient with the HTR2A rs7997012 G/G genotype?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for levomilnacipran stratified by HTR2A rs7997012 genotype."
      }
    },
    {
      "question": "What HTR2A variants are associated with altered levomilnacipran response?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of HTR2A variants and their corresponding impact on levomilnacipran response."
      }
    },
    {
      "question": "What is the function of the HTR2A gene product in the context of levomilnacipran therapy?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of levomilnacipran."
      }
    },
    {
      "question": "What is the dosing recommendation for levomilnacipran in adolescents with the HTR2A rs7997012 A/A genotype?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for levomilnacipran in adolescent patients, adjusted for HTR2A genotype."
      }
    },
    {
      "question": "How should levomilnacipran dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing or therapeutic recommendations for levomilnacipran based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What is the risk of adverse effects to levomilnacipran for individuals with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of levomilnacipran in patients with the SLC6A4 S/S genotype."
      }
    },
    {
      "question": "What is the expected clinical response to levomilnacipran in a patient with the SLC6A4 L/S genotype?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data, such as remission rates, for levomilnacipran stratified by SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered levomilnacipran response?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on levomilnacipran response."
      }
    },
    {
      "question": "What is the function of the SLC6A4 gene product in the mechanism of action of levomilnacipran?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, a primary target of levomilnacipran."
      }
    },
    {
      "question": "What is the dosing recommendation for levomilnacipran in adolescents with the SLC6A4 S/S genotype?",
      "answer": {
        "Drug Name": "levomilnacipran",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing guidelines for levomilnacipran in adolescent patients, adjusted for SLC6A4 genotype."
      }
    },
    {
      "question": "What is the recommended milnacipran dose for a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for milnacipran in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking milnacipran?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using milnacipran."
      }
    },
    {
      "question": "What are the expected plasma concentrations of milnacipran in a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for milnacipran in CYP2B6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2B6 intermediate metabolizer?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 intermediate metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2B6 enzyme in the metabolism of milnacipran?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2B6's role in milnacipran metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for milnacipran in a pediatric patient with a CYP2B6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for milnacipran in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "How should milnacipran dosing be adjusted for a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for milnacipran in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking milnacipran?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using milnacipran."
      }
    },
    {
      "question": "What is the suggested therapeutic range for plasma milnacipran concentrations in a CYP2C19 intermediate metabolizer?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges for milnacipran in CYP2C19 intermediate metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2C19 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 ultrarapid metabolizer phenotype."
      }
    },
    {
      "question": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of milnacipran?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2C19's role in milnacipran metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for milnacipran in an elderly patient with a CYP2C19 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for milnacipran in elderly CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended milnacipran dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for milnacipran in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking milnacipran?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using milnacipran."
      }
    },
    {
      "question": "What are the expected plasma milnacipran concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for milnacipran in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of milnacipran?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2D6's role in milnacipran metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for milnacipran in a pediatric patient with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for milnacipran in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should milnacipran dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for milnacipran based on HTR2A rs6313 genotype."
      }
    },
    {
      "question": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking milnacipran?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or odds ratio for treatment non-response in milnacipran users with the HTR2A rs6313 G/G genotype."
      }
    },
    {
      "question": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking milnacipran?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data (e.g., remission rates) for milnacipran based on HTR2A rs6313 genotype."
      }
    },
    {
      "question": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered milnacipran response?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Definitions of HTR2A genotypes and their association with milnacipran efficacy."
      }
    },
    {
      "question": "What is the function of the HTR2A gene product in the mechanism of action of milnacipran?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for milnacipran."
      }
    },
    {
      "question": "What is the dosing recommendation for milnacipran in an adolescent with the HTR2A rs6313 G/G genotype?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for milnacipran in adolescents based on HTR2A genotype."
      }
    },
    {
      "question": "How should milnacipran dosing be adjusted for an individual with the SLC6A4 l/l genotype?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for milnacipran based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking milnacipran?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or odds ratio for treatment non-response in milnacipran users with the SLC6A4 s/s genotype."
      }
    },
    {
      "question": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking milnacipran?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data (e.g., remission rates) for milnacipran based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR)."
      }
    },
    {
      "question": "What is the function of the SLC6A4 gene product in the mechanism of action of milnacipran?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of the serotonin transporter's (SERT) role as the primary target of milnacipran."
      }
    },
    {
      "question": "What is the dosing recommendation for milnacipran in an adolescent with the SLC6A4 s/s genotype?",
      "answer": {
        "Drug Name": "milnacipran",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for milnacipran in adolescents based on SLC6A4 genotype."
      }
    },
    {
      "question": "What is the recommended paroxetine dose for a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for paroxetine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking paroxetine?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using paroxetine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of paroxetine in a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for paroxetine in CYP2B6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2B6 enzyme in the metabolism of paroxetine?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2B6's role in paroxetine metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for paroxetine in a pediatric patient with a CYP2B6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for paroxetine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "How should paroxetine dosing be adjusted for a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for paroxetine in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking paroxetine?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using paroxetine."
      }
    },
    {
      "question": "What is the suggested therapeutic range for plasma paroxetine concentrations in a CYP2C19 intermediate metabolizer?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges for paroxetine in CYP2C19 intermediate metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of paroxetine?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2C19's role in paroxetine metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for paroxetine in an elderly patient with a CYP2C19 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for paroxetine in elderly CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended paroxetine dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for paroxetine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking paroxetine?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using paroxetine."
      }
    },
    {
      "question": "What are the expected plasma paroxetine concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for paroxetine in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of paroxetine?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2D6's role as the primary metabolic pathway for paroxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for paroxetine in a pediatric patient with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for paroxetine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should paroxetine dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for paroxetine based on HTR2A rs6313 genotype."
      }
    },
    {
      "question": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking paroxetine?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or odds ratio for treatment non-response in paroxetine users with the HTR2A rs6313 G/G genotype."
      }
    },
    {
      "question": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking paroxetine?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data (e.g., remission rates) for paroxetine based on HTR2A rs6313 genotype."
      }
    },
    {
      "question": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered paroxetine response?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Definitions of HTR2A genotypes and their association with paroxetine efficacy."
      }
    },
    {
      "question": "What is the function of the HTR2A gene product in the mechanism of action of paroxetine?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for paroxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for paroxetine in an adolescent with the HTR2A rs6313 G/G genotype?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for paroxetine in adolescents based on HTR2A genotype."
      }
    },
    {
      "question": "How should paroxetine dosing be adjusted for an individual with the SLC6A4 l/l genotype?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for paroxetine based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking paroxetine?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or odds ratio for treatment non-response in paroxetine users with the SLC6A4 s/s genotype."
      }
    },
    {
      "question": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking paroxetine?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data (e.g., remission rates) for paroxetine based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR)."
      }
    },
    {
      "question": "What is the function of the SLC6A4 gene product in the mechanism of action of paroxetine?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of the serotonin transporter's (SERT) role as the primary target of paroxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for paroxetine in an adolescent with the SLC6A4 s/s genotype?",
      "answer": {
        "Drug Name": "paroxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for paroxetine in adolescents based on SLC6A4 genotype."
      }
    },
    {
      "question": "What is the recommended sertraline dose for a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for sertraline in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking sertraline?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using sertraline."
      }
    },
    {
      "question": "What are the expected plasma concentrations of sertraline in a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for sertraline in CYP2B6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 ultrarapid metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2B6 enzyme in the metabolism of sertraline?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2B6's role in sertraline metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for sertraline in a pediatric patient with a CYP2B6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for sertraline in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "How should sertraline dosing be adjusted for a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for sertraline in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking sertraline?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using sertraline."
      }
    },
    {
      "question": "What is the suggested therapeutic range for plasma sertraline concentrations in a CYP2C19 intermediate metabolizer?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges for sertraline in CYP2C19 intermediate metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2C19 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 ultrarapid metabolizer phenotype."
      }
    },
    {
      "question": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of sertraline?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2C19's role as a primary metabolic pathway for sertraline."
      }
    },
    {
      "question": "What is the dosing recommendation for sertraline in an elderly patient with a CYP2C19 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for sertraline in elderly CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended sertraline dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for sertraline in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking sertraline?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using sertraline."
      }
    },
    {
      "question": "What are the expected plasma sertraline concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for sertraline in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of sertraline?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2D6's role in sertraline metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for sertraline in a pediatric patient with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for sertraline in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should sertraline dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for sertraline based on HTR2A rs6313 genotype."
      }
    },
    {
      "question": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking sertraline?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or odds ratio for treatment non-response in sertraline users with the HTR2A rs6313 G/G genotype."
      }
    },
    {
      "question": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking sertraline?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data (e.g., remission rates) for sertraline based on HTR2A rs6313 genotype."
      }
    },
    {
      "question": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered sertraline response?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Definitions of HTR2A genotypes and their association with sertraline efficacy."
      }
    },
    {
      "question": "What is the function of the HTR2A gene product in the mechanism of action of sertraline?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for sertraline."
      }
    },
    {
      "question": "What is the dosing recommendation for sertraline in an adolescent with the HTR2A rs6313 G/G genotype?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for sertraline in adolescents based on HTR2A genotype."
      }
    },
    {
      "question": "How should sertraline dosing be adjusted for an individual with the SLC6A4 l/l genotype?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for sertraline based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking sertraline?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or odds ratio for treatment non-response in sertraline users with the SLC6A4 s/s genotype."
      }
    },
    {
      "question": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking sertraline?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data (e.g., remission rates) for sertraline based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR)."
      }
    },
    {
      "question": "What is the function of the SLC6A4 gene product in the mechanism of action of sertraline?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of the serotonin transporter's (SERT) role as the primary target of sertraline."
      }
    },
    {
      "question": "What is the dosing recommendation for sertraline in an adolescent with the SLC6A4 s/s genotype?",
      "answer": {
        "Drug Name": "sertraline",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for sertraline in adolescents based on SLC6A4 genotype."
      }
    },
    {
      "question": "What is the recommended venlafaxine dose for a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for venlafaxine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking venlafaxine?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using venlafaxine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of venlafaxine in a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for venlafaxine in CYP2B6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2B6 normal metabolizer?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 normal metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2B6 enzyme in the metabolism of venlafaxine?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2B6's role in venlafaxine metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for venlafaxine in a pediatric patient with a CYP2B6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for venlafaxine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "How should venlafaxine dosing be adjusted for a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for venlafaxine in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking venlafaxine?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using venlafaxine."
      }
    },
    {
      "question": "What is the suggested therapeutic range for plasma O-desmethylvenlafaxine concentrations in a CYP2C19 intermediate metabolizer?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges for O-desmethylvenlafaxine in CYP2C19 intermediate metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2C19 normal metabolizer?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 normal metabolizer phenotype."
      }
    },
    {
      "question": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of venlafaxine?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2C19's role in venlafaxine metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for venlafaxine in an elderly patient with a CYP2C19 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for venlafaxine in elderly CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended venlafaxine dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for venlafaxine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking venlafaxine?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using venlafaxine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of O-desmethylvenlafaxine in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for O-desmethylvenlafaxine in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 normal metabolizer?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of venlafaxine?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2D6's role in converting venlafaxine to its active metabolite, O-desmethylvenlafaxine."
      }
    },
    {
      "question": "What is the dosing recommendation for venlafaxine in a pediatric patient with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for venlafaxine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should venlafaxine dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for venlafaxine based on HTR2A rs6313 genotype."
      }
    },
    {
      "question": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking venlafaxine?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or odds ratio for treatment non-response in venlafaxine users with the HTR2A rs6313 G/G genotype."
      }
    },
    {
      "question": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking venlafaxine?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data (e.g., remission rates) for venlafaxine based on HTR2A rs6313 genotype."
      }
    },
    {
      "question": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered venlafaxine response?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Definitions of HTR2A genotypes and their association with venlafaxine efficacy."
      }
    },
    {
      "question": "What is the function of the HTR2A gene product in the mechanism of action of venlafaxine?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for venlafaxine."
      }
    },
    {
      "question": "What is the dosing recommendation for venlafaxine in an adolescent with the HTR2A rs6313 G/G genotype?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for venlafaxine in adolescents based on HTR2A genotype."
      }
    },
    {
      "question": "How should venlafaxine dosing be adjusted for an individual with the SLC6A4 l/l genotype?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for venlafaxine based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking venlafaxine?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or odds ratio for treatment non-response in venlafaxine users with the SLC6A4 s/s genotype."
      }
    },
    {
      "question": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking venlafaxine?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data (e.g., remission rates) for venlafaxine based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR)."
      }
    },
    {
      "question": "What is the function of the SLC6A4 gene product in the mechanism of action of venlafaxine?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of the serotonin transporter's (SERT) role as a primary target of venlafaxine."
      }
    },
    {
      "question": "What is the dosing recommendation for venlafaxine in an adolescent with the SLC6A4 s/s genotype?",
      "answer": {
        "Drug Name": "venlafaxine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for venlafaxine in adolescents based on SLC6A4 genotype."
      }
    },
    {
      "question": "What is the recommended vilazodone dose for a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for vilazodone in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking vilazodone?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using vilazodone."
      }
    },
    {
      "question": "What are the expected plasma concentrations of vilazodone in a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for vilazodone in CYP2B6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2B6 intermediate metabolizer?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 intermediate metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2B6 enzyme in the metabolism of vilazodone?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2B6's role in vilazodone metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for vilazodone in a pediatric patient with a CYP2B6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for vilazodone in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "How should vilazodone dosing be adjusted for a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for vilazodone in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking vilazodone?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using vilazodone."
      }
    },
    {
      "question": "What is the suggested therapeutic range for plasma vilazodone concentrations in a CYP2C19 intermediate metabolizer?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges for vilazodone in CYP2C19 intermediate metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2C19 intermediate metabolizer?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 intermediate metabolizer phenotype."
      }
    },
    {
      "question": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of vilazodone?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2C19's role in vilazodone metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for vilazodone in an elderly patient with a CYP2C19 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for vilazodone in elderly CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended vilazodone dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for vilazodone in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking vilazodone?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using vilazodone."
      }
    },
    {
      "question": "What are the expected plasma vilazodone concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for vilazodone in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of vilazodone?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2D6's role in vilazodone metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for vilazodone in a pediatric patient with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for vilazodone in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should vilazodone dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for vilazodone based on HTR2A rs6313 genotype."
      }
    },
    {
      "question": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking vilazodone?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or odds ratio for treatment non-response in vilazodone users with the HTR2A rs6313 G/G genotype."
      }
    },
    {
      "question": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking vilazodone?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data (e.g., remission rates) for vilazodone based on HTR2A rs6313 genotype."
      }
    },
    {
      "question": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered vilazodone response?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Definitions of HTR2A genotypes and their association with vilazodone efficacy."
      }
    },
    {
      "question": "What is the function of the HTR2A gene product in the mechanism of action of vilazodone?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for vilazodone."
      }
    },
    {
      "question": "What is the dosing recommendation for vilazodone in an adolescent with the HTR2A rs6313 G/G genotype?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for vilazodone in adolescents based on HTR2A genotype."
      }
    },
    {
      "question": "How should vilazodone dosing be adjusted for an individual with the SLC6A4 l/l genotype?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for vilazodone based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking vilazodone?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or odds ratio for treatment non-response in vilazodone users with the SLC6A4 s/s genotype."
      }
    },
    {
      "question": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking vilazodone?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data (e.g., remission rates) for vilazodone based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR)."
      }
    },
    {
      "question": "What is the function of the SLC6A4 gene product in the mechanism of action of vilazodone?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of the serotonin transporter's (SERT) role as a primary target of vilazodone."
      }
    },
    {
      "question": "What is the dosing recommendation for vilazodone in an adolescent with the SLC6A4 s/s genotype?",
      "answer": {
        "Drug Name": "vilazodone",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for vilazodone in adolescents based on SLC6A4 genotype."
      }
    },
    {
      "question": "What is the recommended vortioxetine dose for a CYP2B6 poor metabolizer?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for vortioxetine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking vortioxetine?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using vortioxetine."
      }
    },
    {
      "question": "What are the expected plasma concentrations of vortioxetine in a CYP2B6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for vortioxetine in CYP2B6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2B6 normal metabolizer?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 normal metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2B6 enzyme in the metabolism of vortioxetine?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2B6's role in vortioxetine metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for vortioxetine in a pediatric patient with a CYP2B6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2B6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for vortioxetine in CYP2B6 poor metabolizers."
      }
    },
    {
      "question": "How should vortioxetine dosing be adjusted for a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for vortioxetine in CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking vortioxetine?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using vortioxetine."
      }
    },
    {
      "question": "What is the suggested therapeutic range for plasma vortioxetine concentrations in a CYP2C19 intermediate metabolizer?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges for vortioxetine in CYP2C19 intermediate metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2C19 poor metabolizer?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 poor metabolizer phenotype."
      }
    },
    {
      "question": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of vortioxetine?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2C19's role in vortioxetine metabolism."
      }
    },
    {
      "question": "What is the dosing recommendation for vortioxetine in an elderly patient with a CYP2C19 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2C19",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for vortioxetine in elderly CYP2C19 poor metabolizers."
      }
    },
    {
      "question": "What is the recommended vortioxetine dose for a CYP2D6 poor metabolizer?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for vortioxetine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking vortioxetine?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using vortioxetine."
      }
    },
    {
      "question": "What are the expected plasma vortioxetine concentrations in a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Plasma concentration ranges or AUC data for vortioxetine in CYP2D6 ultrarapid metabolizers."
      }
    },
    {
      "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
      }
    },
    {
      "question": "What is the function of the CYP2D6 enzyme in the metabolism of vortioxetine?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of CYP2D6's role as the primary metabolic pathway for vortioxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for vortioxetine in a pediatric patient with a CYP2D6 poor metabolizer phenotype?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "CYP2D6",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pediatric dosing adjustments for vortioxetine in CYP2D6 poor metabolizers."
      }
    },
    {
      "question": "How should vortioxetine dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for vortioxetine based on HTR2A rs6313 genotype."
      }
    },
    {
      "question": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking vortioxetine?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or odds ratio for treatment non-response in vortioxetine users with the HTR2A rs6313 G/G genotype."
      }
    },
    {
      "question": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking vortioxetine?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data (e.g., remission rates) for vortioxetine based on HTR2A rs6313 genotype."
      }
    },
    {
      "question": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered vortioxetine response?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Definitions of HTR2A genotypes and their association with vortioxetine efficacy."
      }
    },
    {
      "question": "What is the function of the HTR2A gene product in the mechanism of action of vortioxetine?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for vortioxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for vortioxetine in an adolescent with the HTR2A rs6313 G/G genotype?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "HTR2A",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for vortioxetine in adolescents based on HTR2A genotype."
      }
    },
    {
      "question": "How should vortioxetine dosing be adjusted for an individual with the SLC6A4 l/l genotype?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dose adjustment protocol for vortioxetine based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking vortioxetine?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Quantified risk or odds ratio for treatment non-response in vortioxetine users with the SLC6A4 s/s genotype."
      }
    },
    {
      "question": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking vortioxetine?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Pharmacodynamic data (e.g., remission rates) for vortioxetine based on SLC6A4 5-HTTLPR genotype."
      }
    },
    {
      "question": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR)."
      }
    },
    {
      "question": "What is the function of the SLC6A4 gene product in the mechanism of action of vortioxetine?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Description of the serotonin transporter's (SERT) role as a primary target of vortioxetine."
      }
    },
    {
      "question": "What is the dosing recommendation for vortioxetine in an adolescent with the SLC6A4 s/s genotype?",
      "answer": {
        "Drug Name": "vortioxetine",
        "Gene Name": "SLC6A4",
        "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
        "Content to Search": "Dosing adjustments for vortioxetine in adolescents based on SLC6A4 genotype."
      }
    }
  ]
}
]